1792 lines
668 KiB
Text
1792 lines
668 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK578044">
|
|
<meta name="ncbi_domain" content="niceng136er2">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK578044/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for monitoring - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for monitoring - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_title" content="Evidence review for monitoring">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2019/08">
|
|
<meta name="citation_author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_pmid" content="35188722">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK578044/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for monitoring">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="National Guideline Centre (UK)">
|
|
<meta name="DC.Date" content="2019/08">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK578044/">
|
|
<meta name="og:title" content="Evidence review for monitoring">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK578044/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng136er2-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng136er2/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK578044/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E631F7D73DDD10000000000140011.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK578044/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK578044/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK578044/&text=Evidence%20review%20for%20monitoring"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK578044/?report=classic">Switch to classic view</a><a href="/books/n/niceng136er2/pdf/">PDF (2.0M)</a><a href="/books/n/niceng136er2/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK578044%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E631F7D73DDD10000000000140011.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng136er2-lrg.png" alt="Cover of Evidence review for monitoring" /></a></div><div class="bkr_bib"><h1 id="_NBK578044_"><span itemprop="name">Evidence review for monitoring</span></h1><div class="subtitle">Hypertension in adults: diagnosis and management</div><p><b>Evidence review B</b></p><p><i>NICE Guideline, No. 136</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Centre (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2019 Aug</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3503-1</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2019.</div></div><div class="bkr_clear"></div></div><div id="ch2.s1"><h2 id="_ch2_s1_">1. Monitoring blood pressure</h2><div id="ch2.s1.1"><h3>1.1. Review question: In adults with treated primary hypertension, what is the best method of measuring blood pressure (home, ambulatory or clinic measurement) to assess the response to treatment and prevent cardiovascular events?</h3></div><div id="ch2.s1.2"><h3>1.2. Introduction</h3><p>Once an individual has been diagnosed with hypertension, the person will be started on a treatment programme (both pharmacological and non-pharmacological) to lower blood pressure (BP). Individuals respond differently to different treatments and often combinations of multiple treatments are required to achieve the target blood pressure. It is therefore necessary to assess an individual’s response to treatment to identify those who might need additional or alternative treatment strategies.</p><p>Current practice for monitoring response is variable and involves a combination of home, ambulatory and clinic blood pressure measurements. Clinic blood pressure measurements are often higher than those observed with ambulatory or home measurements and are not necessarily a true representation of an individual’s day-to-day blood pressure. Ambulatory or home measurements may therefore provide a more accurate estimation of response to treatment and consequent reduction in cardiovascular events.</p></div><div id="ch2.s1.3"><h3>1.3. PICO table</h3><p>For full details, see the review protocol in <a href="#ch2.appa">appendix A</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab1"><a href="/books/NBK578044/table/ch2.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab1" rid-ob="figobch2tab1"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab1/?report=thumb" src-large="/books/NBK578044/table/ch2.tab1/?report=previmg" alt="Table 1. PICO characteristics of review question." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab1"><a href="/books/NBK578044/table/ch2.tab1/?report=objectonly" target="object" rid-ob="figobch2tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="ch2.s1.4"><h3>1.4. Methods and process</h3><p>This evidence review was developed using the methods and process described in Developing NICE guidelines: the manual.<a class="bibr" href="#ch2.ref32" rid="ch2.ref32"><sup>32</sup></a> Methods specific to this review question are described in the review protocol in <a href="#ch2.appa">appendix A</a>.</p><p>Declarations of interest were recorded according to NICE’s 2018 conflicts of interest policy.</p></div><div id="ch2.s1.5"><h3>1.5. Clinical evidence</h3><div id="ch2.s1.5.1"><h4>1.5.1. Included studies</h4><p>Eight studies were included in the review<a class="bibr" href="#ch2.ref49" rid="ch2.ref49"><sup>49</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref73" rid="ch2.ref73"><sup>73</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref84" rid="ch2.ref84"><sup>84</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref85" rid="ch2.ref85"><sup>85</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref122" rid="ch2.ref122"><sup>122</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref131" rid="ch2.ref131"><sup>131</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref135" rid="ch2.ref135"><sup>135</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref136" rid="ch2.ref136"><sup>136</sup></a>; these are summarised in <a class="figpopup" href="/books/NBK578044/table/ch2.tab2/?report=objectonly" target="object" rid-figpopup="figch2tab2" rid-ob="figobch2tab2">Table 2</a> below. Evidence from these studies is summarised in the clinical evidence summary below (<a class="figpopup" href="/books/NBK578044/table/ch2.tab3/?report=objectonly" target="object" rid-figpopup="figch2tab3" rid-ob="figobch2tab3">Table 3</a>).</p><p>There were 8 comparisons extracted from the included studies:
|
|
<ul id="ch2.l4"><li id="ch2.lt18" class="half_rhythm"><div>Home monitoring without telemonitoring compared to clinic monitoring (n=2),</div></li><li id="ch2.lt19" class="half_rhythm"><div>Home monitoring with telemonitoring compared to clinical monitoring (n=3),</div></li><li id="ch2.lt20" class="half_rhythm"><div>Home monitoring with telemonitoring and pharmacist care compared to clinical monitoring (n=1)</div></li><li id="ch2.lt21" class="half_rhythm"><div>Home monitoring without telemonitoring compared to ambulatory/clinic monitoring (n=1)</div></li><li id="ch2.lt22" class="half_rhythm"><div>Home monitoring without telemonitoring compared to home monitoring with telemonitoring (n=2)</div></li><li id="ch2.lt23" class="half_rhythm"><div>Home monitoring with telemonitoring compared to home monitoring with telemonitoring and pharmacist care (n=1)</div></li><li id="ch2.lt24" class="half_rhythm"><div>Pharmacy monitoring compared to clinical monitoring (n=2)</div></li><li id="ch2.lt25" class="half_rhythm"><div>Home monitoring (with self-titration) and telemonitoring compared to clinic monitoring (n=1).</div></li></ul></p><p>An individual patient data (IPD) meta-analysis was included Tucker 2017<a class="bibr" href="#ch2.ref135" rid="ch2.ref135"><sup>135</sup></a> and all the remaining included studies were open-label RCTs. As an IPD is the highest quality design, any trials prior and up to the date it was published were only included if they had any additional outcomes that were not found in the IPD. The IPD reported outcomes for reduction in clinic blood pressure and proportion controlled to a target. Any studies published after 2017 were included if they met the protocol for this review and all relevant outcomes were extracted.</p><p>See also the study selection flow chart in <a href="#ch2.appc">appendix C</a>, study evidence tables in <a href="#ch2.appd">appendix D</a>, forest plots in <a href="#ch2.appe">appendix E</a> and GRADE tables in <a href="#ch2.appf">appendix F</a>.</p></div><div id="ch2.s1.5.2"><h4>1.5.2. Excluded studies</h4><p>The guideline committee identified 3 systematic reviews as key papers during the development of this evidence review protocol.<a class="bibr" href="#ch2.ref135" rid="ch2.ref135"><sup>135</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref137" rid="ch2.ref137"><sup>137</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref100" rid="ch2.ref100"><sup>100</sup></a></p><p>Omboni 2013<a class="bibr" href="#ch2.ref100" rid="ch2.ref100"><sup>100</sup></a> could not be incorporated as it included trials which deviated from this review protocol, that is, indirect populations without primary hypertension, populations not receiving antihypertensive treatment and follow-up times of less than 12 months. All the trials included in Omboni 2013<a class="bibr" href="#ch2.ref100" rid="ch2.ref100"><sup>100</sup></a> were individually assessed for relevance for inclusion in this evidence review.</p><p>Uhlig 2013<a class="bibr" href="#ch2.ref137" rid="ch2.ref137"><sup>137</sup></a> was also excluded as it consisted of trials comparing blood pressure monitoring methods to usual care; the description of which was either not given or participants were told not to have their blood pressure measured for the duration of the trials (in these trials, the investigator measured all participants’ blood pressure at specified time-points). Also, the treatments given within trials were not standardised for all the participants.</p><p>See the excluded studies lists in <a href="#ch2.appi">appendix I</a>. <a class="figpopup" href="/books/NBK578044/table/ch2.appi.tab2/?report=objectonly" target="object" rid-figpopup="figch2appitab2" rid-ob="figobch2appitab2">Table 32</a> outlines the full excluded studies list, and <a class="figpopup" href="/books/NBK578044/table/ch2.appi.tab1/?report=objectonly" target="object" rid-figpopup="figch2appitab1" rid-ob="figobch2appitab1">Table 31</a> provides additional detail of studies that were included in the previous guideline iteration (CG127) but excluded from this update.</p></div><div id="ch2.s1.5.3"><h4>1.5.3. Summary of clinical studies included in the evidence review</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab2"><a href="/books/NBK578044/table/ch2.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab2" rid-ob="figobch2tab2"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab2/?report=thumb" src-large="/books/NBK578044/table/ch2.tab2/?report=previmg" alt="Table 2. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab2"><a href="/books/NBK578044/table/ch2.tab2/?report=objectonly" target="object" rid-ob="figobch2tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div><p>See <a href="#ch2.appd">appendix D</a> for full evidence tables.</p></div><div id="ch2.s1.5.4"><h4>1.5.4. Quality assessment of clinical studies included in the evidence review</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab3"><a href="/books/NBK578044/table/ch2.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab3" rid-ob="figobch2tab3"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab3/?report=thumb" src-large="/books/NBK578044/table/ch2.tab3/?report=previmg" alt="Table 3. Clinical evidence summary: Home monitoring versus clinic monitoring." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab3"><a href="/books/NBK578044/table/ch2.tab3/?report=objectonly" target="object" rid-ob="figobch2tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Home monitoring versus clinic monitoring. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab4"><a href="/books/NBK578044/table/ch2.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab4" rid-ob="figobch2tab4"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab4/?report=thumb" src-large="/books/NBK578044/table/ch2.tab4/?report=previmg" alt="Table 4. Clinical evidence summary: Home monitoring without telemonitoring versus ambulatory and clinic monitoring." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab4"><a href="/books/NBK578044/table/ch2.tab4/?report=objectonly" target="object" rid-ob="figobch2tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Home monitoring without telemonitoring versus ambulatory and clinic monitoring. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab5"><a href="/books/NBK578044/table/ch2.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab5" rid-ob="figobch2tab5"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab5/?report=thumb" src-large="/books/NBK578044/table/ch2.tab5/?report=previmg" alt="Table 5. Clinical evidence summary: Home monitoring with telemonitoring versus home monitoring without telemonitoring." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab5"><a href="/books/NBK578044/table/ch2.tab5/?report=objectonly" target="object" rid-ob="figobch2tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Home monitoring with telemonitoring versus home monitoring without telemonitoring. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab6"><a href="/books/NBK578044/table/ch2.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab6" rid-ob="figobch2tab6"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab6/?report=thumb" src-large="/books/NBK578044/table/ch2.tab6/?report=previmg" alt="Table 6. Clinical evidence summary: Home monitoring with telemonitoring versus clinic monitoring." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab6"><a href="/books/NBK578044/table/ch2.tab6/?report=objectonly" target="object" rid-ob="figobch2tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Home monitoring with telemonitoring versus clinic monitoring. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab7"><a href="/books/NBK578044/table/ch2.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab7" rid-ob="figobch2tab7"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab7/?report=thumb" src-large="/books/NBK578044/table/ch2.tab7/?report=previmg" alt="Table 7. Clinical evidence summary: Home monitoring with telemonitoring and pharmacist care versus clinic monitoring." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab7"><a href="/books/NBK578044/table/ch2.tab7/?report=objectonly" target="object" rid-ob="figobch2tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Home monitoring with telemonitoring and pharmacist care versus clinic monitoring. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab8"><a href="/books/NBK578044/table/ch2.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab8" rid-ob="figobch2tab8"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab8/?report=thumb" src-large="/books/NBK578044/table/ch2.tab8/?report=previmg" alt="Table 8. Clinical evidence summary: Home monitoring with telemonitoring and pharmacist care versus home monitoring with telemonitoring." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab8"><a href="/books/NBK578044/table/ch2.tab8/?report=objectonly" target="object" rid-ob="figobch2tab8">Table 8</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Home monitoring with telemonitoring and pharmacist care versus home monitoring with telemonitoring. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab9"><a href="/books/NBK578044/table/ch2.tab9/?report=objectonly" target="object" title="Table 9" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab9" rid-ob="figobch2tab9"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab9/?report=thumb" src-large="/books/NBK578044/table/ch2.tab9/?report=previmg" alt="Table 9. Clinical evidence summary: Home-monitoring (with self-titration) and telemonitoring versus clinic monitoring." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab9"><a href="/books/NBK578044/table/ch2.tab9/?report=objectonly" target="object" rid-ob="figobch2tab9">Table 9</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Home-monitoring (with self-titration) and telemonitoring versus clinic monitoring. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab10"><a href="/books/NBK578044/table/ch2.tab10/?report=objectonly" target="object" title="Table 10" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab10" rid-ob="figobch2tab10"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab10/?report=thumb" src-large="/books/NBK578044/table/ch2.tab10/?report=previmg" alt="Table 10. Clinical evidence summary: Pharmacy monitoring versus clinic monitoring." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab10"><a href="/books/NBK578044/table/ch2.tab10/?report=objectonly" target="object" rid-ob="figobch2tab10">Table 10</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Pharmacy monitoring versus clinic monitoring. </p></div></div><p>See <a href="#ch2.appf">appendix F</a> for full GRADE tables.</p></div></div><div id="ch2.s1.6"><h3>1.6. Economic evidence</h3><div id="ch2.s1.6.1"><h4>1.6.1. Included studies</h4><p>One health economic study identified with the relevant comparison and has been included in this review.<a class="bibr" href="#ch2.ref62" rid="ch2.ref62"><sup>62</sup></a> This is summarised in the health economic evidence profile below (<a class="figpopup" href="/books/NBK578044/table/ch2.tab11/?report=objectonly" target="object" rid-figpopup="figch2tab11" rid-ob="figobch2tab11">Table 11</a>) and the health economic evidence tables in <a href="#ch2.apph">appendix H</a>.</p></div><div id="ch2.s1.6.2"><h4>1.6.2. Excluded studies</h4><p>Ten economic studies relating to this review question were identified but were excluded due to a combination of limited applicability and methodological limitations, as well as the availability of more applicable evidence.<a class="bibr" href="#ch2.ref17" rid="ch2.ref17"><sup>17</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref74" rid="ch2.ref74"><sup>74</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref76" rid="ch2.ref76"><sup>76</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref87" rid="ch2.ref87"><sup>87</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref104" rid="ch2.ref104"><sup>104</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref107" rid="ch2.ref107"><sup>107</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref115" rid="ch2.ref115"><sup>115</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref128" rid="ch2.ref128"><sup>128</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref133" rid="ch2.ref133"><sup>133</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#ch2.ref143" rid="ch2.ref143"><sup>143</sup></a></p><p>These are listed in <a href="#ch2.appi">appendix I</a>, with reasons for exclusion given.</p><p>See also the health economic study selection flow chart in <a href="#ch2.appg">appendix G</a>.</p></div><div id="ch2.s1.6.3"><h4>1.6.3. Summary of studies included in the economic evidence review</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab11"><a href="/books/NBK578044/table/ch2.tab11/?report=objectonly" target="object" title="Table 11" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab11" rid-ob="figobch2tab11"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab11/?report=thumb" src-large="/books/NBK578044/table/ch2.tab11/?report=previmg" alt="Table 11. Health economic evidence profile: Self-monitoring (with self-titration) and telemonitoring versus usual care." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab11"><a href="/books/NBK578044/table/ch2.tab11/?report=objectonly" target="object" rid-ob="figobch2tab11">Table 11</a></h4><p class="float-caption no_bottom_margin">Health economic evidence profile: Self-monitoring (with self-titration) and telemonitoring versus usual care. </p></div></div></div><div id="ch2.s1.6.4"><h4>1.6.4. Resource costs</h4><p>
|
|
<b>Some unit costs and considerations are presented and discussed below.</b>
|
|
</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch2tab12"><a href="/books/NBK578044/table/ch2.tab12/?report=objectonly" target="object" title="Table 12" class="img_link icnblk_img figpopup" rid-figpopup="figch2tab12" rid-ob="figobch2tab12"><img class="small-thumb" src="/books/NBK578044/table/ch2.tab12/?report=thumb" src-large="/books/NBK578044/table/ch2.tab12/?report=previmg" alt="Table 12. Staff costs." /></a><div class="icnblk_cntnt"><h4 id="ch2.tab12"><a href="/books/NBK578044/table/ch2.tab12/?report=objectonly" target="object" rid-ob="figobch2tab12">Table 12</a></h4><p class="float-caption no_bottom_margin">Staff costs. </p></div></div></div></div><div id="ch2.s1.7"><h3>1.7. Evidence statements</h3><div id="ch2.s1.7.1"><h4>1.7.1. Clinical evidence statements</h4><div id="ch2.s1.7.1.1"><h5>Home monitoring versus clinic monitoring</h5><p>Very low quality evidence from one study with 678 participants showed a clinically important increase of cardiovascular events for home monitoring compared to clinic monitoring.</p><p>Very low quality evidence from 2 studies with a total of 2,610 participants showed no clinically important difference between home and clinic monitoring for reduction in systolic or diastolic clinic blood pressure. Low to very low quality evidence from single studies ranging from 672 to 1,934 particpants, showed no clinically important difference between home monitoring and clinic monitoring for proportion not meeting target, mean number of consultations and overall defined daily dose and dizziness.</p></div><div id="ch2.s1.7.1.2"><h5>Home monitoring without telemonitoring versus ambulatory and clinic monitoring</h5><p>Low quality evidence from 1 study with 145 participants showed no clinically important difference between home monitoring compared to ambulatory and clinic monitoring for reduction in systolic and diastolic clinic blood pressure.</p></div><div id="ch2.s1.7.1.3"><h5>Home monitoring with telemonitoring versus home monitoring without telemonitoring</h5><p>Very low quality evidence from one study with 650 participants showed a clinically important increase in occurrence of dizziness for home monitoring with telemonitoring compared to without telemonitoring.</p><p>Low to very low quality evidence from 1 study (658 participants) showed no clinically important difference between home monitoring with or without telemonitoring for cardiovascular events, reduction in systolic and diastolic clinic blood pressure, mean number of consultations or overall defined daily dose (number of participants was 655–658 depending on the outcome). Very low quality evidence from 1 study with 100 participants showed no clinically important difference for average number of visits.</p></div><div id="ch2.s1.7.1.4"><h5>Home monitoring with telemonitoring versus clinic monitoring</h5><p>Low quality evidence from 1 study with 493 participants showed a clinically important benefit for home monitoring with telemonitoring compared to clinic monitoring in terms of proportion controlled to a target.</p><p>Very low quality evidence from 1 study with 493 participants showed a greater occurrence of all-cause mortality with home monitoring with telemonitoring compared to clinic monitoring. Very low quality evidence from 2 studies with 1,173 participants showed a greater occurrence of cardiovascular events for home monitoring with telemonitoring.</p><p>Very low quality evidence from 3 studies with a total of 2,357 participants showed no clinically important difference between the monitoring methods for reduction in systolic and diastolic clinic blood pressure. Low to very low quality evidence from single studies ranging from 493 to 1,189 participants showed no clinically important difference between home monitoring with clinic monitoring for quality of life on the emotional, physical and general SF12 subscale, for proportion not meeting a target, mean number of consultations and overall defined daily dose and dizziness.</p></div><div id="ch2.s1.7.1.5"><h5>Home monitoring with telemonitoring and pharmacist care versus clinic monitoring</h5><p>Low quality evidence from 1 study with 484 participants showed a clinically important benefit of home monitoring with telemonitoring and pharmacist interaction for change in systolic blood pressure, proportion controlled to a target and quality of life with the physical SF-12 subscale.</p><p>Very low quality evidence from this study showed a greater occurrence of non-fatal cardiovascular events with home monitoring with telemonitoring and pharmacist interaction compared to clinic monitoring.</p><p>Low to very low quality evidence from the same study showed no clinically important difference for all-cause mortality, change in diastolic blood pressure or quality of life measured on the emotional or general subscales of the SF-12 scale.</p></div><div id="ch2.s1.7.1.6"><h5>Home monitoring with telemonitoring and pharmacist care versus home monitoring with telemonitoring</h5><p>Low to very low quality evidence from the same study failed to demonstrate a clinically important difference for occurrence of non-fatal cardiovascular events, change in diastolic blood pressure or quality of life on the emotional and general subscale of the SF-12 scale.</p><p>Low to very low quality evidence from 1 study with 483 participants showed a clinically important benefit of home monitoring with telemonitoring and pharmacist care compared to home monitoring with telemonitoring (without pharmacist care) for all-cause mortality, change in systolic blood pressure and quality of life on the physical subscale of the SF-12 scale.</p></div><div id="ch2.s1.7.1.7"><h5>Home monitoring (with self-titration) and telemonitoring versus clinic monitoring</h5><p>Low quality evidence from 1 study with 480 participants showed a clinically important benefit of self-monitoring with self-titration for change in systolic blood pressure.</p><p>Low quality evidence from the same study showed no clinically important difference for change in diastolic blood pressure, quality of life, mean number of consultations and mean number of antihypertensive drugs.</p></div><div id="ch2.s1.7.1.8"><h5>Pharmacy monitoring versus clinic monitoring</h5><p>Very low quality evidence from one study with 260 participants showed a clinically important benefit of pharmacy compared to clinic monitoring for all-cause mortality and reduction in systolic blood pressure, but no difference in terms of reduction in diastolic blood pressure, and an increased number of contacts per patient for pharmacy monitoring.</p></div></div><div id="ch2.s1.7.2"><h4>1.7.2. Health economic evidence statements</h4><p>One cost utility analysis found that self-monitoring with self-titration and telemonitoring was cost effective compared to usual care for monitoring blood pressure (ICER: £1,624 for men and £4,923 for women). This analysis was assessed as directly applicable with potentially serious limitations.</p></div></div><div id="ch2.s1.8"><h3>1.8. The committee’s discussion of the evidence</h3><div id="ch2.s1.8.1"><h4>1.8.1. Interpreting the evidence</h4><div id="ch2.s1.8.1.1"><h5>1.8.1.1. The outcomes that matter most</h5><p>The committee considered all-cause mortality, quality of life, stroke and myocardial infarction as critical outcomes during decision-making. Reduction in clinic blood pressure, proportion controlled to a target, average daily dose of antihypertensive medication, average number of visits, intolerance to device and hypotension were considered important for decision-making. There was no evidence on the outcomes of stroke and intolerance to devices.</p></div><div id="ch2.s1.8.1.2"><h5>1.8.1.2. The quality of the evidence</h5><p>Seven studies were included, with evidence ranging from very low to low quality. The evidence was rated as low or very low quality due to risk of bias, imprecision or population indirectness. Although there is evidence for cardiovascular events, it is noted the studies did not pre-specify this as an outcome, which led to questions of reliability and whether these events were recorded systematically within the studies. The events were reported, as it is good practice; however, they were not validated by checking if hospital records tallied up with notes reviews carried out during the study. Furthermore, it was noted that the mortality events were not entirely accurate as some people were lost to follow up, which may also have included more mortality events. The studies within the evidence were also small and therefore not powered to detect differences in cardiovascular events. These factors suggest that this evidence should be interpreted with caution.</p><p>It was noted that the number of people involved in the included studies and the number of events were relatively small, leading to statistical variation. However, the committee acknowledged that these studies were designed and powered to detect achievement of blood pressure targets, rather than the reduction of cardiovascular events. It was noted that the key aspects to consider were the monitoring endpoints rather than cardiovascular events, as that is what most studies accurately report to demonstrate the accuracy and effects of various monitoring technology.</p></div><div id="ch2.s1.8.1.3"><h5>1.8.1.3. Benefits and harms</h5><p>There was a clinically important benefit of home monitoring with telemonitoring when compared to clinic monitoring for the proportion of people controlled to a target. There was a clinically important benefit of home monitoring with telemonitoring and pharmacist care when compared to clinic monitoring for systolic blood pressure reduction, proportion controlled to a target and quality of life with the physical SF-12 subscale. Home monitoring with telemonitoring and pharmacist care also showed a clinically important benefit when compared to home monitoring with telemonitoring, for mortality, systolic blood pressure reduction and quality of life with the physical SF-12 subscale. In addition, home monitoring with self-titration and telemonitoring showed a clinically important benefit when compared to clinic monitoring (for systolic blood pressure reduction). Finally, pharmacy monitoring showed a clinically important benefit when compared to clinic monitoring (for mortality and reduction in systolic blood pressure). There was a clinically important harm for home monitoring with telemonitoring compared to home monitoring without telemonitoring (dizziness) and home monitoring with telemonitoring compared to clinic monitoring (mortality and cardiovascular events). Due to the low quality of the evidence, the committee agreed it was not robust enough to make a strong recommendation to offer home blood pressure monitoring.</p><p>It was noted that the aim of the interventions was to deliver better blood pressure control to a specified target and to make efficient use of NHS resources. The outcome for average number of visits was included, as it was agreed to be the best indicator for this. Furthermore, it was noted that a reduction in number of visits to the GP would help inform patient choice when choosing which monitor to use, as well as being a relevant outcome for the NHS.</p><p>It was noted that the greatest blood pressure reduction was seen with pharmacist input in monitoring; however, the evidence was not considered strong enough to make a recommendation in favour of pharmacist input.</p><p>The committee agreed the evidence showed no difference between clinic and home monitoring. However, it was also noted that the evidence was not robust (as discussed above). It was noted the person’s choice is important and that some will be more willing and motivated to use home monitoring. It is important that people know they have the option to choose the type of monitoring most suitable and preferred to them. The recommendations from CG127 were carried forward to recommend CPMB but with the option to consider HBMP for those who chose to self-monitor their blood pressure.</p><p>It was discussed that home blood pressure monitoring is routinely used and is widespread practice already, especially for those known to have a white coat effect. The committee agreed that adequate training would have to be in place to ensure it is being measured correctly and the machines are used correctly, perhaps through demonstrations. It was also noted that suitably trained personnel or a robust system would have to be available to deal with any problems arising from use of the machines. Additionally, it was discussed that people with hypertension would receive target instructions and those higher than their target would be able to make an appointment to discuss it further. Therefore, the committee agreed to make a consider recommendation on home monitoring provided the correct training and guidance is given, as it is realistic with the most time being spent at home.</p><p>The committee agreed it could not make a recommendation on telemonitoring, as the evidence was not sufficient to support a clear benefit of this technique. In addition, there were variations in the types of telemonitoring methods within the evidence studied. The committee agreed that this was not a priority area for a research recommendation within the guideline as multiple trials were likely on-going as this is a fast-moving field of research, furthermore any specific trial design recommended was likely to be out-of-date by the time it was performed.</p><p>The 2011 iteration of the guideline included a recommendation for further research for the best method of monitoring hypertension in people with atrial fibrillation. No evidence was identified in the updated reviews to inform recommendations for this group; therefore, the committee agreed that this research recommendation should be retained potentially to inform future updates of the guideline.</p></div></div><div id="ch2.s1.8.2"><h4>1.8.2. Cost effectiveness and resource use</h4><p>One UK economic evaluation was identified that compared home measurement with telemonitoring (self-management including self-titration of medication) versus usual care.</p><p>Ten economic evaluations were excluded due to a combination of limited applicability and methodological limitations, as well as the availability of more applicable evidence.</p><p>The included study was a cost–utility analysis based on a Markov model with 1-year cycles and a 35-year time horizon. People began in a ‘well’ state with poorly controlled hypertension with the possibility of moving to other states of stroke, myocardial infarction, angina, heart failure, and death. Each event state had a post state. Baseline risk was based on the Framingham risk calculator. Treatment effect was based on the 12-month difference in systolic blood pressure from the TASMINH2 trial<a class="bibr" href="#ch2.ref84" rid="ch2.ref84"><sup>84</sup></a> and this was translated into a relative risk reduction using a published meta-analysis.<a class="bibr" href="#ch2.ref72" rid="ch2.ref72"><sup>72</sup></a> Treatment effect was assumed to stay the same after 12 months. There were subgroups by sex. The results showed that self-management was cost effective for both men and women with ICERs below £5,000.</p><p>Probabilistic sensitivity analysis was undertaken as well as various 1-way sensitivity analyses: varying the time horizon and relaxing the assumption that the 12-month treatment effect was extrapolated to a lifetime horizon. This was done by reducing the effectiveness for both men and women at different time points in the model. The only time self-management was not cost effective was when no effectiveness difference between the interventions was assumed for women at year 2, at year 3, and at year 5 in the model. The study was rated as directly applicable because it is a UK study from the NHS perspective; it is a cost–utility analysis and has relevant interventions. The quality was rated as having potentially serious limitations because treatment effect was based on a single trial of only 12 months with the effect extrapolated. Additionally, cardiovascular events were based on a risk equation that was based on blood pressure rather than directly from a trial. This possibly overestimates the treatment effect compared to other sources. The baseline risk calculator used is no longer used in practice and is known to overestimate baseline risk. These 2 factors together imply that the ICERs are possibly overestimating the cost effectiveness of the treatment.</p><p>Different methods of monitoring are associated with different costs and resource use. Ambulatory monitoring involves having to purchase the expensive machine and staff being trained to use it so that they can train people who need the device as well as interpret the results that are sent automatically to the surgery. As monitoring is ongoing, unlike diagnosis, then there is a resource impact to monitoring using ambulatory measurement because many more machines will be needed, as only 1 person at a time can use a machine. Home measurement also involves equipment being available for people who need the devices to borrow although machines are not as expensive as ambulatory machines. Again, because of the volume with which machines would be loaned for monitoring, more machines would be needed at GP surgeries. The method of managing the person’s treatment based on the home measurement will also have variable resource use involved; for example, the person could be taught to self-titrate, or there is a telemonitoring component whereby the clinician still oversees medication changes via phone discussion or is alerted to the person’s measurement results electronically somehow and contacts the person. Some of these methods may require infrastructure set up for results to be automatically sent to the clinician and involve training for staff as well as people who will use the devices. The final method is clinic measurement. This is perhaps the most staff-intensive method of monitoring because the person is required to attend a clinic and have a blood pressure measurement taken whenever blood pressure needs to be checked, such as annually. Given the high prevalence of hypertension, a lot of GP and nurse time is occupied with blood pressure monitoring. The main costs involved are therefore the cost of monitors needed, and the cost of staff time consulting with people or checking their blood pressure.</p><p>The goal of monitoring blood pressure is to capture changes in blood pressure accurately that require treatment changes in order to avoid cardiovascular events. Additionally, efficiency is important if ways to monitor can be found that reduce the use of staff time. The different measurement methods themselves also have different accuracies, so this may impact whether someone is correctly identified as having their blood pressure controlled or not.</p><p>The clinical review identified many different monitoring methods for comparison. The outcome data for cardiovascular events had to be interpreted with caution because the studies were not powered to identify these endpoints. For home monitoring versus clinic monitoring, there was some reduction in systolic blood pressure that favoured home monitoring and also a slightly lower number of consultations in the home monitoring arm. For home monitoring with telemonitoring versus clinic, there was also felt to be a clinically beneficial reduction in systolic blood pressure favouring the home monitoring group. The biggest changes in blood pressure were seen when pharmacist involvement was also added to home monitoring. This was, however, considered to be a very intensive intervention involving around 11 sessions of 30 minutes with a pharmacist over the period of the trial, which would have large cost implications; the committee considered this unfeasible in practice. There was not felt to be any benefit of telemonitoring when compared directly to no telemonitoring.</p><p>For the resource use outcomes of average daily dose or number of medications, it was difficult to interpret these outcomes because more pills might also be a positive outcome if they are needed to manage blood pressure.</p><p>The study that the included economic evaluation was based on was an intervention that might be considered more intensive on the spectrum of home monitoring because people were also managing their own medication and therefore received some education as well. This might explain why this study showed a bigger impact on blood pressure reduction than some of the other studies in the review. The individual patient data meta-analysis (IPD) included in the review also showed that there was a positive correlation between the magnitude of the blood pressure decrease and intensity of the intervention. This might be explained because people feel more empowered if they are more in control of their own care and thus perhaps more likely to adhere to treatment. Although the economic evaluation showed that this intervention was cost effective, because it is self-management as a strategy rather than just home monitoring, it is not fully applicable in supporting a recommendation on home monitoring.</p><p>The committee felt that overall there was some evidence that home monitoring has a positive impact on surrogate outcomes of blood pressure and on some resource use outcomes, which led to them making a consider recommendation for home blood pressure monitoring, if the person prefers. It was not thought possible to be more detailed on the type of home monitoring, and this was left open.</p><p>Given this is a consider recommendation, the resource impact is uncertain; however, where it would be implemented if it isn’t already, this would involve some staff training, patient education, and investment in devices. Currently, around 30–40% of people have their own home monitors although not all these people would use them for monitoring. It was also discussed that around half of GP surgeries have the ability to loan home monitors.</p></div></div></div><div id="ch2.rl.r1"><h2 id="_ch2_rl_r1_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="ch2.ref1">Abdoh
|
|
AA, Krousel-Wood
|
|
MA, Re
|
|
RN. Accuracy of telemedicine in detecting uncontrolled hypertension and its impact on patient management. Telemedicine Journal and e-Health. 2003; 9(4):315–323 [<a href="https://pubmed.ncbi.nlm.nih.gov/14980088" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14980088</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="ch2.ref2">Aekplakorn
|
|
W, Suriyawongpaisal
|
|
P, Tansirisithikul
|
|
R, Sakulpipat
|
|
T, Charoensuk
|
|
P. Effectiveness of self-monitoring blood pressure in primary care: A randomized controlled trial. Journal of Primary Care & Community Health. 2016; 7(2):58–64 [<a href="/pmc/articles/PMC5932709/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5932709</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26574566" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26574566</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="ch2.ref3">Albasri
|
|
A, O’Sullivan
|
|
JW, Roberts
|
|
NW, Prinjha
|
|
S, McManus
|
|
RJ, Sheppard
|
|
JP. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: Systematic review and meta-analysis. Journal of Hypertension. 2017; 35(10):1919–1928 [<a href="/pmc/articles/PMC5585128/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5585128</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28594707" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28594707</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="ch2.ref4">Anderegg
|
|
MD, Gums
|
|
TH, Uribe
|
|
L, Coffey
|
|
CS, James
|
|
PA, Carter
|
|
BL. Physician-pharmacist collaborative management: Narrowing the socioeconomic blood pressure gap. Hypertension. 2016; 68(5):1314–1320 [<a href="/pmc/articles/PMC5063695/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5063695</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27600181" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27600181</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="ch2.ref5">Anderson
|
|
C, Dadabhai
|
|
S, Damasceno
|
|
A, Dzudie
|
|
A, Islam
|
|
SMS, Kamath
|
|
D
|
|
et al. Home blood pressure management intervention in low- to middle-income countries: Protocol for a mixed methods study. JMIR Research Protocols. 2017; 6(10):e188 [<a href="/pmc/articles/PMC5662792/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5662792</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29038099" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29038099</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="ch2.ref6">Anonymous. Blood pressure less well controlled with home blood pressure monitoring. Evidence-Based Healthcare and Public Health. 2004; 8(5):253–254</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="ch2.ref7">Antonicelli
|
|
R, Partemi
|
|
M, Spazzafumo
|
|
L, Amadio
|
|
L, Paciaroni
|
|
E. Blood pressure self-measurement in the elderly: Differences between automatic and semi-automatic systems. Journal of Human Hypertension. 1995; 9(4):229–31 [<a href="https://pubmed.ncbi.nlm.nih.gov/7595903" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7595903</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="ch2.ref8">Aoki
|
|
Y, Asayama
|
|
K, Ohkubo
|
|
T, Nishimura
|
|
T, Kikuya
|
|
M, Metoki
|
|
H
|
|
et al. Progress report on the HOMED-BP Study: Hypertension objective treatment based on measurement by electrical devices of blood pressure study. Clinical and Experimental Hypertension. 2004; 26(2):119–27 [<a href="https://pubmed.ncbi.nlm.nih.gov/15038622" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15038622</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="ch2.ref9">Artinian
|
|
NT, Flack
|
|
JM, Nordstrom
|
|
CK, Hockman
|
|
EM, Washington
|
|
OG, Jen
|
|
KL
|
|
et al. Effects of nurse-managed telemonitoring on blood pressure at 12-month follow-up among urban African Americans. Nursing Research. 2007; 56(5):312–322 [<a href="https://pubmed.ncbi.nlm.nih.gov/17846552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17846552</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="ch2.ref10">Artinian
|
|
NT, Washington
|
|
OG, Templin
|
|
TN. Effects of home telemonitoring and community-based monitoring on blood pressure control in urban African Americans: A pilot study. Heart and Lung. 2001; 30(3):191–199 [<a href="https://pubmed.ncbi.nlm.nih.gov/11343005" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11343005</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="ch2.ref11">Asayama
|
|
K, Ohkubo
|
|
T, Hanazawa
|
|
T, Watabe
|
|
D, Hosaka
|
|
M, Satoh
|
|
M
|
|
et al. Does antihypertensive drug class affect day-to-day variability of self-measured home blood pressure? The HOMED-BP Study. Journal of the American Heart Association. 2016; 5(3):e002995 [<a href="/pmc/articles/PMC4943272/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4943272</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27009620" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27009620</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="ch2.ref12">Bailey
|
|
B, Carney
|
|
SL, Gillies
|
|
AA, Smith
|
|
AJ. Antihypertensive drug treatment: A comparison of usual care with self blood pressure measurement. Journal of Human Hypertension. 1999; 13(2):147–150 [<a href="https://pubmed.ncbi.nlm.nih.gov/10100064" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10100064</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="ch2.ref13">Bliziotis
|
|
IA, Destounis
|
|
A, Stergiou
|
|
GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: A systematic review and meta-analysis. Journal of Hypertension. 2012; 30(7):1289–99 [<a href="https://pubmed.ncbi.nlm.nih.gov/22499289" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22499289</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="ch2.ref14">Bosworth
|
|
HB, Olsen
|
|
MK, Dudley
|
|
T, Orr
|
|
M, Neary
|
|
A, Harrelson
|
|
M
|
|
et al. The Take Control of Your Blood pressure (TCYB) study: Study design and methodology. Contemporary Clinical Trials. 2007; 28(1):33–47 [<a href="https://pubmed.ncbi.nlm.nih.gov/16996808" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16996808</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="ch2.ref15">Bosworth
|
|
HB, Olsen
|
|
MK, Grubber
|
|
JM, Neary
|
|
AM, Orr
|
|
MM, Powers
|
|
BJ
|
|
et al. Two self-management interventions to improve hypertension control: A randomized trial. Annals of Internal Medicine. 2009; 151(10):687–95 [<a href="/pmc/articles/PMC2892337/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2892337</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19920269" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19920269</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="ch2.ref16">Bosworth
|
|
HB, Powers
|
|
BJ, Olsen
|
|
MK, McCant
|
|
F, Grubber
|
|
J, Smith
|
|
V
|
|
et al. Home blood pressure management and improved blood pressure control: Results from a randomized controlled trial. Archives of Internal Medicine. 2011; 171(13):1173–1180 [<a href="https://pubmed.ncbi.nlm.nih.gov/21747013" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21747013</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="ch2.ref17">Boubouchairopoulou
|
|
N, Karpettas
|
|
N, Athanasakis
|
|
K, Kollias
|
|
A, Protogerou
|
|
AD, Achimastos
|
|
A
|
|
et al. Cost estimation of hypertension management based on home blood pressure monitoring alone or combined office and ambulatory blood pressure measurements. Journal of the American Society of Hypertension. 2014; 8(10):732–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/25418495" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25418495</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="ch2.ref18">Bray
|
|
EP, Holder
|
|
R, Mant
|
|
J, McManus
|
|
RJ. Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Annals of Medicine. 2010; 42(5):371–86 [<a href="https://pubmed.ncbi.nlm.nih.gov/20504241" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20504241</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="ch2.ref19">Bray
|
|
EP, Jones
|
|
MI, Banting
|
|
M, Greenfield
|
|
S, Hobbs
|
|
FD, Little
|
|
P
|
|
et al. Performance and persistence of a blood pressure self-management intervention: Telemonitoring and self-management in hypertension (TASMINH2) trial. Journal of Human Hypertension. 2015; 29(7):436–441 [<a href="https://pubmed.ncbi.nlm.nih.gov/25566874" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25566874</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="ch2.ref20">Breaux-Shropshire
|
|
TL, Judd
|
|
E, Vucovich
|
|
LA, Shropshire
|
|
TS, Singh
|
|
S. Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes. Integrated Blood Pressure Control. 2015; 8:43–49 [<a href="/pmc/articles/PMC4498728/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4498728</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26170715" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26170715</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="ch2.ref21">Brzozowska-Kiszka
|
|
M, Rajzer
|
|
M, Klocek
|
|
M, Kawecka-Jaszcz
|
|
K. Efficacy of home blood pressure telemonitoring in treatment of patients with essential hypertension. Nadcisnienie Tetnicze. 2010; 14(2):109–119</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="ch2.ref22">Carnahan
|
|
JE, Nugent
|
|
CA. The effects of self-monitoring by patients on the control of hypertension. American Journal of the Medical Sciences. 1975; 269(1):69–73 [<a href="https://pubmed.ncbi.nlm.nih.gov/1130437" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1130437</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="ch2.ref23">Carter
|
|
BL. Improving blood pressure control with physician/pharmacist collaboration. Vnitrni Lekarstvi. 2009; 55(4):389–394 [<a href="https://pubmed.ncbi.nlm.nih.gov/19449756" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19449756</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="ch2.ref24">Carter
|
|
BL, Ardery
|
|
G, Dawson
|
|
JD, James
|
|
PA, Bergus
|
|
GR, Doucette
|
|
WR
|
|
et al. Physician and pharmacist collaboration to improve blood pressure control. Archives of Internal Medicine. 2009; 169(21):1996–2002 [<a href="/pmc/articles/PMC2882170/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2882170</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19933962" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19933962</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="ch2.ref25">Carter
|
|
BL, Bergus
|
|
GR, Dawson
|
|
JD, Farris
|
|
KB, Doucette
|
|
WR, Chrischilles
|
|
EA
|
|
et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. Journal of Clinical Hypertension. 2008; 10(4):260–271 [<a href="/pmc/articles/PMC2453045/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2453045</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18401223" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18401223</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="ch2.ref26">Castro
|
|
MS, Fuchs
|
|
FD, Santos
|
|
MC, Maximiliano
|
|
P, Gus
|
|
M, Moreira
|
|
LB
|
|
et al. Pharmaceutical care program for patients with uncontrolled hypertension. Report of a double-blind clinical trial with ambulatory blood pressure monitoring. American Journal of Hypertension. 2006; 19(5):528–533 [<a href="https://pubmed.ncbi.nlm.nih.gov/16647628" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16647628</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="ch2.ref27">Celis
|
|
H, Den Hond
|
|
E, Staessen
|
|
JA. Self-measurement of blood pressure at home in the management of hypertension. Clinical Medicine & Research. 2005; 3(1):19–26 [<a href="/pmc/articles/PMC1142103/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1142103</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15962017" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15962017</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>28.</dt><dd><div class="bk_ref" id="ch2.ref28">Chabot
|
|
I, Moisan
|
|
J, Gregoire
|
|
JP, Milot
|
|
A. Pharmacist intervention program for control of hypertension. Annals of Pharmacotherapy. 2003; 37(9):1186–1193 [<a href="https://pubmed.ncbi.nlm.nih.gov/12921497" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12921497</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>29.</dt><dd><div class="bk_ref" id="ch2.ref29">Chambers
|
|
LW, Kaczorowski
|
|
J, O’Rielly
|
|
S, Ignagni
|
|
S, Hearps
|
|
SJ. Comparison of blood pressure measurements using an automated blood pressure device in community pharmacies and family physicians’ offices: A randomized controlled trial. CMAJ Open. 2013; 1(1):E37–42 [<a href="/pmc/articles/PMC3985967/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3985967</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25077100" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25077100</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>30.</dt><dd><div class="bk_ref" id="ch2.ref30">Chatellier
|
|
G, Dutrey-Dupagne
|
|
C, Vaur
|
|
L, Zannad
|
|
F, Genes
|
|
N, Elkik
|
|
F
|
|
et al. Home self blood pressure measurement in general practice: The SMART study. American Journal of Hypertension. 1996; 9(7):644–652 [<a href="https://pubmed.ncbi.nlm.nih.gov/8806976" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8806976</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>31.</dt><dd><div class="bk_ref" id="ch2.ref31">Chen
|
|
Z, Ernst
|
|
ME, Ardery
|
|
G, Xu
|
|
Y, Carter
|
|
BL. Physician-pharmacist co-management and 24-hour blood pressure control. Journal of Clinical Hypertension. 2013; 15(5):337–343 [<a href="/pmc/articles/PMC3641686/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3641686</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23614849" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23614849</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>32.</dt><dd><div class="bk_ref" id="ch2.ref32">Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009]. Higgins J, Green S. The Cochrane Collaboration. 2009. Available from: <a href="http://www.cochrane-handbook.org" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">www<wbr style="display:inline-block"></wbr>​.cochrane-handbook.org</a></div></dd></dl><dl class="bkr_refwrap"><dt>33.</dt><dd><div class="bk_ref" id="ch2.ref33">Conen
|
|
D, Tschudi
|
|
P, Martina
|
|
B. Twenty-four hour ambulatory blood pressure for the management of antihypertensive treatment: a randomized controlled trial. Journal of Human Hypertension. 2009; 23(2):122–129 [<a href="https://pubmed.ncbi.nlm.nih.gov/18754021" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18754021</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>34.</dt><dd><div class="bk_ref" id="ch2.ref34">Curtis
|
|
L. Unit costs of health and social care 2014. Canterbury. Personal Social Services Research Unit University of Kent, 2014. Available from: <a href="http://www.pssru.ac.uk/project-pages/unit-costs/2014/index.php" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.pssru.ac.uk<wbr style="display:inline-block"></wbr>​/project-pages/unit-costs/2014/index<wbr style="display:inline-block"></wbr>​.php</a></div></dd></dl><dl class="bkr_refwrap"><dt>35.</dt><dd><div class="bk_ref" id="ch2.ref35">Curtis
|
|
L, Burns
|
|
A. Unit costs of health and social care 2017. Canterbury. Personal Social Services Research Unit University of Kent, 2017. Available from: <a href="https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2017/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.pssru.ac<wbr style="display:inline-block"></wbr>​.uk/project-pages/unit-costs<wbr style="display:inline-block"></wbr>​/unit-costs-2017/</a></div></dd></dl><dl class="bkr_refwrap"><dt>36.</dt><dd><div class="bk_ref" id="ch2.ref36">Curtis
|
|
L, Burns
|
|
A. Unit costs of health and social care 2018. University of Kent, Canterbury. Personal Social Services Research Unit, 2018. Available from: <a href="https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2018/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.pssru.ac<wbr style="display:inline-block"></wbr>​.uk/project-pages/unit-costs<wbr style="display:inline-block"></wbr>​/unit-costs-2018/</a></div></dd></dl><dl class="bkr_refwrap"><dt>37.</dt><dd><div class="bk_ref" id="ch2.ref37">Dalfó i Baqué
|
|
A, Capillas Peréz
|
|
R, Guarch Rocarias
|
|
M, Figueras Sabater
|
|
M, Ylla-Català Passola
|
|
A, Balañá Vilanova
|
|
M
|
|
et al. Effectiveness of self-measurement of blood pressure in patients with hypertension: The Dioampa study. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria. 2005; 35(5):233–237 [<a href="/pmc/articles/PMC7684340/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7684340</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15802109" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15802109</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>38.</dt><dd><div class="bk_ref" id="ch2.ref38">Davidson
|
|
TM, McGillicuddy
|
|
J, Mueller
|
|
M, Brunner-Jackson
|
|
B, Favella
|
|
A, Anderson
|
|
A
|
|
et al. Evaluation of an mHealth medication regimen self-management program for African American and Hispanic uncontrolled hypertensives. Journal of personalized medicine. 2015; 5(4):389–405 [<a href="/pmc/articles/PMC4695862/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4695862</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26593951" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26593951</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>39.</dt><dd><div class="bk_ref" id="ch2.ref39">Dean
|
|
SC, Kerry
|
|
SM, Khong
|
|
TK, Kerry
|
|
SR, Oakeshott
|
|
P. Evaluation of a specialist nurse-led hypertension clinic with consultant backup in two inner city general practices: Randomized controlled trial. Family Practice. 2014; 31(2):172–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/24356073" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24356073</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>40.</dt><dd><div class="bk_ref" id="ch2.ref40">Doane
|
|
J, Buu
|
|
J, Jason Penrod
|
|
M, Bischoff
|
|
M, Conroy
|
|
MB, Stults
|
|
B. Measuring and managing blood pressure in a primary care setting: A pragmatic implementation study. The Journal of the American Board of Family Practice / American Board of Family Practice. 2018; 31(3):375–388 [<a href="https://pubmed.ncbi.nlm.nih.gov/29743221" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29743221</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>41.</dt><dd><div class="bk_ref" id="ch2.ref41">Duan
|
|
Y, Xie
|
|
Z, Dong
|
|
F, Wu
|
|
Z, Lin
|
|
Z, Sun
|
|
N
|
|
et al. Effectiveness of home blood pressure telemonitoring: A systematic review and meta-analysis of randomised controlled studies. Journal of Human Hypertension. 2017; 31(7):427–437 [<a href="https://pubmed.ncbi.nlm.nih.gov/28332506" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28332506</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>42.</dt><dd><div class="bk_ref" id="ch2.ref42">Earle
|
|
KA, Istepanian
|
|
RS, Zitouni
|
|
K, Sungoor
|
|
A, Tang
|
|
B. Mobile telemonitoring for achieving tighter targets of blood pressure control in patients with complicated diabetes: A pilot study. Diabetes Technology & Therapeutics. 2010; 12(7):575–579 [<a href="https://pubmed.ncbi.nlm.nih.gov/20597833" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20597833</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>43.</dt><dd><div class="bk_ref" id="ch2.ref43">Earle
|
|
KA, Taylor
|
|
P, Wyatt
|
|
S, Burnett
|
|
S, Ray
|
|
J. A physician-pharmacist model for the surveillance of blood pressure in the community: A feasibility study. Journal of Human Hypertension. 2001; 15(8):529–33 [<a href="https://pubmed.ncbi.nlm.nih.gov/11494090" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11494090</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>44.</dt><dd><div class="bk_ref" id="ch2.ref44">Fikri-Benbrahim
|
|
N, Faus
|
|
MJ, Martínez-Martínez
|
|
F, Sabater-Hernández
|
|
D. Impact of a community pharmacists’ hypertension-care service on medication adherence. The AFenPA study. Research in Social and Administrative Pharmacy. 2013; 9(6):797–805 [<a href="https://pubmed.ncbi.nlm.nih.gov/23391845" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23391845</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>45.</dt><dd><div class="bk_ref" id="ch2.ref45">Franssen
|
|
M, Farmer
|
|
A, Grant
|
|
S, Greenfield
|
|
S, Heneghan
|
|
C, Hobbs
|
|
R
|
|
et al. Telemonitoring and/or self-monitoring of blood pressure in hypertension (TASMINH4): Protocol for a randomised controlled trial. BMC Cardiovascular Disorders. 2017; 17:58 [<a href="/pmc/articles/PMC5307789/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5307789</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28193176" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28193176</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>46.</dt><dd><div class="bk_ref" id="ch2.ref46">Fuchs
|
|
SC, Mello
|
|
RG, Fuchs
|
|
FC. Home blood pressure monitoring is better predictor of cardiovascular disease and target organ damage than office blood pressure: A systematic review and meta-analysis. Current Cardiology Reports. 2013; 15(11):413 [<a href="https://pubmed.ncbi.nlm.nih.gov/24057836" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24057836</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>47.</dt><dd><div class="bk_ref" id="ch2.ref47">Fujiwara
|
|
T, Nishimura
|
|
T, Ohkuko
|
|
T, Imai
|
|
Y. Rationale and design of HOMED-BP Study: Hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Pressure Monitoring. 2002; 7(1):77–82 [<a href="https://pubmed.ncbi.nlm.nih.gov/12040250" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12040250</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>48.</dt><dd><div class="bk_ref" id="ch2.ref48">George
|
|
J, McNamara
|
|
K, Jackson
|
|
S, Hughes
|
|
J, Peterson
|
|
G, Bailey
|
|
M
|
|
et al. The HAPPY trial: A randomised controlled trial of a community pharmacy-based intervention for improving patient adherence to antihypertensive medicines. International Journal of Pharmacy Practice. 2010; 18:22–23</div></dd></dl><dl class="bkr_refwrap"><dt>49.</dt><dd><div class="bk_ref" id="ch2.ref49">Green
|
|
BB, Cook
|
|
AJ, Ralston
|
|
JD, Fishman
|
|
PA, Catz
|
|
SL, Carlson
|
|
J
|
|
et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: A randomized controlled trial. JAMA. 2008; 299(24):2857–67 [<a href="/pmc/articles/PMC2715866/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2715866</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18577730" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18577730</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>50.</dt><dd><div class="bk_ref" id="ch2.ref50">Halme
|
|
L, Vesalainen
|
|
R, Kaaja
|
|
M, Kantola
|
|
I. Self-monitoring of blood pressure promotes achievement of blood pressure target in primary health care. American Journal of Hypertension. 2005; 18(11):1415–1420 [<a href="https://pubmed.ncbi.nlm.nih.gov/16280273" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16280273</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>51.</dt><dd><div class="bk_ref" id="ch2.ref51">Hansen
|
|
TW, Thijs
|
|
L, Li
|
|
Y, Boggia
|
|
J, Liu
|
|
Y, Asayama
|
|
K
|
|
et al. Ambulatory blood pressure monitoring for risk stratification in obese and non-obese subjects from 10 populations. Journal of Human Hypertension. 2014; 28(9):535–42 [<a href="https://pubmed.ncbi.nlm.nih.gov/24430701" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24430701</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>52.</dt><dd><div class="bk_ref" id="ch2.ref52">He
|
|
J, Irazola
|
|
V, Mills
|
|
KT, Poggio
|
|
R, Beratarrechea
|
|
A, Dolan
|
|
J
|
|
et al. Effect of a community health worker-led multicomponent intervention on blood pressure control in low-income patients in Argentina: A randomized clinical trial. JAMA. 2017; 318(11):1016–1025 [<a href="/pmc/articles/PMC5761321/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5761321</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28975305" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28975305</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>53.</dt><dd><div class="bk_ref" id="ch2.ref53">Hebert
|
|
PL, Sisk
|
|
JE, Tuzzio
|
|
L, Casabianca
|
|
JM, Pogue
|
|
VA, Wang
|
|
JJ
|
|
et al. Nurse-led disease management for hypertension control in a diverse urban community: A randomized trial. Journal of General Internal Medicine. 2012; 27(6):630–639 [<a href="/pmc/articles/PMC3358388/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3358388</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22143452" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22143452</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>54.</dt><dd><div class="bk_ref" id="ch2.ref54">Heinemann
|
|
M, Sellick
|
|
K, Rickard
|
|
C, Reynolds
|
|
P, McGrail
|
|
M. Automated versus manual blood pressure measurement: A randomized crossover trial. International Journal of Nursing Practice. 2008; 14(4):296–302 [<a href="https://pubmed.ncbi.nlm.nih.gov/18715391" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18715391</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>55.</dt><dd><div class="bk_ref" id="ch2.ref55">Hond
|
|
E, Staessen
|
|
JA, Celis
|
|
H, Fagard
|
|
R, Keary
|
|
L, Vandenhoven
|
|
G
|
|
et al. Antihypertensive treatment based on home or office blood pressure: The THOP trial. Blood Pressure Monitoring. 2004; 9(6):311–314 [<a href="https://pubmed.ncbi.nlm.nih.gov/15564986" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15564986</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>56.</dt><dd><div class="bk_ref" id="ch2.ref56">Hosseininasab
|
|
M, Jahangard-Rafsanjani
|
|
Z, Mohagheghi
|
|
A, Sarayani
|
|
A, Rashidian
|
|
A, Javadi
|
|
M
|
|
et al. Self-monitoring of blood pressure for improving adherence to antihypertensive medicines and blood pressure control: A randomized controlled trial. American Journal of Hypertension. 2014; 27(11):1339–1345 [<a href="/pmc/articles/PMC4263942/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4263942</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24771706" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24771706</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>57.</dt><dd><div class="bk_ref" id="ch2.ref57">Hunt
|
|
JS, Siemienczuk
|
|
J, Pape
|
|
G, Rozenfeld
|
|
Y, MacKay
|
|
J, LeBlanc
|
|
BH
|
|
et al. A randomized controlled trial of team-based care: Impact of physician-pharmacist collaboration on uncontrolled hypertension. Journal of General Internal Medicine. 2008; 23(12):1966–1972 [<a href="/pmc/articles/PMC2596500/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2596500</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18815843" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18815843</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>58.</dt><dd><div class="bk_ref" id="ch2.ref58">Irving
|
|
G, Holden
|
|
J, Stevens
|
|
R, McManus
|
|
RJ. Which cuff should I use? Indirect blood pressure measurement for the diagnosis of hypertension in patients with obesity: A diagnostic accuracy review. BMJ Open. 2016; 6(11):e012429 [<a href="/pmc/articles/PMC5129068/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5129068</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27810973" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27810973</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>59.</dt><dd><div class="bk_ref" id="ch2.ref59">Ishikawa
|
|
J, Carroll
|
|
DJ, Kuruvilla
|
|
S, Schwartz
|
|
JE, Pickering
|
|
TG. Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis. Hypertension. 2008; 52(5):856–64 [<a href="/pmc/articles/PMC4593654/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4593654</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18809791" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18809791</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>60.</dt><dd><div class="bk_ref" id="ch2.ref60">Jegatheswaran
|
|
J, Ruzicka
|
|
M, Hiremath
|
|
S, Edwards
|
|
C. Are automated blood pressure monitors comparable to ambulatory blood pressure monitors? A systematic review and meta-analysis. Canadian Journal of Cardiology. 2017; 33(5):644–652 [<a href="https://pubmed.ncbi.nlm.nih.gov/28449834" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28449834</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>61.</dt><dd><div class="bk_ref" id="ch2.ref61">Jones
|
|
MI, Greenfield
|
|
SM, Bray
|
|
EP, Hobbs
|
|
FR, Holder
|
|
R, Little
|
|
P
|
|
et al. Patient self-monitoring of blood pressure and self-titration of medication in primary care: The TASMINH2 trial qualitative study of health professionals’ experiences. British Journal of General Practice. 2013; 63(611):e378–85 [<a href="/pmc/articles/PMC3662454/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3662454</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23735408" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23735408</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>62.</dt><dd><div class="bk_ref" id="ch2.ref62">Kaambwa
|
|
B, Bryan
|
|
S, Jowett
|
|
S, Mant
|
|
J, Bray
|
|
EP, Hobbs
|
|
FD
|
|
et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): A cost-effectiveness analysis. European Journal of Preventive Cardiology. 2014; 21(12):1517–30 [<a href="https://pubmed.ncbi.nlm.nih.gov/23990660" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23990660</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>63.</dt><dd><div class="bk_ref" id="ch2.ref63">Kaambwa
|
|
B, Bryan
|
|
S, Mant
|
|
J, Bray
|
|
EP, Holder
|
|
R, Jones
|
|
M. Randomised controlled trial of telemonitoring and self management in the control of hypertension: Telemonitoring and self management in hypertension (TASMINH2): Economic analysis. Journal of Hypertension. 2010; 28(e-Suppl A):e281–2 [<a href="https://pubmed.ncbi.nlm.nih.gov/20619448" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20619448</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>64.</dt><dd><div class="bk_ref" id="ch2.ref64">Kaihara
|
|
T, Eguchi
|
|
K, Kario
|
|
K. Home BP monitoring using a telemonitoring system is effective for controlling BP in a remote island in Japan. Journal of Clinical Hypertension. 2014; 16(11):814–819 [<a href="/pmc/articles/PMC8031829/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8031829</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25267008" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25267008</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>65.</dt><dd><div class="bk_ref" id="ch2.ref65">Kawano
|
|
Y, Horio
|
|
T, Kamide
|
|
K, Iwashima
|
|
Y, Yoshihara
|
|
F, Nakamura
|
|
S. Blood pressure and medication during long-term antihypertensive therapy based on morning home SBP in hypertensive patients: Hypertension Control Based on Home Systolic Pressure (HOSP) substudy. Clinical and Experimental Hypertension. 2010; 32(4):239–243 [<a href="https://pubmed.ncbi.nlm.nih.gov/20608895" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20608895</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>66.</dt><dd><div class="bk_ref" id="ch2.ref66">Kerby
|
|
TJ, Asche
|
|
SE, Maciosek
|
|
MV, O’Connor
|
|
PJ, Sperl-Hillen
|
|
JM, Margolis
|
|
KL. Adherence to blood pressure telemonitoring in a cluster-randomized clinical trial. Journal of Clinical Hypertension. 2012; 14(10):668–674 [<a href="/pmc/articles/PMC3464948/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3464948</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23031143" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23031143</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>67.</dt><dd><div class="bk_ref" id="ch2.ref67">Kerry
|
|
SM, Markus
|
|
HS, Khong
|
|
TK, Cloud
|
|
GC, Tulloch
|
|
J, Coster
|
|
D
|
|
et al. Home blood pressure monitoring with nurse-led telephone support among patients with hypertension and a history of stroke: A community-based randomized controlled trial. CMAJ : Canadian Medical Association journal. 2013; 185(1):23–31 [<a href="/pmc/articles/PMC3537777/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3537777</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23128283" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23128283</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>68.</dt><dd><div class="bk_ref" id="ch2.ref68">Kim
|
|
JY, Wineinger
|
|
NE, Steinhubl
|
|
SR. The influence of wireless self-monitoring program on the relationship between patient activation and health behaviors, medication adherence, and blood pressure levels in hypertensive patients: A substudy of a randomized controlled trial. Journal of Medical Internet Research. 2016; 18(6):e116 [<a href="/pmc/articles/PMC4935792/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4935792</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27334418" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27334418</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>69.</dt><dd><div class="bk_ref" id="ch2.ref69">Kim
|
|
YN, Shin
|
|
DG, Park
|
|
S, Lee
|
|
CH. Randomized clinical trial to assess the effectiveness of remote patient monitoring and physician care in reducing office blood pressure. Hypertension Research. 2015; 38(7):491–497 [<a href="https://pubmed.ncbi.nlm.nih.gov/25787041" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25787041</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>70.</dt><dd><div class="bk_ref" id="ch2.ref70">Kind
|
|
P, Dolan
|
|
P, Gudex
|
|
C, Williams
|
|
A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998; 316(7133):736–741 [<a href="/pmc/articles/PMC28477/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC28477</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9529408" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9529408</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>71.</dt><dd><div class="bk_ref" id="ch2.ref71">Kushiro
|
|
T, Kario
|
|
K, Saito
|
|
I, Teramukai
|
|
S, Sato
|
|
Y, Okuda
|
|
Y
|
|
et al. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: The HONEST Study. Hypertension Research. 2017; 40(1):87–95 [<a href="/pmc/articles/PMC5222992/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5222992</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27511054" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27511054</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>72.</dt><dd><div class="bk_ref" id="ch2.ref72">Law
|
|
MR, Morris
|
|
JK, Wald
|
|
NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338:b1665 [<a href="/pmc/articles/PMC2684577/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2684577</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19454737" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19454737</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>73.</dt><dd><div class="bk_ref" id="ch2.ref73">Logan
|
|
AG, Irvine
|
|
MJ, McIsaac
|
|
WJ, Tisler
|
|
A, Rossos
|
|
PG, Easty
|
|
A
|
|
et al. Effect of home blood pressure telemonitoring with self-care support on uncontrolled systolic hypertension in diabetics. Hypertension. 2012; 60(1):51–57 [<a href="https://pubmed.ncbi.nlm.nih.gov/22615116" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22615116</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>74.</dt><dd><div class="bk_ref" id="ch2.ref74">Lorgelly
|
|
P, Siatis
|
|
I, Brooks
|
|
A, Slinn
|
|
B, Millar-Craig
|
|
MW, Donnelly
|
|
R
|
|
et al. Is ambulatory blood pressure monitoring cost-effective in the routine surveillance of treated hypertensive patients in primary care?
|
|
British Journal of General Practice. 2003; 53(495):794–6 [<a href="/pmc/articles/PMC1314713/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1314713</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14601356" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14601356</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>75.</dt><dd><div class="bk_ref" id="ch2.ref75">Maciejewski
|
|
ML, Bosworth
|
|
HB, Olsen
|
|
MK, Smith
|
|
VA, Edelman
|
|
D, Powers
|
|
BJ
|
|
et al. Do the benefits of participation in a hypertension self-management trial persist after patients resume usual care?
|
|
Circulation: Cardiovascular Quality and Outcomes. 2014; 7(2):269–275 [<a href="https://pubmed.ncbi.nlm.nih.gov/24619321" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24619321</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>76.</dt><dd><div class="bk_ref" id="ch2.ref76">Madsen
|
|
LB, Christiansen
|
|
T, Kirkegaard
|
|
P, Pedersen
|
|
EB. Economic evaluation of home blood pressure telemonitoring: A randomized controlled trial. Blood Pressure. 2011; 20(2):117–125 [<a href="https://pubmed.ncbi.nlm.nih.gov/21105759" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21105759</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>77.</dt><dd><div class="bk_ref" id="ch2.ref77">Madsen
|
|
LB, Kirkegaard
|
|
P, Pedersen
|
|
EB. Health-related quality of life (SF-36) during telemonitoring of home blood pressure in hypertensive patients: A randomized, controlled study. Blood Pressure. 2008; 17(4):227–232 [<a href="https://pubmed.ncbi.nlm.nih.gov/18815937" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18815937</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>78.</dt><dd><div class="bk_ref" id="ch2.ref78">Magid
|
|
DJ, Olson
|
|
KL, Billups
|
|
SJ, Wagner
|
|
NM, Lyons
|
|
EE, Kroner
|
|
BA. A pharmacist-led, American Heart Association Heart360 Web-enabled home blood pressure monitoring program. Circulation: Cardiovascular Quality and Outcomes. 2013; 6(2):157–163 [<a href="https://pubmed.ncbi.nlm.nih.gov/23463811" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23463811</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>79.</dt><dd><div class="bk_ref" id="ch2.ref79">Margolis
|
|
KL, Asche
|
|
SE, Bergdall
|
|
AR, Dehmer
|
|
SP, Groen
|
|
SE, Kadrmas
|
|
HM
|
|
et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: A cluster randomized clinical trial. JAMA. 2013; 310(1):46–56 [<a href="/pmc/articles/PMC4311883/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4311883</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23821088" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23821088</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>80.</dt><dd><div class="bk_ref" id="ch2.ref80">Margolis
|
|
KL, Kerby
|
|
TJ, Asche
|
|
SE, MacIosek
|
|
MV, Meyers
|
|
PJ, Sperl-Hillen
|
|
JM
|
|
et al. Home blood pressure telemonitoring and case management to control hypertension: Hyperlink design, baseline characteristics, and intervention adherence. Journal of Clinical Hypertension. 2010; 12:(Suppl 1):A81–A2</div></dd></dl><dl class="bkr_refwrap"><dt>81.</dt><dd><div class="bk_ref" id="ch2.ref81">Martinez
|
|
MA, Garcia-Puig
|
|
J, Loeches
|
|
MP, Mateo
|
|
MC, Utiel
|
|
I, Torres
|
|
R
|
|
et al. Home blood pressure vs. clinic blood pressure measurement-based follow up in type II diabetics: Effect on 24-h ambulatory BP and albuminuria. Randomised trial. Medicina Clínica. 2017; 150(11):413–20 [<a href="https://pubmed.ncbi.nlm.nih.gov/28867335" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28867335</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>82.</dt><dd><div class="bk_ref" id="ch2.ref82">McKinstry
|
|
B, Hanley
|
|
J, Wild
|
|
S, Pagliari
|
|
C, Paterson
|
|
M, Lewis
|
|
S
|
|
et al. Telemonitoring based service redesign for the management of uncontrolled hypertension: Multicentre randomised controlled trial. BMJ. 2013; 346:f3030 [<a href="/pmc/articles/PMC3663293/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3663293</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23709583" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23709583</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>83.</dt><dd><div class="bk_ref" id="ch2.ref83">McManus
|
|
RJ, Bray
|
|
EP, Mant
|
|
J, Holder
|
|
R, Greenfield
|
|
S, Bryan
|
|
S
|
|
et al. Protocol for a randomised controlled trial of telemonitoring and self-management in the control of hypertension: Telemonitoring and self-management in hypertension. BMC Cardiovascular Disorders. 2009; 9:6 [<a href="/pmc/articles/PMC2664788/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2664788</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19220913" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19220913</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>84.</dt><dd><div class="bk_ref" id="ch2.ref84">McManus
|
|
RJ, Mant
|
|
J, Bray
|
|
EP, Holder
|
|
R, Jones
|
|
MI, Greenfield
|
|
S
|
|
et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): A randomised controlled trial. The Lancet. 2010; 376(9736):163–172 [<a href="https://pubmed.ncbi.nlm.nih.gov/20619448" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20619448</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>85.</dt><dd><div class="bk_ref" id="ch2.ref85">McManus
|
|
RJ, Mant
|
|
J, Franssen
|
|
M, Nickless
|
|
A, Schwartz
|
|
C, Hodgkinson
|
|
J
|
|
et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. The Lancet. 2018; 391(10124):949–59 [<a href="/pmc/articles/PMC5854463/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5854463</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29499873" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29499873</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>86.</dt><dd><div class="bk_ref" id="ch2.ref86">McManus
|
|
RJ, Mant
|
|
J, Haque
|
|
MS, Bray
|
|
EP, Bryan
|
|
S, Greenfield
|
|
SM
|
|
et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: The TASMIN-SR randomized clinical trial. JAMA. 2014; 312(8):799–808 [<a href="https://pubmed.ncbi.nlm.nih.gov/25157723" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25157723</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>87.</dt><dd><div class="bk_ref" id="ch2.ref87">McManus
|
|
RJ, Mant
|
|
J, Roalfe
|
|
A, Oakes
|
|
RA, Bryan
|
|
S, Pattison
|
|
HM
|
|
et al. Targets and self monitoring in hypertension: Randomised controlled trial and cost effectiveness analysis. BMJ. 2005; 331(7515):493–496 [<a href="/pmc/articles/PMC1199029/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1199029</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16115830" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16115830</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>88.</dt><dd><div class="bk_ref" id="ch2.ref88">Myers
|
|
MG, Godwin
|
|
M, Dawes
|
|
M, Kiss
|
|
A, Tobe
|
|
SW, Kaczorowski
|
|
J. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Family Practice. 2012; 29(4):376–382 [<a href="https://pubmed.ncbi.nlm.nih.gov/22117083" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22117083</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>89.</dt><dd><div class="bk_ref" id="ch2.ref89">Myers
|
|
MG, Godwin
|
|
M, Dawes
|
|
M, Kiss
|
|
A, Tobe
|
|
SW, Kaczorowski
|
|
J. The conventional versus automated measurement of blood pressure in the office (CAMBO) trial: Masked hypertension sub-study. Journal of Hypertension. 2012; 30(10):1937–1941 [<a href="https://pubmed.ncbi.nlm.nih.gov/22828087" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22828087</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>90.</dt><dd><div class="bk_ref" id="ch2.ref90">Nakao
|
|
N, Seno
|
|
H, Kasuga
|
|
H, Toriyama
|
|
T, Kawahara
|
|
H, Fukagawa
|
|
M. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP substudy. American Journal of Nephrology. 2004; 24(5):543–548 [<a href="https://pubmed.ncbi.nlm.nih.gov/15528874" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15528874</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>91.</dt><dd><div class="bk_ref" id="ch2.ref91">National Collaborating Centre for Primary Care. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline 67. London. Royal College of General Practitioners, 2008. Available from: <a href="http://guidance.nice.org.uk/CG67" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://guidance<wbr style="display:inline-block"></wbr>​.nice.org.uk/CG67</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/21834195" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21834195</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>92.</dt><dd><div class="bk_ref" id="ch2.ref92">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/26677490" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26677490</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>93.</dt><dd><div class="bk_ref" id="ch2.ref93">NHS Supply Chain Catalogue. NHS Supply Chain, 2014. Available from: <a href="http://www.supplychain.nhs.uk/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.supplychain.nhs.uk/</a></div></dd></dl><dl class="bkr_refwrap"><dt>94.</dt><dd><div class="bk_ref" id="ch2.ref94">Niiranen
|
|
TJ, Hanninen
|
|
MR, Johansson
|
|
J, Reunanen
|
|
A, Jula
|
|
AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: The Finn-Home study. Hypertension. 2010; 55(6):1346–51 [<a href="https://pubmed.ncbi.nlm.nih.gov/20385970" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20385970</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>95.</dt><dd><div class="bk_ref" id="ch2.ref95">Niiranen
|
|
TJ, Kantola
|
|
IM, Vesalainen
|
|
R, Johansson
|
|
J, Ruuska
|
|
MJ. A comparison of home measurement and ambulatory monitoring of blood pressure in the adjustment of antihypertensive treatment. American Journal of Hypertension. 2006; 19(5):468–474 [<a href="https://pubmed.ncbi.nlm.nih.gov/16647616" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16647616</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>96.</dt><dd><div class="bk_ref" id="ch2.ref96">O’Brien
|
|
C, Bray
|
|
EP, Bryan
|
|
S, Greenfield
|
|
SM, Haque
|
|
MS, Hobbs
|
|
FD
|
|
et al. Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): Protocol for a randomised controlled trial. BMC Cardiovascular Disorders. 2013; 13:21 [<a href="/pmc/articles/PMC3623796/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3623796</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23522245" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23522245</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>97.</dt><dd><div class="bk_ref" id="ch2.ref97">O’Brien
|
|
E, Mee
|
|
F, Atkins
|
|
N, Thomas
|
|
M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: The Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Pressure Monitoring. 1996; 1(1):55–61 [<a href="https://pubmed.ncbi.nlm.nih.gov/10226203" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10226203</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>98.</dt><dd><div class="bk_ref" id="ch2.ref98">Ogedegbe
|
|
G, Chaplin
|
|
W. A randomized controlled trial of the effect of home blood pressure monitoring versus usual care on medication adherence in ambulatory hypertensive patients. Journal of General Internal Medicine. 2005; 20:(Suppl 1):60</div></dd></dl><dl class="bkr_refwrap"><dt>99.</dt><dd><div class="bk_ref" id="ch2.ref99">Omboni
|
|
S, Ferrari
|
|
R. The role of telemedicine in hypertension management: Focus on blood pressure telemonitoring. Current Hypertension Reports. 2015; 17(4):535 [<a href="https://pubmed.ncbi.nlm.nih.gov/25790799" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25790799</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>100.</dt><dd><div class="bk_ref" id="ch2.ref100">Omboni
|
|
S, Gazzola
|
|
T, Carabelli
|
|
G, Parati
|
|
G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: Meta-analysis of randomized controlled studies. Journal of Hypertension. 2013; 31(3):455–67; discussion 467–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/23299557" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23299557</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>101.</dt><dd><div class="bk_ref" id="ch2.ref101">Omboni
|
|
S, Guarda
|
|
A. Impact of home blood pressure telemonitoring and blood pressure control: A meta-analysis of randomized controlled studies. American Journal of Hypertension. 2011; 24(9):989–98 [<a href="https://pubmed.ncbi.nlm.nih.gov/21654858" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21654858</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>102.</dt><dd><div class="bk_ref" id="ch2.ref102">Onzenoort
|
|
HA, Verberk
|
|
WJ, Kroon
|
|
AA, Kessels
|
|
AG, Neef
|
|
C, Kuy
|
|
PH
|
|
et al. Electronic monitoring of adherence, treatment of hypertension, and blood pressure control. American Journal of Hypertension. 2012; 25(1):54–59 [<a href="https://pubmed.ncbi.nlm.nih.gov/21993365" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21993365</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>103.</dt><dd><div class="bk_ref" id="ch2.ref103">Onzenoort
|
|
HA, Verberk
|
|
WJ, Kroon
|
|
AA, Kessels
|
|
AG, Nelemans
|
|
PJ, Kuy
|
|
PH
|
|
et al. Effect of self-measurement of blood pressure on adherence to treatment in patients with mild-to-moderate hypertension. Journal of Hypertension. 2010; 28(3):622–627 [<a href="https://pubmed.ncbi.nlm.nih.gov/19952780" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19952780</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>104.</dt><dd><div class="bk_ref" id="ch2.ref104">Parati
|
|
G, Omboni
|
|
S, Albini
|
|
F, Piantoni
|
|
L, Giuliano
|
|
A, Revera
|
|
M
|
|
et al. Home blood pressure telemonitoring improves hypertension control in general practice: The TeleBPCare study. Journal of Hypertension. 2009; 27(1):198–203 [<a href="https://pubmed.ncbi.nlm.nih.gov/19145785" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19145785</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>105.</dt><dd><div class="bk_ref" id="ch2.ref105">Parati
|
|
G, Omboni
|
|
S, Compare
|
|
A, Grossi
|
|
E, Callus
|
|
E, Venco
|
|
A
|
|
et al. Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: Protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study). Trials. 2013; 14:22 [<a href="/pmc/articles/PMC3576326/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3576326</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23343138" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23343138</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>106.</dt><dd><div class="bk_ref" id="ch2.ref106">Parati
|
|
G, Omboni
|
|
S, Mancia
|
|
G. Difference between office and ambulatory blood pressure and response to antihypertensive treatment. Journal of Hypertension. 1996; 14(6):791–797 [<a href="https://pubmed.ncbi.nlm.nih.gov/8793703" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8793703</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>107.</dt><dd><div class="bk_ref" id="ch2.ref107">Penaloza-Ramos
|
|
MC, Jowett
|
|
S, Mant
|
|
J, Schwartz
|
|
C, Bray
|
|
EP, Sayeed Haque
|
|
M
|
|
et al. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR). European Journal of Preventive Cardiology. 2016; 23(9):902–12 [<a href="https://pubmed.ncbi.nlm.nih.gov/26603745" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26603745</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>108.</dt><dd><div class="bk_ref" id="ch2.ref108">Piper
|
|
MA, Evans
|
|
CV, Burda
|
|
BU, Margolis
|
|
KL, O’Connor
|
|
E, Whitlock
|
|
EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: A systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2015; 162(3):192–204 [<a href="https://pubmed.ncbi.nlm.nih.gov/25531400" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25531400</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>109.</dt><dd><div class="bk_ref" id="ch2.ref109">Poteshkina
|
|
NG, Beloglazova
|
|
IP, Mogutova
|
|
PA. Blood pressure 24-hour monitoring in assessment of aortic stiffness in older patients with arterial hypertension. Russian Journal of Cardiology. 2015; 120(4):27–31</div></dd></dl><dl class="bkr_refwrap"><dt>110.</dt><dd><div class="bk_ref" id="ch2.ref110">Qi
|
|
L, Qiu
|
|
Y, Zhang
|
|
W. Home blood pressure monitoring is a useful measurement for patients with hypertension: A long-term follow-up study. Biomedical Research (India). 2017; 28(7):2898–2902</div></dd></dl><dl class="bkr_refwrap"><dt>111.</dt><dd><div class="bk_ref" id="ch2.ref111">Ragot
|
|
S, Genes
|
|
N, Vaur
|
|
L, Herpin
|
|
D. Comparison of three blood pressure measurement methods for the evaluation of two antihypertensive drugs: Feasibility, agreement, and reproducibility of blood pressure response. American Journal of Hypertension. 2000; 13(6 Pt 1):632–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/10912746" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10912746</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>112.</dt><dd><div class="bk_ref" id="ch2.ref112">Ralston
|
|
JD, Cook
|
|
AJ, Anderson
|
|
ML, Catz
|
|
SL, Fishman
|
|
PA, Carlson
|
|
J
|
|
et al. Home blood pressure monitoring, secure electronic messaging and medication intensification for improving hypertension control: A mediation analysis. Applied Clinical Informatics. 2014; 5(1):232–48 [<a href="/pmc/articles/PMC3974258/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3974258</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24734136" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24734136</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>113.</dt><dd><div class="bk_ref" id="ch2.ref113">Reboldi
|
|
G, Angeli
|
|
F, Simone
|
|
G, Staessen
|
|
JA, Verdecchia
|
|
P. Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension. 2014; 63(3):475–482 [<a href="https://pubmed.ncbi.nlm.nih.gov/24343119" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24343119</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>114.</dt><dd><div class="bk_ref" id="ch2.ref114">Rifkin
|
|
DE, Abdelmalek
|
|
JA, Miracle
|
|
CM, Low
|
|
C, Barsotti
|
|
R, Rios
|
|
P
|
|
et al. Linking clinic and home: A randomized, controlled clinical effectiveness trial of real-time, wireless blood pressure monitoring for older patients with kidney disease and hypertension. Blood Pressure Monitoring. 2013; 18(1):8–15 [<a href="/pmc/articles/PMC4111271/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4111271</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23275313" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23275313</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>115.</dt><dd><div class="bk_ref" id="ch2.ref115">Rodriguez Roca
|
|
GC, Alonso Moreno
|
|
FJ, Garcia Jimenez
|
|
A, Hidalgo Vega
|
|
A, Llisterri Caro
|
|
JL, Barrios Alonso
|
|
V
|
|
et al. Cost-effectiveness of ambulatory blood pressure monitoring in the follow-up of hypertension. Blood Pressure. 2006; 15(1):27–36 [<a href="https://pubmed.ncbi.nlm.nih.gov/16492613" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16492613</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>116.</dt><dd><div class="bk_ref" id="ch2.ref116">Rogers
|
|
MA, Buchan
|
|
DA, Small
|
|
D, Stewart
|
|
CM, Krenzer
|
|
BE. Telemedicine improves diagnosis of essential hypertension compared with usual care. Journal of Telemedicine and Telecare. 2002; 8(6):344–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/12537922" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12537922</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>117.</dt><dd><div class="bk_ref" id="ch2.ref117">Rogers
|
|
MA, Small
|
|
D, Buchan
|
|
DA, Butch
|
|
CA, Stewart
|
|
CM, Krenzer
|
|
BE
|
|
et al. Home monitoring service improves mean arterial pressure in patients with essential hypertension. A randomized, controlled trial. Annals of Internal Medicine. 2001; 134(11):1024–1032 [<a href="https://pubmed.ncbi.nlm.nih.gov/11388815" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11388815</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>118.</dt><dd><div class="bk_ref" id="ch2.ref118">Santschi
|
|
V, Chiolero
|
|
A, Colosimo
|
|
AL, Platt
|
|
RW, Taffe
|
|
P, Burnier
|
|
M
|
|
et al. Improving blood pressure control through pharmacist interventions: A meta-analysis of randomized controlled trials. Journal of the American Heart Association. 2014; 3:e000718 [<a href="/pmc/articles/PMC4187511/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4187511</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24721801" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24721801</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>119.</dt><dd><div class="bk_ref" id="ch2.ref119">Schrader
|
|
J, Lüders
|
|
S, Züchner
|
|
C, Herbold
|
|
M, Schrandt
|
|
G. Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study): A randomised, prospective long-term study to evaluate the benefits of ABPM in patients on antihypertensive treatment. Journal of Human Hypertension. 2000; 14(7):435–440 [<a href="https://pubmed.ncbi.nlm.nih.gov/10918548" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10918548</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>120.</dt><dd><div class="bk_ref" id="ch2.ref120">Schroeder
|
|
K, Fahey
|
|
T, Ebrahim
|
|
S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database of Systematic Reviews
|
|
2004, Issue 3. Art. No.: CD004804. DOI: 10.1002/14651858.CD004804. [<a href="/pmc/articles/PMC9036187/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9036187</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15106262" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15106262</span></a>] [<a href="http://dx.crossref.org/10.1002/14651858.CD004804" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd></dl><dl class="bkr_refwrap"><dt>121.</dt><dd><div class="bk_ref" id="ch2.ref121">Sharman
|
|
JE, Marwick
|
|
TH, Abhayaratna
|
|
WP, Stowasser
|
|
M. Rationale and design of a randomized study to determine the value of central Blood Pressure for GUIDing managEment of hypertension: The BP GUIDE study. American Heart Journal. 2012; 163(5):761–767 [<a href="https://pubmed.ncbi.nlm.nih.gov/22607852" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22607852</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>122.</dt><dd><div class="bk_ref" id="ch2.ref122">Simpson
|
|
SH, Majumdar
|
|
SR, Tsuyuki
|
|
RT, Lewanczuk
|
|
RZ, Spooner
|
|
R, Johnson
|
|
JA. Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: A randomized controlled trial. Diabetes Care. 2011; 34(1):20–6 [<a href="/pmc/articles/PMC3005466/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3005466</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20929988" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20929988</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>123.</dt><dd><div class="bk_ref" id="ch2.ref123">Smith
|
|
SM, Carris
|
|
NW, Dietrich
|
|
E, Gums
|
|
JG, Uribe
|
|
L, Coffey
|
|
CS
|
|
et al. Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. Journal of the American Society of Hypertension. 2016; 10(4):307–317 [<a href="/pmc/articles/PMC4829453/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4829453</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26852290" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26852290</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>124.</dt><dd><div class="bk_ref" id="ch2.ref124">Soghikian
|
|
K, Casper
|
|
SM, Fireman
|
|
BH, Hunkeler
|
|
EM, Hurley
|
|
LB, Tekawa
|
|
IS
|
|
et al. Home blood pressure monitoring. Effect on use of medical services and medical care costs. Medical Care. 1992; 30(9):855–65 [<a href="https://pubmed.ncbi.nlm.nih.gov/1518317" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1518317</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>125.</dt><dd><div class="bk_ref" id="ch2.ref125">Spieker
|
|
C, Zidek
|
|
W, Vetter
|
|
H, Rahn
|
|
KH. Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril. Journal of International Medical Research. 1991; 19(1):39–43 [<a href="https://pubmed.ncbi.nlm.nih.gov/1826891" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1826891</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>126.</dt><dd><div class="bk_ref" id="ch2.ref126">Spruill
|
|
TM, Williams
|
|
O, Teresi
|
|
JA, Lehrer
|
|
S, Pezzin
|
|
L, Waddy
|
|
SP
|
|
et al. Comparative effectiveness of home blood pressure telemonitoring (HBPTM) plus nurse case management versus HBPTM alone among Black and Hispanic stroke survivors: Study protocol for a randomized controlled trial. Trials. 2015; 16:97 [<a href="/pmc/articles/PMC4365522/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4365522</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25873044" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25873044</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>127.</dt><dd><div class="bk_ref" id="ch2.ref127">Staessen
|
|
JA, Byttebier
|
|
G, Buntinx
|
|
F, Celis
|
|
H, O’Brien
|
|
ET, Fagard
|
|
R
|
|
et al. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. JAMA. 1997; 278(13):1065–1072 [<a href="https://pubmed.ncbi.nlm.nih.gov/9315764" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9315764</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>128.</dt><dd><div class="bk_ref" id="ch2.ref128">Staessen
|
|
JA, Den Hond
|
|
E, Celis
|
|
H, Fagard
|
|
R, Keary
|
|
L, Vandenhoven
|
|
G
|
|
et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office: A randomized controlled trial. JAMA. 2004; 291(8):955–964 [<a href="https://pubmed.ncbi.nlm.nih.gov/14982911" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14982911</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>129.</dt><dd><div class="bk_ref" id="ch2.ref129">Stahl
|
|
SM, Kelley
|
|
CR, Neill
|
|
PJ, Grim
|
|
CE, Mamlin
|
|
J. Effects of home blood pressure measurement on long-term BP control. American Journal of Public Health. 1984; 74(7):704–709 [<a href="/pmc/articles/PMC1651666/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1651666</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6742256" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6742256</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>130.</dt><dd><div class="bk_ref" id="ch2.ref130">Stergiou
|
|
GS, Bliziotis
|
|
IA. Home blood pressure monitoring in the diagnosis and treatment of hypertension: A systematic review. American Journal of Hypertension. 2011; 24(2):123–34 [<a href="https://pubmed.ncbi.nlm.nih.gov/20940712" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20940712</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>131.</dt><dd><div class="bk_ref" id="ch2.ref131">Stergiou
|
|
GS, Karpettas
|
|
N, Destounis
|
|
A, Tzamouranis
|
|
D, Nasothimiou
|
|
E, Kollias
|
|
A
|
|
et al. Home blood pressure monitoring alone vs. combined clinic and ambulatory measurements in following treatment-induced changes in blood pressure and organ damage. American Journal of Hypertension. 2014; 27(2):184–192 [<a href="https://pubmed.ncbi.nlm.nih.gov/24190902" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24190902</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>132.</dt><dd><div class="bk_ref" id="ch2.ref132">Stewart
|
|
K, George
|
|
J, Namara
|
|
KP, Jackson
|
|
SL, Peterson
|
|
GM, Bereznicki
|
|
LR
|
|
et al. A multifaceted pharmacist intervention to improve antihypertensive adherence: A cluster-randomized, controlled trial (HAPPy trial). Journal of Clinical Pharmacy and Therapeutics. 2014; 39(5):527–534 [<a href="https://pubmed.ncbi.nlm.nih.gov/24943987" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24943987</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>133.</dt><dd><div class="bk_ref" id="ch2.ref133">Stoddart
|
|
A, Hanley
|
|
J, Wild
|
|
S, Pagliari
|
|
C, Paterson
|
|
M, Lewis
|
|
S
|
|
et al. Telemonitoring-based service redesign for the management of uncontrolled hypertension (HITS): Cost and cost-effectiveness analysis of a randomised controlled trial. BMJ Open. 2013; 3(5):e002681 [<a href="/pmc/articles/PMC3657667/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3657667</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23793650" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23793650</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>134.</dt><dd><div class="bk_ref" id="ch2.ref134">Torres
|
|
A, Fite
|
|
B, Gascon
|
|
P, Barau
|
|
M, Guayta-Escolies
|
|
R, Estrada-Campmany
|
|
M
|
|
et al. Effectiveness of a pharmaceutical care program in the improvement of blood pressure monitoring in poorly controlled hypertensive patients. PressFarm Study. Hipertension y Riesgo Vascular. 2010; 27(1):13–22</div></dd></dl><dl class="bkr_refwrap"><dt>135.</dt><dd><div class="bk_ref" id="ch2.ref135">Tucker
|
|
KL, Sheppard
|
|
JP, Stevens
|
|
R, Bosworth
|
|
HB, Bove
|
|
A, Bray
|
|
EP
|
|
et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Medicine. 2017; 14(9):e1002389 [<a href="/pmc/articles/PMC5604965/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5604965</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28926573" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28926573</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>136.</dt><dd><div class="bk_ref" id="ch2.ref136">Tucker
|
|
KL, Sheppard
|
|
JP, Stevens
|
|
R, Bosworth
|
|
HB, Bove
|
|
A, Bray
|
|
EP
|
|
et al. Individual patient data meta-analysis of self-monitoring of blood pressure (BP-SMART): A protocol. BMJ Open. 2015; 5(9):e008532 [<a href="/pmc/articles/PMC4577873/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4577873</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26373404" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26373404</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>137.</dt><dd><div class="bk_ref" id="ch2.ref137">Uhlig
|
|
K, Patel
|
|
K, Ip
|
|
S, Kitsios
|
|
GD, Balk
|
|
EM. Self-measured blood pressure monitoring in the management of hypertension: A systematic review and meta-analysis. Annals of Internal Medicine. 2013; 159(3):185–94 [<a href="https://pubmed.ncbi.nlm.nih.gov/23922064" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23922064</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>138.</dt><dd><div class="bk_ref" id="ch2.ref138">Ulm
|
|
K, Huntgeburth
|
|
U, Gnahn
|
|
H, Briesenick
|
|
C, Pürner
|
|
K, Middeke
|
|
M. Effect of an intensive nurse-managed medical care programme on ambulatory blood pressure in hypertensive patients. Archives of Cardiovascular Diseases. 2010; 103(3):142–149 [<a href="https://pubmed.ncbi.nlm.nih.gov/20417445" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20417445</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>139.</dt><dd><div class="bk_ref" id="ch2.ref139">van der Wel
|
|
MC, Buunk
|
|
IE, van Weel
|
|
C, Thien
|
|
TA, Bakx
|
|
JC. A novel approach to office blood pressure measurement: 30-minute office blood pressure vs daytime ambulatory blood pressure. Annals of Family Medicine. 2011; 9(2):128–35 [<a href="/pmc/articles/PMC3056860/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3056860</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21403139" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21403139</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>140.</dt><dd><div class="bk_ref" id="ch2.ref140">Varis
|
|
J, Kantola
|
|
I. The choice of home blood pressure result reporting method is essential: Results mailed to physicians did not improve hypertension control compared with ordinary office-based blood pressure treatment. Blood Pressure. 2010; 19(5):319–24 [<a href="https://pubmed.ncbi.nlm.nih.gov/20367560" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20367560</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>141.</dt><dd><div class="bk_ref" id="ch2.ref141">Verberk
|
|
WJ, Kessels
|
|
AG, Thien
|
|
T. Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis. Blood Pressure Monitoring. 2011; 16(3):149–55 [<a href="https://pubmed.ncbi.nlm.nih.gov/21527847" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21527847</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>142.</dt><dd><div class="bk_ref" id="ch2.ref142">Verberk
|
|
WJ, Kroon
|
|
AA, Kessels
|
|
AG, Dirksen
|
|
C, Nelemans
|
|
PJ, Lenders
|
|
JW
|
|
et al. Home versus Office blood pressure MEasurements: Reduction of Unnecessary treatment Study: Rationale and study design of the HOMERUS trial. Blood Pressure. 2003; 12(5–6):326–333 [<a href="https://pubmed.ncbi.nlm.nih.gov/14763665" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14763665</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>143.</dt><dd><div class="bk_ref" id="ch2.ref143">Verberk
|
|
WJ, Kroon
|
|
AA, Lenders
|
|
JW, Kessels
|
|
AG, van Montfrans
|
|
GA, Smit
|
|
AJ
|
|
et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: A randomized, controlled trial. Hypertension. 2007; 50(6):1019–1025 [<a href="https://pubmed.ncbi.nlm.nih.gov/17938383" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17938383</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>144.</dt><dd><div class="bk_ref" id="ch2.ref144">Verdecchia
|
|
P, Angeli
|
|
F, Gentile
|
|
G, Reboldi
|
|
G. More versus less intensive blood pressure-lowering strategy: Cumulative evidence and trial sequential analysis. Hypertension. 2016; 68(3):642–53 [<a href="https://pubmed.ncbi.nlm.nih.gov/27456518" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27456518</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>145.</dt><dd><div class="bk_ref" id="ch2.ref145">Vollmer
|
|
WM, Appel
|
|
LJ, Svetkey
|
|
LP, Moore
|
|
TJ, Vogt
|
|
TM, Conlin
|
|
PR
|
|
et al. Comparing office-based and ambulatory blood pressure monitoring in clinical trials. Journal of Human Hypertension. 2005; 19(1):77–82 [<a href="https://pubmed.ncbi.nlm.nih.gov/15361888" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15361888</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>146.</dt><dd><div class="bk_ref" id="ch2.ref146">Wakefield
|
|
BJ, Holman
|
|
JE, Ray
|
|
A, Scherubel
|
|
M, Adams
|
|
MR, Hillis
|
|
SL
|
|
et al. Effectiveness of home telehealth in comorbid diabetes and hypertension: A randomized, controlled trial. Telemedicine Journal and e-Health. 2011; 17(4):254–261 [<a href="https://pubmed.ncbi.nlm.nih.gov/21476945" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21476945</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>147.</dt><dd><div class="bk_ref" id="ch2.ref147">Wakefield
|
|
BJ, Holman
|
|
JE, Ray
|
|
A, Scherubel
|
|
M, Adams
|
|
MR, Hills
|
|
SL
|
|
et al. Outcomes of a home telehealth intervention for patients with diabetes and hypertension. Telemedicine Journal and e-Health. 2012; 18(8):575–579 [<a href="https://pubmed.ncbi.nlm.nih.gov/22873700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22873700</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>148.</dt><dd><div class="bk_ref" id="ch2.ref148">Wakefield
|
|
BJ, Koopman
|
|
RJ, Keplinger
|
|
LE, Bomar
|
|
M, Bernt
|
|
B, Johanning
|
|
JL
|
|
et al. Effect of home telemonitoring on glycemic and blood pressure control in primary care clinic patients with diabetes. Telemedicine Journal and e-Health. 2014; 20(3):199–205 [<a href="/pmc/articles/PMC3934666/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3934666</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24404819" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24404819</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>149.</dt><dd><div class="bk_ref" id="ch2.ref149">Wang
|
|
J, Wu
|
|
J, Yang
|
|
J, Zhuang
|
|
Y, Chen
|
|
J, Qian
|
|
W
|
|
et al. Effects of pharmaceutical care interventions on blood pressure and medication adherence of patients with primary hypertension in China. Clinical Research and Regulatory Affairs. 2011; 28(1):1–6</div></dd></dl><dl class="bkr_refwrap"><dt>150.</dt><dd><div class="bk_ref" id="ch2.ref150">Weber
|
|
CA, Ernst
|
|
ME, Sezate
|
|
GS, Zheng
|
|
S, Carter
|
|
BL. Pharmacist-physician comanagement of hypertension and reduction in 24-hour ambulatory blood pressures. Archives of Internal Medicine. 2010; 170(18):1634–1639 [<a href="/pmc/articles/PMC2992979/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2992979</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20937921" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20937921</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>151.</dt><dd><div class="bk_ref" id="ch2.ref151">Xu
|
|
L, Fang
|
|
WY, Zhu
|
|
F, Zhang
|
|
HG, Liu
|
|
K. A coordinated PCP-Cardiologist Telemedicine Model (PCTM) in China’s community hypertension care: Study protocol for a randomized controlled trial. Trials. 2017; 18(1):236 [<a href="/pmc/articles/PMC5445306/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5445306</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28545514" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28545514</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>152.</dt><dd><div class="bk_ref" id="ch2.ref152">Yatabe
|
|
MS, Yatabe
|
|
J, Asayama
|
|
K, Staessen
|
|
JA, Mujaj
|
|
B, Thijs
|
|
L
|
|
et al. The rationale and design of reduction of uncontrolled hypertension by Remote Monitoring and Telemedicine (REMOTE) study. Blood Pressure. 2018; 27(2):99–105 [<a href="https://pubmed.ncbi.nlm.nih.gov/29172715" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29172715</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>153.</dt><dd><div class="bk_ref" id="ch2.ref153">Yates
|
|
G. Adjustment of antihypertensive medication using home based, patient monitored blood pressure reduced both intensity of treatment and blood pressure control. Evidence-Based Nursing. 2004; 7(3):80 [<a href="https://pubmed.ncbi.nlm.nih.gov/15252908" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15252908</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>154.</dt><dd><div class="bk_ref" id="ch2.ref154">Zarnke
|
|
KB. Hypertension management using home blood pressure monitors and patient-initiated drug dosage adjustments: A randomized equivalence trial. London, Ontario. The University of Western Ontario. 1998. Masters of Science</div></dd></dl><dl class="bkr_refwrap"><dt>155.</dt><dd><div class="bk_ref" id="ch2.ref155">Zarnke
|
|
KB, Feagan
|
|
BG, Mahon
|
|
JL, Feldman
|
|
RD. A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. American Journal of Hypertension. 1997; 10(1):58–67 [<a href="https://pubmed.ncbi.nlm.nih.gov/9008249" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9008249</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>156.</dt><dd><div class="bk_ref" id="ch2.ref156">Zhao
|
|
PX, Wang
|
|
C, Qin
|
|
L, Xiao
|
|
Q, Guo
|
|
YH, Wen
|
|
AD. Effect of clinical pharmacist’s pharmaceutical care intervention to control hypertensive outpatients in China. African Journal of Pharmacy and Pharmacology. 2012; 6(1):48–56</div></dd></dl></dl></div><div id="appendixesappgroup2"><h2 id="_appendixesappgroup2_">Appendices</h2><div id="ch2.appa"><h3>Appendix A. Review protocols</h3><p id="ch2.appa.tab1"><a href="/books/NBK578044/table/ch2.appa.tab1/?report=objectonly" target="object" rid-ob="figobch2appatab1" class="figpopup">Table 13. Review protocol: Monitoring</a></p><p id="ch2.appa.tab2"><a href="/books/NBK578044/table/ch2.appa.tab2/?report=objectonly" target="object" rid-ob="figobch2appatab2" class="figpopup">Table 14. Health economic review protocol</a></p></div><div id="ch2.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied with the methodology outlined in <a href="https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual 2014, updated 2017</a>.</p><p>For more detailed information, please see the Methodology Review.</p><div id="ch2.appb.s1"><h4>B.1. Clinical search literature search strategy</h4><p>Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.</p><p id="ch2.appb.tab1"><a href="/books/NBK578044/table/ch2.appb.tab1/?report=objectonly" target="object" rid-ob="figobch2appbtab1" class="figpopup">Table 15. Database date parameters and filters used</a></p><p id="ch2.appb.tab2"><a href="/books/NBK578044/table/ch2.appb.tab2/?report=objectonly" target="object" rid-ob="figobch2appbtab2" class="figpopup">Table 16. Medline (Ovid) search terms</a></p><p id="ch2.appb.tab3"><a href="/books/NBK578044/table/ch2.appb.tab3/?report=objectonly" target="object" rid-ob="figobch2appbtab3" class="figpopup">Table 17. Embase (Ovid) search terms</a></p><p id="ch2.appb.tab4"><a href="/books/NBK578044/table/ch2.appb.tab4/?report=objectonly" target="object" rid-ob="figobch2appbtab4" class="figpopup">Table 18. Cochrane Library (Wiley) search terms</a></p></div><div id="ch2.appb.s2"><h4>B.2. Health Economics literature search strategy</h4><p>Health economic evidence was identified by conducting a broad search relating to hypertension in adults population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics, economic modelling and quality of life studies.</p><p id="ch2.appb.tab5"><a href="/books/NBK578044/table/ch2.appb.tab5/?report=objectonly" target="object" rid-ob="figobch2appbtab5" class="figpopup">Table 19. Database date parameters and filters used</a></p><p id="ch2.appb.tab6"><a href="/books/NBK578044/table/ch2.appb.tab6/?report=objectonly" target="object" rid-ob="figobch2appbtab6" class="figpopup">Table 20. Medline (Ovid) search terms</a></p><p id="ch2.appb.tab7"><a href="/books/NBK578044/table/ch2.appb.tab7/?report=objectonly" target="object" rid-ob="figobch2appbtab7" class="figpopup">Table 21. Embase (Ovid) search terms</a></p><p id="ch2.appb.tab8"><a href="/books/NBK578044/table/ch2.appb.tab8/?report=objectonly" target="object" rid-ob="figobch2appbtab8" class="figpopup">Table 22. NHS EED and HTA (CRD) search terms</a></p></div></div><div id="ch2.appc"><h3>Appendix C. Clinical evidence selection</h3><p id="ch2.appc.fig1"><a href="/books/NBK578044/figure/ch2.appc.fig1/?report=objectonly" target="object" rid-ob="figobch2appcfig1" class="figpopup">Figure 1. Flow chart of clinical study selection for the review of monitoring</a></p></div><div id="ch2.appd"><h3>Appendix D. Clinical evidence tables</h3><p id="ch2.appd.et1"><a href="/books/NBK578044/bin/ch2-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (320K)</span></p></div><div id="ch2.appe"><h3>Appendix E. Forest plots</h3><div id="ch2.appe.s1"><h4>E.1. Home monitoring versus clinic monitoring</h4><p id="ch2.appe.fig1"><a href="/books/NBK578044/figure/ch2.appe.fig1/?report=objectonly" target="object" rid-ob="figobch2appefig1" class="figpopup">Figure 2. Cardiovascular events, 12 months</a></p><p id="ch2.appe.fig2"><a href="/books/NBK578044/figure/ch2.appe.fig2/?report=objectonly" target="object" rid-ob="figobch2appefig2" class="figpopup">Figure 3. Reduction in clinic blood pressure (mmHg), systolic (change in clinic systolic blood pressure), 12 months</a></p><p id="ch2.appe.fig3"><a href="/books/NBK578044/figure/ch2.appe.fig3/?report=objectonly" target="object" rid-ob="figobch2appefig3" class="figpopup">Figure 4. Reduction in clinic blood pressure (mmHg), diastolic (change in clinic diastolic blood pressure), 12 months</a></p><p id="ch2.appe.fig4"><a href="/books/NBK578044/figure/ch2.appe.fig4/?report=objectonly" target="object" rid-ob="figobch2appefig4" class="figpopup">Figure 5. Proportion not meeting target (varied target due to IPD – mode 140/90 mmHg), 12 months</a></p><p id="ch2.appe.fig5"><a href="/books/NBK578044/figure/ch2.appe.fig5/?report=objectonly" target="object" rid-ob="figobch2appefig5" class="figpopup">Figure 6. Overall defined daily dose, 12 months</a></p><p id="ch2.appe.fig6"><a href="/books/NBK578044/figure/ch2.appe.fig6/?report=objectonly" target="object" rid-ob="figobch2appefig6" class="figpopup">Figure 7. Mean number of consultations for hypertension, 12 months</a></p><p id="ch2.appe.fig7"><a href="/books/NBK578044/figure/ch2.appe.fig7/?report=objectonly" target="object" rid-ob="figobch2appefig7" class="figpopup">Figure 8. Dizziness, hypertension specific symptoms (no further details of definition) 12 months</a></p></div><div id="ch2.appe.s2"><h4>E.2. Home monitoring without telemonitoring versus ambulatory and clinic monitoring</h4><p id="ch2.appe.fig8"><a href="/books/NBK578044/figure/ch2.appe.fig8/?report=objectonly" target="object" rid-ob="figobch2appefig8" class="figpopup">Figure 9. Reduction in clinic blood pressure (mmHg), systolic, 12 months</a></p><p id="ch2.appe.fig9"><a href="/books/NBK578044/figure/ch2.appe.fig9/?report=objectonly" target="object" rid-ob="figobch2appefig9" class="figpopup">Figure 10. Reduction in clinic blood pressure (mmHg), diastolic, 12 months</a></p></div><div id="ch2.appe.s3"><h4>E.3. Home monitoring with telemonitoring versus home monitoring without telemonitoring</h4><p id="ch2.appe.fig10"><a href="/books/NBK578044/figure/ch2.appe.fig10/?report=objectonly" target="object" rid-ob="figobch2appefig10" class="figpopup">Figure 11. Cardiovascular events, 12 months</a></p><p id="ch2.appe.fig11"><a href="/books/NBK578044/figure/ch2.appe.fig11/?report=objectonly" target="object" rid-ob="figobch2appefig11" class="figpopup">Figure 12. Clinic blood pressure (mmHg), systolic, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig12"><a href="/books/NBK578044/figure/ch2.appe.fig12/?report=objectonly" target="object" rid-ob="figobch2appefig12" class="figpopup">Figure 13. Clinic blood pressure (mmHg), diastolic, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig13"><a href="/books/NBK578044/figure/ch2.appe.fig13/?report=objectonly" target="object" rid-ob="figobch2appefig13" class="figpopup">Figure 14. Overall defined daily dose, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig14"><a href="/books/NBK578044/figure/ch2.appe.fig14/?report=objectonly" target="object" rid-ob="figobch2appefig14" class="figpopup">Figure 15. Average number of GP visits, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig15"><a href="/books/NBK578044/figure/ch2.appe.fig15/?report=objectonly" target="object" rid-ob="figobch2appefig15" class="figpopup">Figure 16. Mean number of consultations for hypertension, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig16"><a href="/books/NBK578044/figure/ch2.appe.fig16/?report=objectonly" target="object" rid-ob="figobch2appefig16" class="figpopup">Figure 17. Dizziness, hypertension specific symptoms (no further details of definition) 12 months<sup>a</sup></a></p></div><div id="ch2.appe.s4"><h4>E.4. Home monitoring with telemonitoring versus clinic monitoring</h4><p id="ch2.appe.fig17"><a href="/books/NBK578044/figure/ch2.appe.fig17/?report=objectonly" target="object" rid-ob="figobch2appefig17" class="figpopup">Figure 18. All-cause mortality, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig18"><a href="/books/NBK578044/figure/ch2.appe.fig18/?report=objectonly" target="object" rid-ob="figobch2appefig18" class="figpopup">Figure 19. Cardiovascular events 12 months<sup>a</sup></a></p><p id="ch2.appe.fig19"><a href="/books/NBK578044/figure/ch2.appe.fig19/?report=objectonly" target="object" rid-ob="figobch2appefig19" class="figpopup">Figure 20. Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 months</a></p><p id="ch2.appe.fig20"><a href="/books/NBK578044/figure/ch2.appe.fig20/?report=objectonly" target="object" rid-ob="figobch2appefig20" class="figpopup">Figure 21. Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig21"><a href="/books/NBK578044/figure/ch2.appe.fig21/?report=objectonly" target="object" rid-ob="figobch2appefig21" class="figpopup">Figure 22. Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig22"><a href="/books/NBK578044/figure/ch2.appe.fig22/?report=objectonly" target="object" rid-ob="figobch2appefig22" class="figpopup">Figure 23. Reduction in clinic blood pressure (mmHg), systolic 12 months</a></p><p id="ch2.appe.fig23"><a href="/books/NBK578044/figure/ch2.appe.fig23/?report=objectonly" target="object" rid-ob="figobch2appefig23" class="figpopup">Figure 24. Reduction in clinic blood pressure (mmHg), diastolic 12 months</a></p><p id="ch2.appe.fig24"><a href="/books/NBK578044/figure/ch2.appe.fig24/?report=objectonly" target="object" rid-ob="figobch2appefig24" class="figpopup">Figure 25. Proportion controlled to a target, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig25"><a href="/books/NBK578044/figure/ch2.appe.fig25/?report=objectonly" target="object" rid-ob="figobch2appefig25" class="figpopup">Figure 26. Proportion not meeting target (varied target due to IPD – mode 140/90 mmHg), 12 months</a></p><p id="ch2.appe.fig26"><a href="/books/NBK578044/figure/ch2.appe.fig26/?report=objectonly" target="object" rid-ob="figobch2appefig26" class="figpopup">Figure 27. Overall defined daily dose, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig27"><a href="/books/NBK578044/figure/ch2.appe.fig27/?report=objectonly" target="object" rid-ob="figobch2appefig27" class="figpopup">Figure 28. Mean number of consultations for hypertension, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig28"><a href="/books/NBK578044/figure/ch2.appe.fig28/?report=objectonly" target="object" rid-ob="figobch2appefig28" class="figpopup">Figure 29. Dizziness, hypertension specific symptoms (no further definition), 12 months<sup>a</sup></a></p></div><div id="ch2.appe.s5"><h4>E.5. Home monitoring with telemonitoring and pharmacist care versus clinic monitoring</h4><p id="ch2.appe.fig29"><a href="/books/NBK578044/figure/ch2.appe.fig29/?report=objectonly" target="object" rid-ob="figobch2appefig29" class="figpopup">Figure 30. All-cause mortality, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig30"><a href="/books/NBK578044/figure/ch2.appe.fig30/?report=objectonly" target="object" rid-ob="figobch2appefig30" class="figpopup">Figure 31. Non-fatal Cardiovascular events (no further details given), 1 yeara<sup>a</sup></a></p><p id="ch2.appe.fig31"><a href="/books/NBK578044/figure/ch2.appe.fig31/?report=objectonly" target="object" rid-ob="figobch2appefig31" class="figpopup">Figure 32. Reduction in blood pressure (mmHg), systolic, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig32"><a href="/books/NBK578044/figure/ch2.appe.fig32/?report=objectonly" target="object" rid-ob="figobch2appefig32" class="figpopup">Figure 33. Reduction in blood pressure (mmHg), diastolic, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig33"><a href="/books/NBK578044/figure/ch2.appe.fig33/?report=objectonly" target="object" rid-ob="figobch2appefig33" class="figpopup">Figure 34. Proportion controlled to a target, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig34"><a href="/books/NBK578044/figure/ch2.appe.fig34/?report=objectonly" target="object" rid-ob="figobch2appefig34" class="figpopup">Figure 35. Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig35"><a href="/books/NBK578044/figure/ch2.appe.fig35/?report=objectonly" target="object" rid-ob="figobch2appefig35" class="figpopup">Figure 36. Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig36"><a href="/books/NBK578044/figure/ch2.appe.fig36/?report=objectonly" target="object" rid-ob="figobch2appefig36" class="figpopup">Figure 37. Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></a></p></div><div id="ch2.appe.s6"><h4>E.6. Home monitoring with telemonitoring and pharmacist care versus home monitoring with telemonitoring</h4><p id="ch2.appe.fig37"><a href="/books/NBK578044/figure/ch2.appe.fig37/?report=objectonly" target="object" rid-ob="figobch2appefig37" class="figpopup">Figure 38. All-cause mortality, 12 months</a></p><p id="ch2.appe.fig38"><a href="/books/NBK578044/figure/ch2.appe.fig38/?report=objectonly" target="object" rid-ob="figobch2appefig38" class="figpopup">Figure 39. Non-fatal Cardiovascular events (no further details given), 12 months</a></p><p id="ch2.appe.fig39"><a href="/books/NBK578044/figure/ch2.appe.fig39/?report=objectonly" target="object" rid-ob="figobch2appefig39" class="figpopup">Figure 40. Change in blood pressure (mmHg), systolic, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig40"><a href="/books/NBK578044/figure/ch2.appe.fig40/?report=objectonly" target="object" rid-ob="figobch2appefig40" class="figpopup">Figure 41. Reduction in blood pressure (mmHg), diastolic, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig41"><a href="/books/NBK578044/figure/ch2.appe.fig41/?report=objectonly" target="object" rid-ob="figobch2appefig41" class="figpopup">Figure 42. Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig42"><a href="/books/NBK578044/figure/ch2.appe.fig42/?report=objectonly" target="object" rid-ob="figobch2appefig42" class="figpopup">Figure 43. Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig43"><a href="/books/NBK578044/figure/ch2.appe.fig43/?report=objectonly" target="object" rid-ob="figobch2appefig43" class="figpopup">Figure 44. Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></a></p></div><div id="ch2.appe.s7"><h4>E.7. Home-monitoring (with self-titration) and telemonitoring versus clinic monitoring</h4><p id="ch2.appe.fig44"><a href="/books/NBK578044/figure/ch2.appe.fig44/?report=objectonly" target="object" rid-ob="figobch2appefig44" class="figpopup">Figure 45. Clinic blood pressure (mmHg), systolic, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig45"><a href="/books/NBK578044/figure/ch2.appe.fig45/?report=objectonly" target="object" rid-ob="figobch2appefig45" class="figpopup">Figure 46. Clinic blood pressure (mmHg), diastolic, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig46"><a href="/books/NBK578044/figure/ch2.appe.fig46/?report=objectonly" target="object" rid-ob="figobch2appefig46" class="figpopup">Figure 47. Quality of life, EQ-5D, 0.594 to 1, higher score is better, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig47"><a href="/books/NBK578044/figure/ch2.appe.fig47/?report=objectonly" target="object" rid-ob="figobch2appefig47" class="figpopup">Figure 48. Mean number of consultations for hypertension, 12 months<sup>a</sup></a></p><p id="ch2.appe.fig48"><a href="/books/NBK578044/figure/ch2.appe.fig48/?report=objectonly" target="object" rid-ob="figobch2appefig48" class="figpopup">Figure 49. Mean number of antihypertensive drugs, 12 months<sup>a</sup></a></p></div><div id="ch2.appe.s8"><h4>E.8. Pharmacy monitoring versus clinic monitoring</h4><p id="ch2.appe.fig49"><a href="/books/NBK578044/figure/ch2.appe.fig49/?report=objectonly" target="object" rid-ob="figobch2appefig49" class="figpopup">Figure 50. All-cause mortality, 12 months</a></p><p id="ch2.appe.fig50"><a href="/books/NBK578044/figure/ch2.appe.fig50/?report=objectonly" target="object" rid-ob="figobch2appefig50" class="figpopup">Figure 51. Reduction in blood pressure (mmHg), systolic, 12 months</a></p><p id="ch2.appe.fig51"><a href="/books/NBK578044/figure/ch2.appe.fig51/?report=objectonly" target="object" rid-ob="figobch2appefig51" class="figpopup">Figure 52. Reduction in blood pressure (mmHg), diastolic, 12 months</a></p></div></div><div id="ch2.appf"><h3>Appendix F. GRADE tables</h3><p id="ch2.appf.tab1"><a href="/books/NBK578044/table/ch2.appf.tab1/?report=objectonly" target="object" rid-ob="figobch2appftab1" class="figpopup">Table 23. Clinical evidence profile: Home monitoring versus clinic monitoring</a></p><p id="ch2.appf.tab2"><a href="/books/NBK578044/table/ch2.appf.tab2/?report=objectonly" target="object" rid-ob="figobch2appftab2" class="figpopup">Table 24. Clinical evidence profile: Home monitoring versus ambulatory/clinic monitoring</a></p><p id="ch2.appf.tab3"><a href="/books/NBK578044/table/ch2.appf.tab3/?report=objectonly" target="object" rid-ob="figobch2appftab3" class="figpopup">Table 25. Clinical evidence profile: Home monitoring with telemonitoring versus home monitoring</a></p><p id="ch2.appf.tab4"><a href="/books/NBK578044/table/ch2.appf.tab4/?report=objectonly" target="object" rid-ob="figobch2appftab4" class="figpopup">Table 26. Clinical evidence profile: Home monitoring with telemonitoring versus clinic monitoring</a></p><p id="ch2.appf.tab5"><a href="/books/NBK578044/table/ch2.appf.tab5/?report=objectonly" target="object" rid-ob="figobch2appftab5" class="figpopup">Table 27. Clinical evidence profile: Home monitoring with telemonitoring and pharmacist care versus clinic monitoring</a></p><p id="ch2.appf.tab6"><a href="/books/NBK578044/table/ch2.appf.tab6/?report=objectonly" target="object" rid-ob="figobch2appftab6" class="figpopup">Table 28. Clinical evidence profile: Home monitoring with telemonitoring and pharmacist care versus home monitoring with telemonitoring</a></p><p id="ch2.appf.tab7"><a href="/books/NBK578044/table/ch2.appf.tab7/?report=objectonly" target="object" rid-ob="figobch2appftab7" class="figpopup">Table 29. Clinical evidence profile: Home-monitoring (with self-titration) and telemonitoring versus clinic monitoring</a></p><p id="ch2.appf.tab8"><a href="/books/NBK578044/table/ch2.appf.tab8/?report=objectonly" target="object" rid-ob="figobch2appftab8" class="figpopup">Table 30. Clinical evidence profile: Pharmacy versus clinic monitoring</a></p></div><div id="ch2.appg"><h3>Appendix G. Health economic evidence selection</h3><p id="ch2.appg.fig1"><a href="/books/NBK578044/figure/ch2.appg.fig1/?report=objectonly" target="object" rid-ob="figobch2appgfig1" class="figpopup">Figure 53. Flow chart of health economic study selection for the guideline</a></p></div><div id="ch2.apph"><h3>Appendix H. Health economic evidence tables</h3><p id="ch2.apph.et1"><a href="/books/NBK578044/bin/ch2-apph-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (203K)</span></p></div><div id="ch2.appi"><h3>Appendix I. Excluded studies</h3><div id="ch2.appi.s1"><h4>I.1. Excluded clinical studies</h4><p id="ch2.appi.tab1"><a href="/books/NBK578044/table/ch2.appi.tab1/?report=objectonly" target="object" rid-ob="figobch2appitab1" class="figpopup">Table 31. Studies excluded from the clinical review that were included in the previous guideline (CG127)</a></p><p id="ch2.appi.tab2"><a href="/books/NBK578044/table/ch2.appi.tab2/?report=objectonly" target="object" rid-ob="figobch2appitab2" class="figpopup">Table 32. Studies excluded from the clinical review</a></p></div><div id="ch2.appi.s2"><h4>I.2. Excluded health economic studies</h4><p id="ch2.appi.tab3"><a href="/books/NBK578044/table/ch2.appi.tab3/?report=objectonly" target="object" rid-ob="figobch2appitab3" class="figpopup">Table 33. Studies excluded from the health economic review</a></p></div></div><div id="ch2.appj"><h3>Appendix J. Research recommendations</h3><div id="ch2.appj.s1"><h4>J.1. Automated blood pressure monitoring in people with atrial fibrillation</h4><p>
|
|
<b>Research question: Which automated blood pressure monitors are most accurate for people with hypertension and atrial fibrillation?</b>
|
|
</p><p>
|
|
<b>Why this is important:</b>
|
|
</p><p>Atrial fibrillation (AF) is a key risk factor for stroke and is increasingly prevalent with an ageing population. The combination of AF and hypertension puts individuals at a higher risk still. Overall, it is estimated that 1.4 million people in England have AF, which is 2.5% of the population, and 65% of those with AF are aged over 65. Currently, automated blood pressure monitors are used for the majority of NHS consultations and blood pressure measurements both in primary and secondary care; however, most measurements from automated blood pressure monitors are inaccurate in people with AF because the oscillometric algorithms designed to measure blood pressure are validated in sinus rhythm and do not necessarily function in AF, especially when the heart rhythm is very irregular.</p><p id="ch2.appj.tab1"><a href="/books/NBK578044/table/ch2.appj.tab1/?report=objectonly" target="object" rid-ob="figobch2appjtab1" class="figpopup">Criteria for selecting high-priority research recommendations</a></p></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Intervention evidence review underpinning recommendations 1.4.15 and 1.4.17 to 1.4.19 in the guideline</p><p>This evidence review was developed by the National Guideline Centre</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2019.</div><div class="small"><span class="label">Bookshelf ID: NBK578044</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35188722" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">35188722</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobch2tab1"><div id="ch2.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_ch2.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_ch2.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults (over 18 years) with treated primary hypertension</td></tr><tr><th id="hd_b_ch2.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_ch2.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Different methods of measuring blood pressure followed by appropriate treatment* based on the blood pressure measurement (test plus treatment):
|
|
<ul id="ch2.l1"><li id="ch2.lt1" class="half_rhythm"><div>Home measurement (HBPM) without telemonitoring</div></li><li id="ch2.lt2" class="half_rhythm"><div>Home measurement with telemonitoring</div></li><li id="ch2.lt3" class="half_rhythm"><div>Ambulatory measurement (ABPM)</div></li><li id="ch2.lt4" class="half_rhythm"><div>Clinic/office measurement (CBPM)</div></li><li id="ch2.lt5" class="half_rhythm"><div>Pharmacy measurement</div></li></ul></td></tr><tr><th id="hd_b_ch2.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparisons</th><td headers="hd_b_ch2.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compared against each other</td></tr><tr><th id="hd_b_ch2.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Outcomes
|
|
</th><td headers="hd_b_ch2.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All outcomes to be measured at a minimum of 12 months. Where multiple time points are reported within each study, the longest time point only will be extracted.</p>
|
|
<p><b><u>Critical</u></b>
|
|
<ul id="ch2.l2"><li id="ch2.lt6" class="half_rhythm"><div>All-cause mortality</div></li><li id="ch2.lt7" class="half_rhythm"><div>Health-related quality of life</div></li><li id="ch2.lt8" class="half_rhythm"><div>Stroke (ischaemic or haemorrhagic)</div></li><li id="ch2.lt9" class="half_rhythm"><div>Myocardial infarction</div></li></ul>
|
|
<b><u>Important</u></b>
|
|
<ul id="ch2.l3"><li id="ch2.lt10" class="half_rhythm"><div>Reduction in clinic BP</div></li><li id="ch2.lt11" class="half_rhythm"><div>Proportion of people controlled to a target</div></li><li id="ch2.lt12" class="half_rhythm"><div>Average daily dose of antihypertensive medication</div></li><li id="ch2.lt13" class="half_rhythm"><div>Average number of visits</div></li><li id="ch2.lt14" class="half_rhythm"><div>Side effect 1: Intolerance to device</div></li><li id="ch2.lt15" class="half_rhythm"><div>Side effect 2: Hypotension (dizziness)</div></li><li id="ch2.lt16" class="half_rhythm"><div>[Combined cardiovascular disease outcomes in the absence of MI and stroke data]</div></li><li id="ch2.lt17" class="half_rhythm"><div>[Coronary heart disease outcome in the absence of MI data]</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_ch2.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_ch2.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Randomised control trials (RCT) and systematic reviews (SR)</p>
|
|
<p>Non-randomised studies in the absence of RCT and SR evidence</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2tab2"><div id="ch2.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch2.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_ch2.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Intervention and comparison</th><th id="hd_h_ch2.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Details</th><th id="hd_h_ch2.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Population</th><th id="hd_h_ch2.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Green 2008<a class="bibr" href="#ch2.ref49" rid="ch2.ref49"><sup>49</sup></a></td><td headers="hd_h_ch2.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Home monitoring with telemonitoring, n=259</p>
|
|
<p>versus Home monitoring with telemonitoring with pharmacist care in addition to physician contact, n=261</p>
|
|
<p>versus Usual Care, n=258</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HBPM with telemonitoring: OmronHem-705 device used. Blood pressure measured for at least 2 days per week with a minimum of 2 measurements at a time (duration not specified). HBPM target of 135/85mmHg, CBPM target of 140/90mmHg. Readings sent via email. Number of GP visits or communications not specified.</p>
|
|
<p>HBPM with telemonitoring and pharmacist care: Those assigned to home BP monitoring and Web training plus pharmacist care had the same strategy as home blood pressure monitoring with telemonitoring plus a pharmacist assisting them to improve their BP through telephone calls. HBPM target of 135/85mmHg, CBPM target of 140/90mmHg. The communication occurred every 2 weeks until BP was controlled. Number of GP visits not specified.</p>
|
|
<p>Usual care: Those assigned to usual care were told their BP was not in control and were encouraged to work with their physician to improve it. No further details given for number of GP visits and communication.</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults without Type 2 diabetes (n=778)</p>
|
|
<p>Mean age =59.1 years (SD =8.5 years)</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 12 months:
|
|
<ul id="ch2.l5"><li id="ch2.lt26" class="half_rhythm"><div>Mortality</div></li><li id="ch2.lt27" class="half_rhythm"><div>Non-fatal cardiovascular events</div></li><li id="ch2.lt28" class="half_rhythm"><div>Change in blood pressure</div></li><li id="ch2.lt29" class="half_rhythm"><div>Proportion controlled to a target</div></li><li id="ch2.lt30" class="half_rhythm"><div>Quality of life</div></li></ul></td><td headers="hd_h_ch2.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Downgraded for intervention indirectness as it was comparing with usual care not clearly stating clinic measurement</td></tr><tr><td headers="hd_h_ch2.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Logan 2012<a class="bibr" href="#ch2.ref73" rid="ch2.ref73"><sup>73</sup></a></td><td headers="hd_h_ch2.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Home monitoring with telemonitoring, n=55</p>
|
|
<p>versus</p>
|
|
<p>Home monitoring without telemonitoring, n=55</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HBPM with telemonitoring: Validated Bluetooth-enabled home BP device used. Guideline target of <130/80mmHg. BP readings were automatically transmitted by a smartphone to application servers. Messages instructed people whose BP fell outside the target range to take additional BP readings, which were then used to provide advice on the urgency to make a follow-up visit with their physician. No further details given for number of measurements, GP visits or how often measurements were taken.</p>
|
|
<p>HBPM without telemonitoring: Subjects were issued with an identical appearing home BP device but without built-in Bluetooth capability for use during the study. No further details given for GP visits, communications or how often measurements were taken.</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults with diabetes (n=110)</p>
|
|
<p>Mean age =62.9 years (SD=8.4 years)</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 12 months:
|
|
<ul id="ch2.l6"><li id="ch2.lt31" class="half_rhythm"><div>Number of GP visits</div></li></ul></td><td headers="hd_h_ch2.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Downgraded for population indirectness, as it did not specify type of diabetes present</td></tr><tr><td headers="hd_h_ch2.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">McManus 2010<a class="bibr" href="#ch2.ref84" rid="ch2.ref84"><sup>84</sup></a></td><td headers="hd_h_ch2.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Home monitoring (with self-titration) and telemonitoring, n=263</p>
|
|
<p>versus Clinic monitoring, n=264</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Home monitoring (HM) with telemonitoring: Participants were trained to monitor their own blood pressure for the first week of each month, with 2 self-measurements being made each morning with a 5-min interval and the second reading acted upon. A validated automated sphygmomanometer (Omron 705IT) was used to transmit blood pressure readings to the research team by means of an automated modem device, which was connected to the sphygmomanometer and plugged into a telephone socket. If participants had 2 consecutive months of readings above target, they were instructed to make medication changes in accordance with the titration schedule by requesting a new prescription without seeing their family doctor. Participants returned to their family doctor for a further titration schedule if blood pressure remained above target after 2 changes. Home targets were 130/85 mmHg for people without diabetes and 130/75 mmHg for participants with diabetes. Monthly summaries of each participant’s blood pressure readings were sent to their family doctor. Number of GP visits not stated.</p>
|
|
<p>Clinic monitoring: They were asked to attend a review by their family doctor. Number of GP visits not stated. No specific instructions were given to the clinicians about the content of this visit other than to review medication.</p>
|
|
<p>Thereafter, care was at the discretion of the family doctor. No further details given for communications and targets were not specified.</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults with diabetes (n=35)</p>
|
|
<p>Mean age =66.4 years (SD=8.8 years)</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 12 months:
|
|
<ul id="ch2.l7"><li id="ch2.lt32" class="half_rhythm"><div>Quality of life</div></li><li id="ch2.lt33" class="half_rhythm"><div>Change in clinic blood pressure</div></li></ul></td><td headers="hd_h_ch2.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Downgraded for population indirectness, as it did not specify type of diabetes</p>
|
|
<p>Participants receiving more than 2 antihypertensive drugs at baseline were excluded</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">McManus 2018<a class="bibr" href="#ch2.ref85" rid="ch2.ref85"><sup>85</sup></a></td><td headers="hd_h_ch2.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Home monitoring without telemonitoring, n=395</p>
|
|
<p>versus</p>
|
|
<p>Home monitoring with telemonitoring, n=393</p>
|
|
<p>versus</p>
|
|
<p>Clinic monitoring, n=394</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HBPM without telemonitoring: Device used was a validated automated electronic sphygmomanometer (Omron M10-IT). Participants were asked to monitor their own blood pressure in their non-dominant arm, twice each morning and evening, for the first week of every month using standard recommendations. At the end of each monitoring week, they were asked to record their readings on paper and send them for review to their practice in a reply-paid envelope. Attending clinicians were asked to review their readings on a monthly basis. BP targets: <135/85 mmHg at home for those younger than 80 years, <145/85 mmHg at home for those 80 years or older, and <135/75 mmHg at home for those with diabetes. Clinicians in the trial had complete freedom to adjust antihypertensive and other medication as they sought fit, regardless of which group an individual was randomly assigned to and with no restriction on type of drug used. No further details given on number of GP visits.</p>
|
|
<p>HBPM with telemonitoring: Participants were trained to send readings via a simple free SMS text-based telemonitoring service with web-based data entry back up. They were asked to monitor their own blood pressure in their non-dominant arm, twice each morning and evening, for the first week of every month using standard recommendations. They were prompted to make contact with their practice if their average blood pressure was above target, and presented readings to attending clinicians via a web interface. Attending clinicians were asked to review their readings on a monthly basis. BP targets: <135/85 mmHg at home for those younger than 80 years, <145/85 mmHg at home for those 80 years or older, and <135/75 mmHg at home for those with diabetes. Clinicians in the trial had complete freedom to adjust antihypertensive and other medication as they sought fit, regardless of which group an individual was randomly assigned to and with no restriction on type of drug used. No further details given on number of GP visits.</p>
|
|
<p>Clinic monitoring: Participants were managed with titration of antihypertensive treatment based on clinic blood pressure measurements at the discretion of their attending health-care professional. Attending clinicians were asked to review participants as often as they wished. BP targets: <135/85 mmHg at home for those younger than 80 years, <145/85 mmHg at home for those 80 years or older, and <135/75 mmHg at home for those with diabetes. Clinicians in the trial had complete freedom to adjust antihypertensive and other medication as they sought fit, regardless of which group an individual was randomly assigned to and with no restriction on type of drug used. No further details given on number of GP visits or communications.</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults with diabetes (n=108)</p>
|
|
<p>Mean age =66.93 years (SD=9.43 years)</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 12 months:
|
|
<ul id="ch2.l8"><li id="ch2.lt34" class="half_rhythm"><div>Change in clinic blood pressure</div></li><li id="ch2.lt35" class="half_rhythm"><div>Cardiovascul ar events</div></li><li id="ch2.lt36" class="half_rhythm"><div>Overall defined daily dose</div></li><li id="ch2.lt37" class="half_rhythm"><div>Mean number of consultations</div></li><li id="ch2.lt38" class="half_rhythm"><div>Quality of life</div></li><li id="ch2.lt39" class="half_rhythm"><div>Dizziness</div></li></ul></td><td headers="hd_h_ch2.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Downgraded for population indirectness, as it did not specify type of diabetes present</td></tr><tr><td headers="hd_h_ch2.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Simpson 2011<a class="bibr" href="#ch2.ref122" rid="ch2.ref122"><sup>122</sup></a></td><td headers="hd_h_ch2.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Pharmacy monitoring, n=131</p>
|
|
<p>versus</p>
|
|
<p>Usual care, n=129</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Pharmacy monitoring: Blood pressure was measured according to the Canadian Hypertension Education Program recommendations using the BPTru BPM-100 automated machine set to report the average of 5 measurements at 1-minute intervals, no further details on how often. Pharmacists collaborated with primary care physicians and recommended medication changes where appropriate, as per guideline recommendations. No further details given on number of GP visits or communication and targets were not specified.</p>
|
|
<p>Usual care: Participants received usual care by the primary care team without contributions from study pharmacists, except for standardized blood pressure measurements at the end of the follow-up period. No further details given for number of GP visits or communication and targets were not specified.</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults with Type 2 diabetes (n=260)</p>
|
|
<p>Mean age =59.1 years (SD=11.6 years)</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 12 months:
|
|
<ul id="ch2.l9"><li id="ch2.lt40" class="half_rhythm"><div>All-cause mortality</div></li><li id="ch2.lt41" class="half_rhythm"><div>Change in blood pressure</div></li><li id="ch2.lt42" class="half_rhythm"><div>Number of visits</div></li></ul></td><td headers="hd_h_ch2.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Downgraded for intervention indirectness as it was comparing with usual care not clearly stating clinic measurement.</td></tr><tr><td headers="hd_h_ch2.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stergiou 2014<a class="bibr" href="#ch2.ref131" rid="ch2.ref131"><sup>131</sup></a></td><td headers="hd_h_ch2.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Home monitoring without telemonitoring, n=73</p>
|
|
<p>versus</p>
|
|
<p>Ambulatory and clinic monitoring, n=72</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HBPM without telemonitoring: Used validated oscillometric devices with automated memory. Treatment titration during the 12-month follow-up period was made exclusively based on home BP measurements. Target of average home BP <135/85 mmHg for low/moderate-risk participants and <125/80 mmHg for high-risk participants. Treatment titration was performed at 4-week intervals until the pre-set BP goal was reached. Participants were treated for 12 months with the aim to reach the pre-set BP goals. Controlled hypertension was defined as home BP levels at the pre-set goal in 2 visits 4 weeks apart. No further details given for number of GP visits, communication or number of measurements.</p>
|
|
<p>Ambulatory and clinic monitoring: Ambulatory BP was monitored on a routine workday at 20-minute intervals for 24 hours using validated oscillometric devices. Treatment titration during the 12-month follow-up period was made on clinic and ambulatory BP measurements. Target was to reach clinic BP <140/90 mmHg and awake ambulatory BP <135/85 mmHg for low/moderate-risk people and <130/80 mmHg and <125/80 mmHg, respectively, for high-risk people. Treatment titration was performed at 4-week intervals until the pre-set BP goal was reached. Participants were treated for 12 months with the aim to reach the pre-set BP goals. No further details given for number of GP visits, communication or number of measurements.</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults with diabetes (n=145)</p>
|
|
<p>Mean age=50.75 years (SD=10.3 years)</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 12 months:
|
|
<ul id="ch2.l10"><li id="ch2.lt43" class="half_rhythm"><div>Change in clinic blood pressure</div></li></ul></td><td headers="hd_h_ch2.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Downgraded for population indirectness, as it did not specify type of diabetes present</td></tr><tr><td headers="hd_h_ch2.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tucker 2017<a class="bibr" href="#ch2.ref135" rid="ch2.ref135"><sup>135</sup></a></td><td headers="hd_h_ch2.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Home monitoring with telemonitoring (HM with TM), n=616</p>
|
|
<p>versus</p>
|
|
<p>Home monitoring without telemonitoring (HM), n=973</p>
|
|
<p>versus</p>
|
|
<p>Usual care, (n=961 in HM, n=573 in HM with TM)</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HBPM with telemonitoring: Self-monitoring had to be without medical professional input (that is, by participant with or without carer support) and using a validated monitor, with or without other co-interventions, and where a comparator group had no organised self-measurement of BP. Targets ranged from 120/75 to 140/90 from home and from 130/80 to 140/90 for clinic. Number of readings/sessions ranged from 1 to 3. Self-monitoring ranged from occurring daily for 1 week every 2 months to daily for the first week of each month. No further details given on number of GP visits or communication.</p>
|
|
<p>HBPM without telemonitoring: Self-monitoring had to be without medical professional input (that is, by participant with or without carer support) and using a validated monitor, with or without other co-interventions, and where a comparator group had no organised self-measurement of BP. Targets ranged from 120/75 to 140/90 from home and from 130/80 to 140/90 for clinic. Number of readings/sessions ranged from 1 to 3. Self-monitoring ranged from occurring daily for 1 week every 2 months to daily for the first week of each month. No further details given on the telemonitoring aspect. No further details given on number of GP visits or communication.</p>
|
|
<p>Usual care: No further details given about usual care. Targets ranged from 120/75 to 140/90 from home and from 130/80 to 140/90 for clinic. No further details given on number of GP visits or communication.</p>
|
|
</td><td headers="hd_h_ch2.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults (n=3,123)</td><td headers="hd_h_ch2.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">At 12 months:
|
|
<ul id="ch2.l11"><li id="ch2.lt44" class="half_rhythm"><div>Proportion of people controlled to a target</div></li><li id="ch2.lt45" class="half_rhythm"><div>Change in clinic blood pressure</div></li></ul></td><td headers="hd_h_ch2.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>IPD</p>
|
|
<p>Tucker 2015<a class="bibr" href="#ch2.ref136" rid="ch2.ref136"><sup>136</sup></a> merged with this study</p>
|
|
<p>Downgraded once for intervention indirectness and once for population indirectness, as it was comparing with usual care not clearly stating clinic measurement and did not specify type of diabetes present</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2tab3"><div id="ch2.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Clinical evidence summary: Home monitoring versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab3_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch2.tab3_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab3_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch2.tab3_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch2.tab3_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch2.tab3_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch2.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.tab3_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch2.tab3_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch2.tab3_1_1_1_5" id="hd_h_ch2.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Control</th><th headers="hd_h_ch2.tab3_1_1_1_5" id="hd_h_ch2.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Home monitoring without telemonitoring versus clinic monitoring (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Cardiovascular events (new atrial fibrillation, angina, myocardial infarction, coronary artery bypass graft or angioplasty, stroke, peripheral vascular disease, or heart failure)</td><td headers="hd_h_ch2.tab3_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>678</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>3</sup><sup>,</sup><sup>4</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.42</p>
|
|
<p>(0.61 to 3.33)</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1 hd_h_ch2.tab3_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 per 1,000</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 more per 1,000 (from 10 fewer to 61 more)</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in clinic blood pressure, (systolic blood pressure, change scores)</td><td headers="hd_h_ch2.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2,610</p>
|
|
<p>(2 studies)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>5</sup></p>
|
|
<p>due to risk of bias, indirectness,</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>1</sup>Control group risk not available.</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in clinic blood pressure, systolic blood pressure, in the intervention groups was 2.23 mmHg lower (3.84 to 0.63 lower)</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in clinic blood pressure, (diastolic blood pressure, change scores)</td><td headers="hd_h_ch2.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2,610</p>
|
|
<p>(2 studies)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>5</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>1</sup>Control group risk not available.</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in clinic blood pressure, diastolic blood pressure, in clinic diastolic blood pressure in the intervention groups was 1.31 mmHg lower (2.19 to 0.44 lower)</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Proportion not meeting target (varied target due to IPD – mode 140/90mmHg)</p>
|
|
<p>(Uncontrolled blood pressure – not meeting trial target)</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1,934</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>4</sup><sup>,</sup><sup>5</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.99</p>
|
|
<p>(0.72 to 1.36)</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1 hd_h_ch2.tab3_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 per 1,000</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 fewer per 1,000 (from 20 fewer to 26 more)</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Overall defined daily dose</td><td headers="hd_h_ch2.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>678</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean overall defined daily dose in the control groups was 2.27</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean overall defined daily dose in the intervention groups was 0.15 higher (0.11 lower to 0.41 higher)</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mean number of consultations for hypertension</td><td headers="hd_h_ch2.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>678</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of consultations for hypertension in the control groups was 2.1</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of consultations for hypertension in the intervention groups was 0.30 lower (0.65 lower to 0.05 higher)</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Dizziness, hypertension specific symptoms, (no further details of definition)</td><td headers="hd_h_ch2.tab3_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>672</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>3</sup><sup>,</sup><sup>4</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.88</p>
|
|
<p>(0.63 to 1.24)</p>
|
|
</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1 hd_h_ch2.tab3_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">175 per 1,000</td><td headers="hd_h_ch2.tab3_1_1_1_5 hd_h_ch2.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 fewer per 1,000 (from 65 fewer to 42 more)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.tab3_1"><p class="no_margin">Control group risk not available.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.tab3_2"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.tab3_3"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch2.tab3_4"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch2.tab3_5"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population and intervention respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab4"><div id="ch2.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Clinical evidence summary: Home monitoring without telemonitoring versus ambulatory and clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab4_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch2.tab4_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab4_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch2.tab4_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch2.tab4_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch2.tab4_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch2.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.tab4_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch2.tab4_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch2.tab4_1_1_1_5" id="hd_h_ch2.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Ambulatory monitoring</th><th headers="hd_h_ch2.tab4_1_1_1_5" id="hd_h_ch2.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with home monitoring without TM (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in clinic blood pressure, systolic blood pressure, change score</td><td headers="hd_h_ch2.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>145</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness,</p>
|
|
</td><td headers="hd_h_ch2.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab4_1_1_1_5 hd_h_ch2.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>1</sup>Control group risk not available</td><td headers="hd_h_ch2.tab4_1_1_1_5 hd_h_ch2.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in clinic blood pressure, systolic blood pressure, in the intervention groups was 2.1 mmHg lower (6.8 lower to 2.6 higher)</td></tr><tr><td headers="hd_h_ch2.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in clinic blood pressure, diastolic blood pressure, change score</td><td headers="hd_h_ch2.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>145</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness,</p>
|
|
</td><td headers="hd_h_ch2.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab4_1_1_1_5 hd_h_ch2.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>1</sup>Control group risk not available</td><td headers="hd_h_ch2.tab4_1_1_1_5 hd_h_ch2.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in clinic blood pressure, diastolic blood pressure, in the intervention groups was 1.4 mmHg lower (4.3 lower to 1.5 higher)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.tab4_1"><p class="no_margin">Control group not available.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.tab4_2"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.tab4_3"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab5"><div id="ch2.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Clinical evidence summary: Home monitoring with telemonitoring versus home monitoring without telemonitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab5_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch2.tab5_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab5_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch2.tab5_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch2.tab5_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch2.tab5_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch2.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.tab5_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch2.tab5_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch2.tab5_1_1_1_5" id="hd_h_ch2.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Home monitoring without TM</th><th headers="hd_h_ch2.tab5_1_1_1_5" id="hd_h_ch2.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with home monitoring with TM (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab5_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Cardiovascular events (new atrial fibrillation, angina, myocardial infarction, coronary artery bypass graft or angioplasty, stroke, peripheral vascular disease, or heart failure)</td><td headers="hd_h_ch2.tab5_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>658</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>3</sup><sup>,</sup><sup>4</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.91</p>
|
|
<p>(0.41 to 2.04)</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1 hd_h_ch2.tab5_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 per 1,000</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 fewer per 1,000 (from 22 fewer to 38 more)</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in clinic blood pressure, systolic blood pressure, final score</td><td headers="hd_h_ch2.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>655</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in clinic blood pressure, systolic in the control group was 137 mmHg</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in clinic blood pressure, systolic blood pressure, in the intervention group was 1.00 mmHg lower (3.51 lower to 1.51 higher)</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in clinic blood pressure, diastolic blood pressure, final score</td><td headers="hd_h_ch2.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>655</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in clinic blood pressure, diastolic in the control groups was 77.8 mmHg</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in clinic blood pressure, diastolic blood pressure, in the intervention group was 0.90 mmHg higher (0.62 lower to 2.42 higher)</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Overall defined daily dose</td><td headers="hd_h_ch2.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>658</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean overall defined daily dose in the control groups was 2.42</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean overall defined daily dose in the intervention groups was 0.27 higher (0 to 0.54 higher)</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Average number of GP visits</td><td headers="hd_h_ch2.tab5_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>100</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>3</sup><sup>,</sup><sup>4</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.64</p>
|
|
<p>(0.19 to 2.13)</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1 hd_h_ch2.tab5_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">122 per 1,000</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44 fewer per 1,000 (from 99 fewer to 138 more)</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mean number of consultations for hypertension</td><td headers="hd_h_ch2.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>658</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of consultations for hypertension in the control groups was 1.8</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of consultations for hypertension in the intervention groups was 0.40 higher (0.01 to 0.79 higher)</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Dizziness, hypertension specific symptoms</td><td headers="hd_h_ch2.tab5_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>650</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>3</sup><sup>,</sup><sup>4</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.43</p>
|
|
<p>(1.03 to 1.98)</p>
|
|
</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1 hd_h_ch2.tab5_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">154 per 1,000</td><td headers="hd_h_ch2.tab5_1_1_1_5 hd_h_ch2.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66 more per 1,000 (from 5 more to 151 more)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.tab5_1"><p class="no_margin">Control group risk not available.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.tab5_2"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.tab5_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch2.tab5_4"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab6"><div id="ch2.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">Clinical evidence summary: Home monitoring with telemonitoring versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab6_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch2.tab6_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab6_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch2.tab6_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch2.tab6_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch2.tab6_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch2.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.tab6_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch2.tab6_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch2.tab6_1_1_1_5" id="hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Control</th><th headers="hd_h_ch2.tab6_1_1_1_5" id="hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Home monitoring with telemonitoring versus clinic monitoring (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>493</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>3</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Peto OR 7.45</p>
|
|
<p>(0.46 to 119.44)</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1 hd_h_ch2.tab6_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 events in control arm</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 more per 1,000 (from 10 fewer to 20 more)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Cardiovascular events (defined as new atrial fibrillation, angina, myocardial infarction, coronary artery bypass graft or angioplasty, stroke, peripheral vascular disease, or heart failure in 1 study, defined as non-fatal cardiovascular events in another)</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1,173</p>
|
|
<p>(2 studies)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>3</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.43</p>
|
|
<p>(0.66 to 3.08)</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1 hd_h_ch2.tab6_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 per 1,000</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 more per 1,000 (from 6 fewer to 35 more)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, emotional subscale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>493</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life – emotional scale in the control groups was 71.5</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - emotional scale in the intervention groups was 0.6 higher (2.45 lower to 3.65 higher)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, physical subscale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>493</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life – physical in the control groups was 78.1</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - physical in the intervention groups was 0.4 lower (5.53 lower to 4.73 higher)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, general subscale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>493</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life – general in the control groups was 66.7</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - general in the intervention groups was 0.1 lower (3.75 lower to 3.55 higher)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in clinic blood pressure – systolic blood pressure, change score</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2,357</p>
|
|
<p>(3 studies)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>5</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due to risk of bias, inconsistency, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>4</sup>Control group risk not available.</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in clinic blood pressure – systolic blood pressure in the intervention groups was 3.08 mmHg lower (5.89 to 0.58 lower)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in clinic blood pressure - diastolic blood pressure, change score</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2,357</p>
|
|
<p>(3 studies)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due to risk of bias, indirectness,</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>4</sup>Control group risk not available.</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in clinic blood pressure - diastolic blood pressure in the intervention groups was 0.83 mmHg lower (1.51 to 0.15 lower)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Proportion controlled to a target</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>493</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>3</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.22</p>
|
|
<p>(0.95 to 1.56)</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1 hd_h_ch2.tab6_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">304 per 1,000</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67 more per 1,000 (from 15 fewer to 170 more)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Proportion not meeting target (varied target due to IPD – mode 140/90 mmHg)</p>
|
|
<p>(Uncontrolled blood pressure – not meeting trial target)</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1,189</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>3</sup><sup>,</sup><sup>6</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.90</p>
|
|
<p>(0.69 to 1.15)</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1 hd_h_ch2.tab6_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">164 per 1,000</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 fewer per 1,000 (from 51 fewer to 25 more)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Overall defined daily dose</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>680</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean overall defined daily dose in the control groups was 2.27</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean overall defined daily dose in the intervention groups was 0.42 higher (0.16 to 0.68 higher)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mean number of consultations for hypertension</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>680</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of consultations for hypertension in the control groups was 2.1</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of consultations for hypertension in the intervention groups was 0.10 higher (0.25 lower to 0.45 higher)</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Dizziness, hypertension specific symptoms, (no further details of definition)</td><td headers="hd_h_ch2.tab6_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>674</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.26</p>
|
|
<p>(0.93 to 1.71)</p>
|
|
</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1 hd_h_ch2.tab6_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">175 per 1,000</td><td headers="hd_h_ch2.tab6_1_1_1_5 hd_h_ch2.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 more per 1,000 (from 12 fewer to 124 more)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.tab6_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.tab6_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.tab6_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch2.tab6_4"><p class="no_margin">Control group risk not available.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch2.tab6_5"><p class="no_margin">‘Downgraded by 1 or 2 incrments due to heterogeneity, unexplained by subgroup analyses so random effects was used.</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="ch2.tab6_6"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect intervention respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab7"><div id="ch2.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">Clinical evidence summary: Home monitoring with telemonitoring and pharmacist care versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab7_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch2.tab7_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab7_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch2.tab7_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch2.tab7_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch2.tab7_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch2.tab7_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.tab7_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch2.tab7_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch2.tab7_1_1_1_5" id="hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Clinic monitoring</th><th headers="hd_h_ch2.tab7_1_1_1_5" id="hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Home monitoring with TM and pharmacist care (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab7_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality</td><td headers="hd_h_ch2.tab7_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>484</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Peto OR 7.71</p>
|
|
<p>(0.15 to 388.76)</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1 hd_h_ch2.tab7_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 events in control group</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0 more per 1,000 (from 10 fewer to 20 more)</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Non-fatal Cardiovascular events, no further details given</td><td headers="hd_h_ch2.tab7_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>484</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.56</p>
|
|
<p>(0.26 to 9.27)</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1 hd_h_ch2.tab7_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 per 1,000</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 more per 1,000 (from 6 fewer to 67 more)</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in blood pressure, systolic change score</td><td headers="hd_h_ch2.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>484</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in systolic blood pressure in the control group was −5.3 mmHg</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in systolic blood pressure in the intervention groups was 8.90 mmHg lower (11.43 to 6.37 lower)</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in blood pressure, diastolic change score</td><td headers="hd_h_ch2.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>484</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in diastolic blood pressure in the control groups was −3.5 mmHg</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in diastolic blood pressure in the intervention groups was 3.50 mmHg lower (4.91 to 2.09 lower)</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Proportion controlled to a target</td><td headers="hd_h_ch2.tab7_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>484</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.84</p>
|
|
<p>(1.48 to 2.28)</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1 hd_h_ch2.tab7_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">308 per 1,000</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">259 more per 1,000 (from 148 more to 394 more)</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, emotional subscale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>484</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - emotional scale in the control groups was 71.5</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - emotional scale in the intervention groups was 0.20 higher (3.14 lower to 3.54 higher)</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, physical subscale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>484</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - physical in the control groups was 78.1</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - physical in the intervention groups was 2.90 higher (1.93 lower to 7.73 higher)</td></tr><tr><td headers="hd_h_ch2.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, general subscale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>484</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - general in the control groups was 66.7</td><td headers="hd_h_ch2.tab7_1_1_1_5 hd_h_ch2.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - general in the intervention groups was 0.10 lower (3.9 lower to 3.7 higher)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.tab7_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.tab7_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect intervention respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.tab7_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab8"><div id="ch2.tab8" class="table"><h3><span class="label">Table 8</span><span class="title">Clinical evidence summary: Home monitoring with telemonitoring and pharmacist care versus home monitoring with telemonitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab8_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch2.tab8_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab8_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch2.tab8_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch2.tab8_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch2.tab8_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch2.tab8_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.tab8_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch2.tab8_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch2.tab8_1_1_1_5" id="hd_h_ch2.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Home monitoring with telemonitoring</th><th headers="hd_h_ch2.tab8_1_1_1_5" id="hd_h_ch2.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Home monitoring with TM + pharmacist care (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab8_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality</td><td headers="hd_h_ch2.tab8_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>483</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.52</p>
|
|
<p>(0.05 to 5.69)</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1 hd_h_ch2.tab8_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 per 1,000</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 fewer per 1,000 (from 8 fewer to 38 more)</td></tr><tr><td headers="hd_h_ch2.tab8_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Non-fatal Cardiovascular events</td><td headers="hd_h_ch2.tab8_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>483</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.78</p>
|
|
<p>(0.18 to 3.44)</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1 hd_h_ch2.tab8_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 per 1,000</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 fewer per 1,000 (from 13 fewer to 39 more)</td></tr><tr><td headers="hd_h_ch2.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in blood pressure, systolic change score</td><td headers="hd_h_ch2.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>483</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in systolic blood pressure in the control groups was −8.2mmHg</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in systolic blood pressure in the intervention groups was 6.00 mmHg lower (8.53 to 3.47 lower)</td></tr><tr><td headers="hd_h_ch2.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in blood pressure, diastolic change score</td><td headers="hd_h_ch2.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>483</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in diastolic blood pressure in the control groups was −4.4mmHg</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in diastolic blood pressure in the intervention groups was 2.60 mmHg lower (4.01 to 1.19 lower)</td></tr><tr><td headers="hd_h_ch2.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, emotional sub scale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>483</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - emotional scale in the control groups was 72.1</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - emotional scale in the intervention groups was 0.40 lower (3.67 lower to 2.87 higher)</td></tr><tr><td headers="hd_h_ch2.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, physical sub scale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>483</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - physical in the control groups was 77.7</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - physical in the intervention groups was 3.30 higher (1.77 lower to 8.37 higher)</td></tr><tr><td headers="hd_h_ch2.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, SF-12, general sub scale, 0–100, high is good outcome</td><td headers="hd_h_ch2.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>483</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - general in the control groups was 66.6</td><td headers="hd_h_ch2.tab8_1_1_1_5 hd_h_ch2.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life - general in the intervention groups was 0.00 higher (3.85 lower to 3.85 higher)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.tab8_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.tab8_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect intervention respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.tab8_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab9"><div id="ch2.tab9" class="table"><h3><span class="label">Table 9</span><span class="title">Clinical evidence summary: Home-monitoring (with self-titration) and telemonitoring versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab9_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch2.tab9_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab9_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch2.tab9_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch2.tab9_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch2.tab9_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch2.tab9_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.tab9_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch2.tab9_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch2.tab9_1_1_1_5" id="hd_h_ch2.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Clinic/office</th><th headers="hd_h_ch2.tab9_1_1_1_5" id="hd_h_ch2.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Self-monitoring (with self-titration) and telemonitoring (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in blood pressure, systolic final score</td><td headers="hd_h_ch2.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>480</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean blood pressure systolic in the control groups was 140.3mmHg</td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in blood pressure systolic in the intervention groups was 5.60mmHg lower (8.91 to 2.29 lower)</td></tr><tr><td headers="hd_h_ch2.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in blood pressure, diastolic final score</td><td headers="hd_h_ch2.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>480</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean blood pressure diastolic in the control groups was 79.8mmHg</td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in blood pressure diastolic in the intervention groups was 2.30 mmHg lower (4.41 to 0.19 lower)</td></tr><tr><td headers="hd_h_ch2.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quality of life, EQ-5D,</td><td headers="hd_h_ch2.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>480</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life, EQ-5D, in the control groups was 0.838</td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean quality of life, eq-5d, in the intervention groups was 0.01 lower (0.06 lower to 0.03 higher)</td></tr><tr><td headers="hd_h_ch2.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mean number of consultations for hypertension</td><td headers="hd_h_ch2.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>480</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of consultations in the control groups was 3.5</td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of consultations in the intervention groups was 0.30 lower (0.72 lower to 0.12 higher)</td></tr><tr><td headers="hd_h_ch2.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mean number of antihypertensive drugs</td><td headers="hd_h_ch2.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>480</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of antihypertensive drugs in the control groups was 1.7</td><td headers="hd_h_ch2.tab9_1_1_1_5 hd_h_ch2.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean number of antihypertensive drugs in the intervention groups was 0.40 higher (0.12 to 0.68 higher)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.tab9_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.tab9_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab10"><div id="ch2.tab10" class="table"><h3><span class="label">Table 10</span><span class="title">Clinical evidence summary: Pharmacy monitoring versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab10_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_ch2.tab10_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_ch2.tab10_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_ch2.tab10_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_ch2.tab10_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_ch2.tab10_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_ch2.tab10_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.tab10_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_ch2.tab10_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_ch2.tab10_1_1_1_5" id="hd_h_ch2.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Clinic/office</th><th headers="hd_h_ch2.tab10_1_1_1_5" id="hd_h_ch2.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Pharmacy (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab10_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality</td><td headers="hd_h_ch2.tab10_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>260</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Peto OR 0.13</p>
|
|
<p>(0 to 6.72)</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_1 hd_h_ch2.tab10_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 per 1,000</td><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 fewer per 1,000 (from 30 fewer to 10 more)</td></tr><tr><td headers="hd_h_ch2.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in blood pressure, systolic blood pressure, change score</td><td headers="hd_h_ch2.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>260</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, indirectness, imprecision</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in blood pressure, systolic in the control group was 2.5 mmHg</td><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in blood pressure, systolic blood pressure, in the intervention group was 4.90 mmHg lower (8.75 to 1.05 lower)</td></tr><tr><td headers="hd_h_ch2.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reduction in blood pressure, diastolic blood pressure, change score</td><td headers="hd_h_ch2.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>260</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, indirectness</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean change in blood pressure, diastolic in the control group was 0.6 mmHg</td><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The mean reduction in blood pressure, diastolic blood pressure, in the intervention group was 2.90 mmHg lower (5.70 to 0.10 lower)</td></tr><tr><td headers="hd_h_ch2.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Contacts per patients with all resources (excluding pharmacists)</td><td headers="hd_h_ch2.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>260</p>
|
|
<p>(1 study)</p>
|
|
<p>1 years</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>VERY LOW</p>
|
|
<p>due to risk of bias, indirectness,</p>
|
|
</td><td headers="hd_h_ch2.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The median number of contacts per participant in the control group was 2. The interquartile range was 2 to 5.</td><td headers="hd_h_ch2.tab10_1_1_1_5 hd_h_ch2.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The median number of contacts per participant in the intervention group was 3. The interquartile range was 1 to 6.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.tab10_1"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect intervention respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.tab10_2"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.tab10_3"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab11"><div id="ch2.tab11" class="table"><h3><span class="label">Table 11</span><span class="title">Health economic evidence profile: Self-monitoring (with self-titration) and telemonitoring versus usual care</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_ch2.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Applicability</th><th id="hd_h_ch2.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Limitations</th><th id="hd_h_ch2.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other comments</th><th id="hd_h_ch2.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Incremental cost</th><th id="hd_h_ch2.tab11_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Incremental effects (QALYs)</th><th id="hd_h_ch2.tab11_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost effectiveness</th><th id="hd_h_ch2.tab11_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Uncertainty</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Kaambwa 2013<a class="bibr" href="#ch2.ref93" rid="ch2.ref93"><sup>93</sup></a></p>
|
|
<p>(UK)</p>
|
|
</td><td headers="hd_h_ch2.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Directly applicable<sup>(a)</sup></td><td headers="hd_h_ch2.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations<sup>(b)</sup></td><td headers="hd_h_ch2.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost–utility analysis. Markov model comparing self-management with usual care. One-year cycles. 35-year time horizon. People begin in a ‘well’ state with poorly controlled hypertension, with the possibility of moving to other states of stroke, myocardial infarction, angina, heart failure, and death. Each event state has a post state. Baseline risk based on Framingham. Extrapolation of effect from a 12-month trial based on translating BP reduction from TASMINH2 trial into a relative risk reduction from Law 2009.</td><td headers="hd_h_ch2.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Men:</p>
|
|
<p>£383</p>
|
|
<p>Women:</p>
|
|
<p>£576</p>
|
|
</td><td headers="hd_h_ch2.tab11_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Men:</p>
|
|
<p>0.24</p>
|
|
<p>Women:</p>
|
|
<p>0.12</p>
|
|
</td><td headers="hd_h_ch2.tab11_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Men:</p>
|
|
<p>£1,624 per QALY gained</p>
|
|
<p>Women:</p>
|
|
<p>£4,923 per QALY gained</p>
|
|
</td><td headers="hd_h_ch2.tab11_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Probabilistic sensitivity analysis undertaken. Probability of being cost effective at £20,000 threshold was 99% for both men and women.</p>
|
|
<p>Sensitivity analyses undertaken varying time horizon and relaxing assumption that extrapolated effectiveness difference in BP for entire time horizon by reducing the effectiveness for both men and women at different time points in the model. The only time this made self-management not cost effective was when no effectiveness difference between the interventions was assumed for women at year 2 in the model, at year 3, and at year 5.</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Abbreviations: CUA: cost utility analysis; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life years; RCT: randomised controlled trial</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="ch2.tab11_1"><p class="no_margin">UK study, CUA, long-term time horizon. Appropriate interventions.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="ch2.tab11_2"><p class="no_margin">Based on a trial of only 12 months and extrapolating this effect. CV events based on risk equation rather than directly from a trial. Relative treatment effect based on mapping BP changes. No adverse events. Costs may be out of date.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2tab12"><div id="ch2.tab12" class="table"><h3><span class="label">Table 12</span><span class="title">Staff costs</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Resource</th><th id="hd_h_ch2.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost per appointment</th><th id="hd_h_ch2.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Source</th></tr></thead><tbody><tr><td headers="hd_h_ch2.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GP</td><td headers="hd_h_ch2.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£37</td><td headers="hd_h_ch2.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Per patient contact lasting 9.22 minutes. PSSRU 2018<a class="bibr" href="#ch2.ref36" rid="ch2.ref36"><sup>36</sup></a></td></tr><tr><td headers="hd_h_ch2.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nurse (GP practice)</td><td headers="hd_h_ch2.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10.85</td><td headers="hd_h_ch2.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Based on 15.5 minutes of patient contact from PSSRU 2015, and £42 per hour (including qualifications) from PSSRU 2018<a class="bibr" href="#ch2.ref36" rid="ch2.ref36"><sup>36</sup></a></td></tr><tr><td headers="hd_h_ch2.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Community pharmacist</td><td headers="hd_h_ch2.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£18.75</td><td headers="hd_h_ch2.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Assuming the same duration of contact as a nurse (15.5 minutes of patient contact).</p>
|
|
<p>Community pharmacist cost was last included in the 2014 PSSRU<a class="bibr" href="#ch2.ref34" rid="ch2.ref34"><sup>34</sup></a>, this has been inflated to 2015/16 costs<sup>(a)</sup>.</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="ch2.tab12_1"><p class="no_margin">This is the latest available inflation index available from the PSSRU2017 based on the hospital & community health services (HCHS) pay and prices index. <a class="bibr" href="#ch2.ref35" rid="ch2.ref35"><sup>35</sup></a></p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2appatab1"><div id="ch2.appa.tab1" class="table"><h3><span class="label">Table 13</span><span class="title">Review protocol: Monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appa.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Field</th><th id="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Content</th></tr></thead><tbody><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">In adults with treated primary hypertension, what is the best method of measuring blood pressure (home, ambulatory or clinic measurement) to assess the response to treatment and prevent cardiovascular events?</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention review</p>
|
|
<p>A review of health economic evidence related to the same review question was conducted in parallel with this review. For details, see the health economic review protocol for this NICE guideline.</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The aim of this review is to assess which is the best method of measuring blood pressure (home, ambulatory or clinic measurement) to assess the response to treatment and prevent cardiovascular events in adults aged 18 years or older with treated primary hypertension.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – population / disease / condition / issue / domain</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population: Adults (over 18 years) with treated primary hypertension</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Different methods of measuring blood pressure followed by appropriate treatment* based on the blood pressure measurement (test plus treatment):
|
|
<ul id="ch2.l12"><li id="ch2.lt46" class="half_rhythm"><div>HBPM without telemonitoring</div></li><li id="ch2.lt47" class="half_rhythm"><div>HBPM with telemonitoring</div></li><li id="ch2.lt48" class="half_rhythm"><div>ABPM</div></li><li id="ch2.lt49" class="half_rhythm"><div>CBPM</div></li><li id="ch2.lt50" class="half_rhythm"><div>Pharmacy measurement</div></li></ul>
|
|
Stratify results by:
|
|
<ul id="ch2.l13"><li id="ch2.lt51" class="half_rhythm"><div>Upper arm cuff</div></li><li id="ch2.lt52" class="half_rhythm"><div>Wrist cuff</div></li><li id="ch2.lt53" class="half_rhythm"><div>Non-oscillometric</div></li></ul>
|
|
* All participants in the study should be receiving the same treatment</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – comparator(s) / control or reference (gold) standard</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compared against each other</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes and prioritisation</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All outcomes to be measured at a minimum of 12 months. Where multiple time points are reported within each study, the longest time point only will be extracted.</p>
|
|
<p><b>Critical</b>
|
|
<ul id="ch2.l14"><li id="ch2.lt54" class="half_rhythm"><div>All-cause mortality</div></li><li id="ch2.lt55" class="half_rhythm"><div>Health-related quality of life</div></li><li id="ch2.lt56" class="half_rhythm"><div>Stroke (ischaemic or haemorrhagic)</div></li><li id="ch2.lt57" class="half_rhythm"><div>Myocardial infarction</div></li></ul>
|
|
<b>Important</b>
|
|
<ul id="ch2.l15"><li id="ch2.lt58" class="half_rhythm"><div>Reduction in clinic BP</div></li><li id="ch2.lt59" class="half_rhythm"><div>Proportion of people controlled to a target</div></li><li id="ch2.lt60" class="half_rhythm"><div>Average daily dose of antihypertensive medication</div></li><li id="ch2.lt61" class="half_rhythm"><div>Average number of visits</div></li><li id="ch2.lt62" class="half_rhythm"><div>Side effect 1: Intolerance to device</div></li><li id="ch2.lt63" class="half_rhythm"><div>Side effect 2: Hypotension (dizziness)</div></li><li id="ch2.lt64" class="half_rhythm"><div>[Combined cardiovascular disease outcomes in the absence of MI and stroke data]</div></li><li id="ch2.lt65" class="half_rhythm"><div>[Coronary heart disease outcome in the absence of MI data]</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – study design</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RCTs and SRs</p>
|
|
<p>Non-randomised studies in the absence of RCT and SR evidence</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other inclusion exclusion criteria</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Minimum follow up time: 1 year</p>
|
|
<p>Exclusions:
|
|
<ul id="ch2.l16"><li id="ch2.lt66" class="half_rhythm"><div>Studies including participants with type 1 diabetes or chronic kidney disease (A3 or above [heavy proteinuria]).</div></li><li id="ch2.lt67" class="half_rhythm"><div>Indirect populations with secondary causes of hypertension such as tumours or structural vascular defects (Conn’s adenoma, phaeochromocytoma, renovascular hypertension)</div></li><li id="ch2.lt68" class="half_rhythm"><div>Pregnant women</div></li><li id="ch2.lt69" class="half_rhythm"><div>Crossover trials</div></li><li id="ch2.lt70" class="half_rhythm"><div>Children (younger than 18 years)</div></li><li id="ch2.lt71" class="half_rhythm"><div>Studies with a population of inpatients</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity / subgroup analysis, or meta-regression</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Subgroups in the presence of heterogeneity:
|
|
<ul id="ch2.l17"><li id="ch2.lt72" class="half_rhythm"><div>Age (75 as a cut off)*</div></li><li id="ch2.lt73" class="half_rhythm"><div>Presence or absence of type 2 diabetes</div></li><li id="ch2.lt74" class="half_rhythm"><div>Family origin (African and Caribbean, White, South Asian)</div></li><li id="ch2.lt75" class="half_rhythm"><div>Severity (stage 1 [BP 140–59/90–99] versus moderate stage 2 to severe [BP 160/100])</div></li></ul>
|
|
*To note that we will also extract evidence in those aged 80 years and older if this evidence is reported separately.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process – duplicate screening / selection / analysis</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A senior research fellow will undertake quality assurance prior to completion.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management (software)</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).</p>
|
|
<p>GRADEpro will be used to assess the quality of evidence for each outcome.</p>
|
|
<p>Endnote will be used for bibliography, citations, sifting and reference management.</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources – databases and dates</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Medline, Embase, the Cochrane Library</p>
|
|
<p>Language: Restrict to English only</p>
|
|
<p>Key paper:
|
|
<ul id="ch2.l18"><li id="ch2.lt76" class="half_rhythm"><div>SR Tucker 2017: Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis</div></li><li id="ch2.lt77" class="half_rhythm"><div>Uhlig 2013: Self-Measured Blood Pressure Monitoring in the Management of hypertension. A Systematic Review and Meta-analysis</div></li><li id="ch2.lt78" class="half_rhythm"><div>Omboni 2013: Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yes, 2011</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://www.nice.org.uk/guidance/cg127" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.nice.org.uk/guidance/cg127</a>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to previous protocol</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see section 4.5 of <a href="https://www.nice.org.uk/article/pmg20/chapter/4-Developing-review-questions-and-planning-the-evidence-review#planning-the-evidence-review" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy – for 1 database</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>For details, please see <a href="#ch2.appb">appendix B</a></p>
|
|
<p>Cut off of 2000</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process – forms / duplicate</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table format will be used, and published as <a href="#ch2.appd">appendix D</a> of the evidence report.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items – define all variables to be collected</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see evidence tables in <a href="#ch2.appd">Appendix D</a> (clinical evidence tables) or <a href="#ch2.apph">H</a> (health economic evidence tables).</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at outcome / study level</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Standard study checklists were used to appraise individual studies critically. For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></p>
|
|
<p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.gradeworkinggroup.org/</a></p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative synthesis</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see section 6.4 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for quantitative analysis – combining studies and exploring (in)consistency</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see the separate Methods report for this guideline.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment – publication bias, selective reporting bias</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Confidence in cumulative evidence</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see sections 6.4 and 9.1 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale / context – what is known</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details, please see the introduction to the evidence review.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of authors and guarantor</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>A <a href="https://www.nice.org.uk/guidance/cg127/history" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">multidisciplinary committee</a> developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired by Anthony Wierzbicki in line with section 3 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
<p>Staff from the NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details, please see <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding / support</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The NGC is funded by NICE and hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The NGC is funded by NICE and hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NICE funds the NGC to develop guidelines for those working in the NHS, public health and social care in England.</td></tr><tr><td headers="hd_h_ch2.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration number</td><td headers="hd_h_ch2.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CRD42018087407</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appatab2"><div id="ch2.appa.tab2" class="table"><h3><span class="label">Table 14</span><span class="title">Health economic review protocol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appa.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appa.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch2.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Review question</th><th id="hd_h_ch2.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All questions – health economic evidence</th></tr></thead><tbody><tr><td headers="hd_h_ch2.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Objectives</b>
|
|
</td><td headers="hd_h_ch2.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To identify health economic studies relevant to any of the review questions.</td></tr><tr><td headers="hd_h_ch2.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search criteria</b>
|
|
</td><td headers="hd_h_ch2.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul id="ch2.l19"><li id="ch2.lt79" class="half_rhythm"><div>Populations, interventions and comparators must be as specified in the clinical review protocol above.</div></li><li id="ch2.lt80" class="half_rhythm"><div>Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</div></li><li id="ch2.lt81" class="half_rhythm"><div>Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</div></li><li id="ch2.lt82" class="half_rhythm"><div>Unpublished reports will not be considered unless submitted as part of a call for evidence.</div></li><li id="ch2.lt83" class="half_rhythm"><div>Studies must be in English.</div></li></ul></td></tr><tr><td headers="hd_h_ch2.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search strategy</b>
|
|
</td><td headers="hd_h_ch2.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A health economic study search will be undertaken using population-specific terms and a health economic study filter – see <a href="#ch2.appb">appendix B</a> below. No date cut-off from the previous guideline was used.</td></tr><tr><td headers="hd_h_ch2.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Review strategy</b>
|
|
</td><td headers="hd_h_ch2.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2002, abstract-only studies and studies from non-OECD countries or the US will also be excluded.</p>
|
|
<p>Studies published after 2002 that were included in the previous guideline(s) will be reassessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is also identified.</p>
|
|
<p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<a class="bibr" href="#ch2.ref92" rid="ch2.ref92"><sup>92</sup></a></p>
|
|
<p><b>Inclusion and exclusion criteria</b>
|
|
<ul id="ch2.l20"><li id="ch2.lt84" class="half_rhythm"><div>If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’, then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</div></li><li id="ch2.lt85" class="half_rhythm"><div>If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’, then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</div></li><li id="ch2.lt86" class="half_rhythm"><div>If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both, then there is discretion over whether it should be included.</div></li></ul>
|
|
<b>Where there is discretion</b></p>
|
|
<p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to exclude selectively the remaining studies. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p>
|
|
<p>The health economist will be guided by the following hierarchies.</p>
|
|
<p><i>Setting:</i>
|
|
<ul id="ch2.l21"><li id="ch2.lt87" class="half_rhythm"><div>UK NHS (most applicable).</div></li><li id="ch2.lt88" class="half_rhythm"><div>OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).</div></li><li id="ch2.lt89" class="half_rhythm"><div>OECD countries with predominantly private health insurance systems (for example, Switzerland).</div></li><li id="ch2.lt90" class="half_rhythm"><div>Studies set in non-OECD countries or in the US will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Health economic study type:</i>
|
|
<ul id="ch2.l22"><li id="ch2.lt91" class="half_rhythm"><div>Cost–utility analysis (most applicable).</div></li><li id="ch2.lt92" class="half_rhythm"><div>Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).</div></li><li id="ch2.lt93" class="half_rhythm"><div>Comparative cost analysis.</div></li><li id="ch2.lt94" class="half_rhythm"><div>Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Year of analysis:</i>
|
|
<ul id="ch2.l23"><li id="ch2.lt95" class="half_rhythm"><div>The more recent the study, the more applicable it will be.</div></li><li id="ch2.lt96" class="half_rhythm"><div>Studies published in 2002 or later (including any such studies included in the previous guideline[s]) but that depend on unit costs and resource data entirely or predominantly before 2002 will be rated as ‘Not applicable’.</div></li><li id="ch2.lt97" class="half_rhythm"><div>Studies published before 2002 (including any such studies included in the previous guideline[s]) will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Quality and relevance of effectiveness data used in the health economic analysis:</i>
|
|
<ul id="ch2.l24"><li id="ch2.lt98" class="half_rhythm"><div>The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review, the more useful the analysis will be for decision-making in the guideline.</div></li><li id="ch2.lt99" class="half_rhythm"><div>Generally, economic evaluations based on excludes from the clinical review will be excluded.</div></li></ul></p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appbtab1"><div id="ch2.appb.tab1" class="table"><h3><span class="label">Table 15</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch2.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Database</th><th id="hd_h_ch2.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dates searched</th><th id="hd_h_ch2.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_ch2.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline (OVID)</td><td headers="hd_h_ch2.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1946–02 October 2018</td><td headers="hd_h_ch2.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Randomised controlled trials</p>
|
|
<p>Systematic review studies</p>
|
|
<p>Observational studies</p>
|
|
<p>Diagnostic tests studies</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase (OVID)</td><td headers="hd_h_ch2.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974–02 October 2018</td><td headers="hd_h_ch2.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Randomised controlled trials</p>
|
|
<p>Systematic review studies</p>
|
|
<p>Observational studies</p>
|
|
<p>Diagnostic tests studies</p>
|
|
<p>Prognostic studies</p>
|
|
<p>Qualitative studies</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The Cochrane Library (Wiley)</td><td headers="hd_h_ch2.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Cochrane Reviews to Issue 8 of 12, August 2018</p>
|
|
<p>CENTRAL to Issue 7 of 12, July 2018</p>
|
|
<p>DARE and NHSEED to Issue 2 of 4, April 2015</p>
|
|
<p>HTA to Issue 4 of 4, October 2016</p>
|
|
</td><td headers="hd_h_ch2.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appbtab2"><div id="ch2.appb.tab2" class="table"><h3><span class="label">Table 16</span><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appb.tab2_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypertens*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(elevat* adj2 blood adj pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(high adj blood adj pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(increase* adj2 blood pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systolic or diastolic or arterial) adj2 pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp pregnancy/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Hypertension, Pregnancy-Induced/ not exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(pre eclampsia or pre-eclampsia or preeclampsia).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Hypertension, Portal/ not exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Hypertension, Pulmonary/ not exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Intracranial Hypertension/ not exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Ocular Hypertension/ not exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Diabetes Mellitus, Type 1/ not exp Diabetes Mellitus, Type 2/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/8–15</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 not 16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18–25</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 not 27</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/28–34</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 35</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 not 37</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 38 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Blood Pressure Determination/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blood Pressure Monitoring, Ambulatory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((ambulatory or home or self or office or clinic or surgery or pharmac* or telemonitor* or daytime or 12 hour or 24 hour or continuous) adj3 (blood pressure* or BP)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(ABPM or HBPM).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blood Pressure Monitors/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Sphygmomanometers/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((blood pressure or BP) adj3 (monitor* or meter* or device*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((arm* or wrist* or cuff or non cuff or automatic or electronic or digital or wireless or remote) adj3 (monitor* or meter* or measur*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sphygmomanometer*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/40–47</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 and 49</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">controlled clinical trial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomi#ed.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo.ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomly.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinical Trials as topic.sh.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">trial.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/51–57</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-Analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Meta-Analysis as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/59–68</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Epidemiologic studies/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Observational study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Cohort studies/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cohort adj (study or studies or analys* or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Controlled Before-After Studies/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Historically Controlled Study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interrupted Time Series Analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(before adj2 after adj2 (study or studies or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/70–79</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp case control study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case control*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/81–82</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80 or 83</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cross-sectional studies/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/85–86</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80 or 87</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80 or 83 or 87</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “sensitivity and specificity”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sensitivity or specificity).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((pre test or pretest or post test) adj probability).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(predictive value* or PPV or NPV).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">likelihood ratio*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">likelihood function/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((area under adj4 curve) or AUC).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">98.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">99.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">gold standard.ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/90–99</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">101.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comparative study.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">102.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50 and (58 or 69 or 89 or 100) or (50 and 101)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appbtab3"><div id="ch2.appb.tab3" class="table"><h3><span class="label">Table 17</span><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appb.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appb.tab3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypertens*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(elevat* adj2 blood adj pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(high adj blood adj pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(increase* adj2 blood pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systolic or diastolic or arterial) adj2 pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1–6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp pregnancy/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Maternal Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(pre eclampsia or pre-eclampsia or preeclampsia).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Hypertension, Portal/ not exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Hypertension, Pulmonary/ not exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Intracranial Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Ocular Hypertension/ not exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Diabetes Mellitus, Type 1/ not exp Diabetes Mellitus, Type 2/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/8–15</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 not 16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/ or case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18–22</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 not 24</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/25–32</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 33</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 not 35</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 36 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">blood pressure measurement/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*blood pressure monitoring/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((ambulatory or home or self or office or clinic or surgery or pharmac* or telemonitor* or daytime or 12 hour or 24 hour or continuous) adj3 (blood pressure* or BP)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(ABPM or HBPM).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp blood pressure monitor/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp blood pressure meter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Sphygmomanometer/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((blood pressure or BP) adj3 (monitor* or meter* or device*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((blood pressure or BP) adj measur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((arm* or wrist* or cuff or non cuff or automatic or electronic or digital or wireless or remote) adj3 (monitor* or meter* or measur*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sphygmomanometer*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/38–47</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 and 49</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">factorial*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(crossover* or cross over*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((doubl* or singl*) adj blind*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(assign* or allocat* or volunteer* or placebo*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">crossover procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">single blind procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">double blind procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/51–59</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">systematic review/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">meta-analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/61–70</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinical study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Observational study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">family study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">longitudinal study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">retrospective study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">prospective study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cohort analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">follow-up/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cohort*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79 and 80</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cohort adj (study or studies or analys* or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(before adj2 after adj2 (study or studies or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/72–78,81–85</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp case control study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case control*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/87–88</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86 or 89</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cross-sectional study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/91–92</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86 or 93</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86 or 89 or 93</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “sensitivity and specificity”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(sensitivity or specificity).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">98.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((pre test or pretest or post test) adj probability).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">99.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(predictive value* or PPV or NPV).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">likelihood ratio*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">101.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((area under adj4 curve) or AUC).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">102.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">103.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">104.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">diagnostic accuracy/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">105.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">diagnostic test accuracy study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">106.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">gold standard.ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">107.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/96–106</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">108.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comparative study.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">109.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50 and (60 or 71 or 95 or 107) or (50 and 108)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appbtab4"><div id="ch2.appb.tab4" class="table"><h3><span class="label">Table 18</span><span class="title">Cochrane Library (Wiley) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appb.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appb.tab4_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Hypertension] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hypertens*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(elevat* near/2 blood next pressur*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(high near/1 blood near/1 pressur*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(increase* near/2 blood pressur*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systolic or diastolic or arterial) near/2 pressur*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #1 or #6)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Blood Pressure Determination] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Blood Pressure Monitoring, Ambulatory] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((ambulatory or home or self or office or clinic or surgery or pharmac* or telemonitor* or daytime or 12 hour or 24 hour or continuous) near/3 (blood pressure* or BP)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(ABPM or HBPM):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Blood Pressure Monitors] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Sphygmomanometers] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((blood pressure or BP) near/3 (monitor* or meter* or device*)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((arm* or wrist* or cuff or non cuff or automatic or electronic or digital or wireless or remote) near/3 (monitor* or meter* or measur*)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">sphygmomanometer*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #8–#16)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7 and #17</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appbtab5"><div id="ch2.appb.tab5" class="table"><h3><span class="label">Table 19</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appb.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appb.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_ch2.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Database</th><th id="hd_h_ch2.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dates searched</th><th id="hd_h_ch2.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_ch2.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline</td><td headers="hd_h_ch2.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014 – 28 August 2018</td><td headers="hd_h_ch2.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health economics studies</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase</td><td headers="hd_h_ch2.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014 – 28 August 2018</td><td headers="hd_h_ch2.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health economics studies</p>
|
|
</td></tr><tr><td headers="hd_h_ch2.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Centre for Research and Dissemination (CRD)</td><td headers="hd_h_ch2.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HTA - Inception – 28 August 2018</p>
|
|
<p>NHSEED - Inception to March 2015</p>
|
|
</td><td headers="hd_h_ch2.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appbtab6"><div id="ch2.appb.tab6" class="table"><h3><span class="label">Table 20</span><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appb.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appb.tab6_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">hypertens*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(elevat* adj2 blood adj pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(high adj blood adj pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(increase* adj2 blood pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">((systolic or diastolic or arterial) adj2 pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">or/1–6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">or/8–15</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16 not 17</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">or/18–24</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7 not 25</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">limit 26 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Value of life/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp “Costs and Cost Analysis”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Economics, Hospital/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Economics, Medical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Economics, Nursing/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Economics, Pharmaceutical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp “Fees and Charges”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Budgets/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">or/28–43</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">27 and 44</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appbtab7"><div id="ch2.appb.tab7" class="table"><h3><span class="label">Table 21</span><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appb.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appb.tab7_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Hypertension/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">hypertens*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(elevat* adj2 blood adj pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(high adj blood adj pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(increase* adj2 blood pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">((systolic or diastolic or arterial) adj2 pressur*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">or/1–6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">case report/ or case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">or/8–12</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13 not 14</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Experimental Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">or/15–22</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7 not 23</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">limit 24 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">health economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp economic evaluation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp health care cost/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">exp fee/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">budget/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">funding/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">or/26–38</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25 and 39</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appbtab8"><div id="ch2.appb.tab8" class="table"><h3><span class="label">Table 22</span><span class="title">NHS EED and HTA (CRD) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appb.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appb.tab8_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MeSH DESCRIPTOR Hypertension EXPLODE ALL TREES IN NHSEED,HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Hypertens*) IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(elevat* adj2 blood adj pressur*) IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(high adj blood adj pressur*) IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(increase* adj2 blood pressur*) IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">((systolic or diastolic or arterial) adj2 pressur*) IN NHSEED, HTA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#1 OR #2 OR #3 OR #4 OR #5 OR #6</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobch2appcfig1"><div id="ch2.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Flow%20chart%20of%20clinical%20study%20selection%20for%20the%20review%20of%20monitoring.&p=BOOKS&id=578044_ch2appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appcf1.jpg" alt="Figure 1. Flow chart of clinical study selection for the review of monitoring." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Flow chart of clinical study selection for the review of monitoring</span></h3></div></article><article data-type="fig" id="figobch2appefig1"><div id="ch2.appe.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20Cardiovascular%20events%2C%2012%20months.&p=BOOKS&id=578044_ch2appef1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef1.jpg" alt="Figure 2. Cardiovascular events, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">Cardiovascular events<sup><a href="#ch2.appe.fig1.fn1">1</a></sup>, 12 months</span></h3><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appe.fig1.fn1"><p class="no_top_margin">(new atrial fibrillation, angina, myocardial infarction, coronary artery bypass graft or angioplasty, stroke, peripheral vascular disease, or heart failure)</p></div></dd></dl></dl></div></div></article><article data-type="fig" id="figobch2appefig2"><div id="ch2.appe.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20Reduction%20in%20clinic%20blood%20pressure%20(mmHg)%2C%20systolic%20(change%20in%20clinic%20systolic%20blood%20pressure)%2C%2012%20months.&p=BOOKS&id=578044_ch2appef2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef2.jpg" alt="Figure 3. Reduction in clinic blood pressure (mmHg), systolic (change in clinic systolic blood pressure), 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3</span><span class="title">Reduction in clinic blood pressure (mmHg), systolic (change in clinic systolic blood pressure), 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig3"><div id="ch2.appe.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%204.%20Reduction%20in%20clinic%20blood%20pressure%20(mmHg)%2C%20diastolic%20(change%20in%20clinic%20diastolic%20blood%20pressure)%2C%2012%20months.&p=BOOKS&id=578044_ch2appef3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef3.jpg" alt="Figure 4. Reduction in clinic blood pressure (mmHg), diastolic (change in clinic diastolic blood pressure), 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 4</span><span class="title">Reduction in clinic blood pressure (mmHg), diastolic (change in clinic diastolic blood pressure), 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig4"><div id="ch2.appe.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%205.%20Proportion%20not%20meeting%20target%20(varied%20target%20due%20to%20IPD%20%02013%20mode%20140%2F90%20mmHg)%2C%2012%20months.&p=BOOKS&id=578044_ch2appef4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef4.jpg" alt="Figure 5. Proportion not meeting target (varied target due to IPD – mode 140/90 mmHg), 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 5</span><span class="title">Proportion not meeting target (varied target due to IPD – mode 140/90 mmHg), 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig5"><div id="ch2.appe.fig5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%206.%20Overall%20defined%20daily%20dose%2C%2012%20months.&p=BOOKS&id=578044_ch2appef5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef5.jpg" alt="Figure 6. Overall defined daily dose, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 6</span><span class="title">Overall defined daily dose, 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig6"><div id="ch2.appe.fig6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%207.%20Mean%20number%20of%20consultations%20for%20hypertension%2C%2012%20months.&p=BOOKS&id=578044_ch2appef6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef6.jpg" alt="Figure 7. Mean number of consultations for hypertension, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 7</span><span class="title">Mean number of consultations for hypertension, 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig7"><div id="ch2.appe.fig7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%208.%20Dizziness%2C%20hypertension%20specific%20symptoms%20(no%20further%20details%20of%20definition)%2012%20months.&p=BOOKS&id=578044_ch2appef7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef7.jpg" alt="Figure 8. Dizziness, hypertension specific symptoms (no further details of definition) 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 8</span><span class="title">Dizziness, hypertension specific symptoms (no further details of definition) 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig8"><div id="ch2.appe.fig8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%209.%20Reduction%20in%20clinic%20blood%20pressure%20(mmHg)%2C%20systolic%2C%2012%20months.&p=BOOKS&id=578044_ch2appef8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef8.jpg" alt="Figure 9. Reduction in clinic blood pressure (mmHg), systolic, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 9</span><span class="title">Reduction in clinic blood pressure (mmHg), systolic, 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig9"><div id="ch2.appe.fig9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2010.%20Reduction%20in%20clinic%20blood%20pressure%20(mmHg)%2C%20diastolic%2C%2012%20months.&p=BOOKS&id=578044_ch2appef9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef9.jpg" alt="Figure 10. Reduction in clinic blood pressure (mmHg), diastolic, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 10</span><span class="title">Reduction in clinic blood pressure (mmHg), diastolic, 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig10"><div id="ch2.appe.fig10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2011.%20Cardiovascular%20events%2C%2012%20months.&p=BOOKS&id=578044_ch2appef10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef10.jpg" alt="Figure 11. Cardiovascular events, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 11</span><span class="title">Cardiovascular events<sup><a href="#ch2.appe.fig10.fn1">1</a></sup>, 12 months<sup><a href="#ch2.appe.fig10.fn2">a</a></sup></span></h3><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appe.fig10.fn1"><p class="no_top_margin">(new atrial fibrillation, angina, myocardial infarction, coronary artery bypass graft or angioplasty, stroke, peripheral vascular disease, or heart failure,</p></div></dd></dl><dl class="bkr_refwrap"><dt>a</dt><dd><div id="ch2.appe.fig10.fn2"><p class="no_top_margin">Home monitoring (HM), Telemonitoring (TM)</p></div></dd></dl></dl></div></div></article><article data-type="fig" id="figobch2appefig11"><div id="ch2.appe.fig11" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2012.%20Clinic%20blood%20pressure%20(mmHg)%2C%20systolic%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef11.jpg" alt="Figure 12. Clinic blood pressure (mmHg), systolic, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 12</span><span class="title">Clinic blood pressure (mmHg), systolic, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig12"><div id="ch2.appe.fig12" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2013.%20Clinic%20blood%20pressure%20(mmHg)%2C%20diastolic%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef12.jpg" alt="Figure 13. Clinic blood pressure (mmHg), diastolic, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 13</span><span class="title">Clinic blood pressure (mmHg), diastolic, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig13"><div id="ch2.appe.fig13" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2014.%20Overall%20defined%20daily%20dose%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef13.jpg" alt="Figure 14. Overall defined daily dose, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 14</span><span class="title">Overall defined daily dose, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig14"><div id="ch2.appe.fig14" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2015.%20Average%20number%20of%20GP%20visits%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef14.jpg" alt="Figure 15. Average number of GP visits, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 15</span><span class="title">Average number of GP visits, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig15"><div id="ch2.appe.fig15" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2016.%20Mean%20number%20of%20consultations%20for%20hypertension%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef15.jpg" alt="Figure 16. Mean number of consultations for hypertension, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 16</span><span class="title">Mean number of consultations for hypertension, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig16"><div id="ch2.appe.fig16" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2017.%20Dizziness%2C%20hypertension%20specific%20symptoms%20(no%20further%20details%20of%20definition)%2012%20monthsa.&p=BOOKS&id=578044_ch2appef16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef16.jpg" alt="Figure 17. Dizziness, hypertension specific symptoms (no further details of definition) 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 17</span><span class="title">Dizziness, hypertension specific symptoms (no further details of definition) 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig17"><div id="ch2.appe.fig17" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2018.%20All-cause%20mortality%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef17.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef17.jpg" alt="Figure 18. All-cause mortality, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 18</span><span class="title">All-cause mortality, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig18"><div id="ch2.appe.fig18" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2019.%20Cardiovascular%20events%2012%20monthsa.&p=BOOKS&id=578044_ch2appef18.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef18.jpg" alt="Figure 19. Cardiovascular events 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 19</span><span class="title">Cardiovascular events<sup><a href="#ch2.appe.fig18.fn1">1</a></sup> 12 months<sup>a</sup></span></h3><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appe.fig18.fn1"><p class="no_top_margin">(defined as new atrial fibrillation, angina, myocardial infarction, coronary artery bypass graft or angioplasty, stroke, peripheral vascular disease, or heart failure in 1 study, defined as non-fatal cardiovascular events in another),</p></div></dd></dl></dl></div></div></article><article data-type="fig" id="figobch2appefig19"><div id="ch2.appe.fig19" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2020.%20Quality%20of%20life%2C%20SF-12%2C%20emotional%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20months.&p=BOOKS&id=578044_ch2appef19.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef19.jpg" alt="Figure 20. Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 20</span><span class="title">Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig20"><div id="ch2.appe.fig20" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2021.%20Quality%20of%20life%2C%20SF-12%2C%20physical%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef20.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef20.jpg" alt="Figure 21. Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 21</span><span class="title">Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig21"><div id="ch2.appe.fig21" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2022.%20Quality%20of%20life%2C%20SF-12%2C%20general%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef21.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef21.jpg" alt="Figure 22. Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 22</span><span class="title">Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig22"><div id="ch2.appe.fig22" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2023.%20Reduction%20in%20clinic%20blood%20pressure%20(mmHg)%2C%20systolic%2012%20months.&p=BOOKS&id=578044_ch2appef22.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef22.jpg" alt="Figure 23. Reduction in clinic blood pressure (mmHg), systolic 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 23</span><span class="title">Reduction in clinic blood pressure (mmHg), systolic 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig23"><div id="ch2.appe.fig23" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2024.%20Reduction%20in%20clinic%20blood%20pressure%20(mmHg)%2C%20diastolic%2012%20months.&p=BOOKS&id=578044_ch2appef23.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef23.jpg" alt="Figure 24. Reduction in clinic blood pressure (mmHg), diastolic 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 24</span><span class="title">Reduction in clinic blood pressure (mmHg), diastolic 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig24"><div id="ch2.appe.fig24" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2025.%20Proportion%20controlled%20to%20a%20target%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef24.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef24.jpg" alt="Figure 25. Proportion controlled to a target, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 25</span><span class="title">Proportion controlled to a target, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig25"><div id="ch2.appe.fig25" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2026.%20Proportion%20not%20meeting%20target%20(varied%20target%20due%20to%20IPD%20%02013%20mode%20140%2F90%20mmHg)%2C%2012%20months.&p=BOOKS&id=578044_ch2appef25.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef25.jpg" alt="Figure 26. Proportion not meeting target (varied target due to IPD – mode 140/90 mmHg), 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 26</span><span class="title">Proportion not meeting target (varied target due to IPD – mode 140/90 mmHg), 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig26"><div id="ch2.appe.fig26" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2027.%20Overall%20defined%20daily%20dose%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef26.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef26.jpg" alt="Figure 27. Overall defined daily dose, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 27</span><span class="title">Overall defined daily dose, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig27"><div id="ch2.appe.fig27" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2028.%20Mean%20number%20of%20consultations%20for%20hypertension%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef27.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef27.jpg" alt="Figure 28. Mean number of consultations for hypertension, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 28</span><span class="title">Mean number of consultations for hypertension, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig28"><div id="ch2.appe.fig28" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2029.%20Dizziness%2C%20hypertension%20specific%20symptoms%20(no%20further%20definition)%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef28.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef28.jpg" alt="Figure 29. Dizziness, hypertension specific symptoms (no further definition), 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 29</span><span class="title">Dizziness, hypertension specific symptoms (no further definition), 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig29"><div id="ch2.appe.fig29" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2030.%20All-cause%20mortality%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef29.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef29.jpg" alt="Figure 30. All-cause mortality, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 30</span><span class="title">All-cause mortality, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig30"><div id="ch2.appe.fig30" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2031.%20Non-fatal%20Cardiovascular%20events%20(no%20further%20details%20given)%2C%201%20yearaa.&p=BOOKS&id=578044_ch2appef30.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef30.jpg" alt="Figure 31. Non-fatal Cardiovascular events (no further details given), 1 yearaa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 31</span><span class="title">Non-fatal Cardiovascular events (no further details given), 1 yeara<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig31"><div id="ch2.appe.fig31" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2032.%20Reduction%20in%20blood%20pressure%20(mmHg)%2C%20systolic%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef31.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef31.jpg" alt="Figure 32. Reduction in blood pressure (mmHg), systolic, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 32</span><span class="title">Reduction in blood pressure (mmHg), systolic, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig32"><div id="ch2.appe.fig32" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2033.%20Reduction%20in%20blood%20pressure%20(mmHg)%2C%20diastolic%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef32.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef32.jpg" alt="Figure 33. Reduction in blood pressure (mmHg), diastolic, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 33</span><span class="title">Reduction in blood pressure (mmHg), diastolic, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig33"><div id="ch2.appe.fig33" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2034.%20Proportion%20controlled%20to%20a%20target%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef33.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef33.jpg" alt="Figure 34. Proportion controlled to a target, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 34</span><span class="title">Proportion controlled to a target, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig34"><div id="ch2.appe.fig34" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2035.%20Quality%20of%20life%2C%20SF-12%2C%20emotional%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef34.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef34.jpg" alt="Figure 35. Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 35</span><span class="title">Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig35"><div id="ch2.appe.fig35" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2036.%20Quality%20of%20life%2C%20SF-12%2C%20physical%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef35.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef35.jpg" alt="Figure 36. Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 36</span><span class="title">Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig36"><div id="ch2.appe.fig36" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2037.%20Quality%20of%20life%2C%20SF-12%2C%20general%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef36.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef36.jpg" alt="Figure 37. Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 37</span><span class="title">Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig37"><div id="ch2.appe.fig37" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2038.%20All-cause%20mortality%2C%2012%20months.&p=BOOKS&id=578044_ch2appef37.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef37.jpg" alt="Figure 38. All-cause mortality, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 38</span><span class="title">All-cause mortality, 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig38"><div id="ch2.appe.fig38" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2039.%20Non-fatal%20Cardiovascular%20events%20(no%20further%20details%20given)%2C%2012%20months.&p=BOOKS&id=578044_ch2appef38.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef38.jpg" alt="Figure 39. Non-fatal Cardiovascular events (no further details given), 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 39</span><span class="title">Non-fatal Cardiovascular events (no further details given), 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig39"><div id="ch2.appe.fig39" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2040.%20Change%20in%20blood%20pressure%20(mmHg)%2C%20systolic%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef39.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef39.jpg" alt="Figure 40. Change in blood pressure (mmHg), systolic, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 40</span><span class="title">Change in blood pressure (mmHg), systolic, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig40"><div id="ch2.appe.fig40" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2041.%20Reduction%20in%20blood%20pressure%20(mmHg)%2C%20diastolic%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef40.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef40.jpg" alt="Figure 41. Reduction in blood pressure (mmHg), diastolic, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 41</span><span class="title">Reduction in blood pressure (mmHg), diastolic, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig41"><div id="ch2.appe.fig41" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2042.%20Quality%20of%20life%2C%20SF-12%2C%20emotional%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef41.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef41.jpg" alt="Figure 42. Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 42</span><span class="title">Quality of life, SF-12, emotional subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig42"><div id="ch2.appe.fig42" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2043.%20Quality%20of%20life%2C%20SF-12%2C%20physical%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef42.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef42.jpg" alt="Figure 43. Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 43</span><span class="title">Quality of life, SF-12, physical subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig43"><div id="ch2.appe.fig43" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2044.%20Quality%20of%20life%2C%20SF-12%2C%20general%20subscale%2C%200%02013100%20scale%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef43.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef43.jpg" alt="Figure 44. Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 44</span><span class="title">Quality of life, SF-12, general subscale, 0–100 scale, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig44"><div id="ch2.appe.fig44" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2045.%20Clinic%20blood%20pressure%20(mmHg)%2C%20systolic%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef44.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef44.jpg" alt="Figure 45. Clinic blood pressure (mmHg), systolic, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 45</span><span class="title">Clinic blood pressure (mmHg), systolic, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig45"><div id="ch2.appe.fig45" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2046.%20Clinic%20blood%20pressure%20(mmHg)%2C%20diastolic%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef45.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef45.jpg" alt="Figure 46. Clinic blood pressure (mmHg), diastolic, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 46</span><span class="title">Clinic blood pressure (mmHg), diastolic, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig46"><div id="ch2.appe.fig46" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2047.%20Quality%20of%20life%2C%20EQ-5D%2C%200.594%20to%201%2C%20higher%20score%20is%20better%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef46.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef46.jpg" alt="Figure 47. Quality of life, EQ-5D, 0.594 to 1, higher score is better, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 47</span><span class="title">Quality of life, EQ-5D, 0.594 to 1, higher score is better, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig47"><div id="ch2.appe.fig47" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2048.%20Mean%20number%20of%20consultations%20for%20hypertension%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef47.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef47.jpg" alt="Figure 48. Mean number of consultations for hypertension, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 48</span><span class="title">Mean number of consultations for hypertension, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig48"><div id="ch2.appe.fig48" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2049.%20Mean%20number%20of%20antihypertensive%20drugs%2C%2012%20monthsa.&p=BOOKS&id=578044_ch2appef48.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef48.jpg" alt="Figure 49. Mean number of antihypertensive drugs, 12 monthsa." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 49</span><span class="title">Mean number of antihypertensive drugs, 12 months<sup>a</sup></span></h3></div></article><article data-type="fig" id="figobch2appefig49"><div id="ch2.appe.fig49" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2050.%20All-cause%20mortality%2C%2012%20months.&p=BOOKS&id=578044_ch2appef49.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef49.jpg" alt="Figure 50. All-cause mortality, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 50</span><span class="title">All-cause mortality, 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig50"><div id="ch2.appe.fig50" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2051.%20Reduction%20in%20blood%20pressure%20(mmHg)%2C%20systolic%2C%2012%20months.&p=BOOKS&id=578044_ch2appef50.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef50.jpg" alt="Figure 51. Reduction in blood pressure (mmHg), systolic, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 51</span><span class="title">Reduction in blood pressure (mmHg), systolic, 12 months</span></h3></div></article><article data-type="fig" id="figobch2appefig51"><div id="ch2.appe.fig51" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2052.%20Reduction%20in%20blood%20pressure%20(mmHg)%2C%20diastolic%2C%2012%20months.&p=BOOKS&id=578044_ch2appef51.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appef51.jpg" alt="Figure 52. Reduction in blood pressure (mmHg), diastolic, 12 months." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 52</span><span class="title">Reduction in blood pressure (mmHg), diastolic, 12 months</span></h3></div></article><article data-type="table-wrap" id="figobch2appftab1"><div id="ch2.appf.tab1" class="table"><h3><span class="label">Table 23</span><span class="title">Clinical evidence profile: Home monitoring versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appf.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appf.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.appf.tab1_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch2.appf.tab1_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch2.appf.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch2.appf.tab1_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab1_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch2.appf.tab1_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab1_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch2.appf.tab1_1_1_1_1" id="hd_h_ch2.appf.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch2.appf.tab1_1_1_1_1" id="hd_h_ch2.appf.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch2.appf.tab1_1_1_1_1" id="hd_h_ch2.appf.tab1_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch2.appf.tab1_1_1_1_1" id="hd_h_ch2.appf.tab1_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch2.appf.tab1_1_1_1_1" id="hd_h_ch2.appf.tab1_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch2.appf.tab1_1_1_1_1" id="hd_h_ch2.appf.tab1_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch2.appf.tab1_1_1_1_1" id="hd_h_ch2.appf.tab1_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch2.appf.tab1_1_1_1_2" id="hd_h_ch2.appf.tab1_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Home monitoring without telemonitoring versus clinic/office monitoring</th><th headers="hd_h_ch2.appf.tab1_1_1_1_2" id="hd_h_ch2.appf.tab1_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_ch2.appf.tab1_1_1_1_3" id="hd_h_ch2.appf.tab1_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch2.appf.tab1_1_1_1_3" id="hd_h_ch2.appf.tab1_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_h_ch2.appf.tab1_1_1_2_3 hd_h_ch2.appf.tab1_1_1_2_4 hd_h_ch2.appf.tab1_1_1_2_5 hd_h_ch2.appf.tab1_1_1_2_6 hd_h_ch2.appf.tab1_1_1_2_7 hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_h_ch2.appf.tab1_1_1_2_9 hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_h_ch2.appf.tab1_1_1_2_11 hd_h_ch2.appf.tab1_1_1_1_4 hd_h_ch2.appf.tab1_1_1_1_5" id="hd_b_ch2.appf.tab1_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Cardiovascular events (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_3 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_4 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_5 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_6 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_7 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>12/328</p>
|
|
<p>(3.7%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_9 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.6%</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.42 (0.61 to 3.33)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_11 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11 more per 1,000 (from 10 fewer to 61 more)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_4 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_5 hd_b_ch2.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_h_ch2.appf.tab1_1_1_2_3 hd_h_ch2.appf.tab1_1_1_2_4 hd_h_ch2.appf.tab1_1_1_2_5 hd_h_ch2.appf.tab1_1_1_2_6 hd_h_ch2.appf.tab1_1_1_2_7 hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_h_ch2.appf.tab1_1_1_2_9 hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_h_ch2.appf.tab1_1_1_2_11 hd_h_ch2.appf.tab1_1_1_1_4 hd_h_ch2.appf.tab1_1_1_1_5" id="hd_b_ch2.appf.tab1_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in clinic BP - change in clinic systolic BP (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_3 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_4 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_5 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>4</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_6 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_7 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1301</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_9 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1309</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_11 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 2.23 lower (3.84 to 0.63 lower)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_4 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_5 hd_b_ch2.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_h_ch2.appf.tab1_1_1_2_3 hd_h_ch2.appf.tab1_1_1_2_4 hd_h_ch2.appf.tab1_1_1_2_5 hd_h_ch2.appf.tab1_1_1_2_6 hd_h_ch2.appf.tab1_1_1_2_7 hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_h_ch2.appf.tab1_1_1_2_9 hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_h_ch2.appf.tab1_1_1_2_11 hd_h_ch2.appf.tab1_1_1_1_4 hd_h_ch2.appf.tab1_1_1_1_5" id="hd_b_ch2.appf.tab1_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in clinic BP - change in clinic diastolic BP (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_3 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_4 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_5 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>4</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_6 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_7 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1301</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_9 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1309</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_11 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 1.31 lower (2.19 to 0.44 lower)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_4 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_5 hd_b_ch2.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_h_ch2.appf.tab1_1_1_2_3 hd_h_ch2.appf.tab1_1_1_2_4 hd_h_ch2.appf.tab1_1_1_2_5 hd_h_ch2.appf.tab1_1_1_2_6 hd_h_ch2.appf.tab1_1_1_2_7 hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_h_ch2.appf.tab1_1_1_2_9 hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_h_ch2.appf.tab1_1_1_2_11 hd_h_ch2.appf.tab1_1_1_1_4 hd_h_ch2.appf.tab1_1_1_1_5" id="hd_b_ch2.appf.tab1_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Uncontrolled BP (not meeting trial target; follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_3 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_4 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_5 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>4</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_6 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_7 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>70/973</p>
|
|
<p>(7.2%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_9 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.3%</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.99 (0.72 to 1.36)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_11 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 fewer per 1,000 (from 20 fewer to 26 more)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_4 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_5 hd_b_ch2.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_h_ch2.appf.tab1_1_1_2_3 hd_h_ch2.appf.tab1_1_1_2_4 hd_h_ch2.appf.tab1_1_1_2_5 hd_h_ch2.appf.tab1_1_1_2_6 hd_h_ch2.appf.tab1_1_1_2_7 hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_h_ch2.appf.tab1_1_1_2_9 hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_h_ch2.appf.tab1_1_1_2_11 hd_h_ch2.appf.tab1_1_1_1_4 hd_h_ch2.appf.tab1_1_1_1_5" id="hd_b_ch2.appf.tab1_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Overall defined daily dose (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_3 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_4 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_5 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_6 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_7 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">328</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_9 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">350</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_11 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.15 higher (0.11 lower to 0.41 higher)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_4 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_5 hd_b_ch2.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_h_ch2.appf.tab1_1_1_2_3 hd_h_ch2.appf.tab1_1_1_2_4 hd_h_ch2.appf.tab1_1_1_2_5 hd_h_ch2.appf.tab1_1_1_2_6 hd_h_ch2.appf.tab1_1_1_2_7 hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_h_ch2.appf.tab1_1_1_2_9 hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_h_ch2.appf.tab1_1_1_2_11 hd_h_ch2.appf.tab1_1_1_1_4 hd_h_ch2.appf.tab1_1_1_1_5" id="hd_b_ch2.appf.tab1_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Mean number of consultations for hypertension (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_3 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_4 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_5 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_6 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_7 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">328</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_9 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">350</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_11 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.30 lower (0.65 lower to 0.05 higher)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_4 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_5 hd_b_ch2.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_h_ch2.appf.tab1_1_1_2_3 hd_h_ch2.appf.tab1_1_1_2_4 hd_h_ch2.appf.tab1_1_1_2_5 hd_h_ch2.appf.tab1_1_1_2_6 hd_h_ch2.appf.tab1_1_1_2_7 hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_h_ch2.appf.tab1_1_1_2_9 hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_h_ch2.appf.tab1_1_1_2_11 hd_h_ch2.appf.tab1_1_1_1_4 hd_h_ch2.appf.tab1_1_1_1_5" id="hd_b_ch2.appf.tab1_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Dizziness (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_1 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_2 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_3 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_4 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_5 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_6 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab1_1_1_1_1 hd_h_ch2.appf.tab1_1_1_2_7 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_8 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>50/324</p>
|
|
<p>(15.4%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_2 hd_h_ch2.appf.tab1_1_1_2_9 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17.5%</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_10 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.88 (0.63 to 1.24)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_3 hd_h_ch2.appf.tab1_1_1_2_11 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">21 fewer per 1,000 (from 65 fewer to 42 more)</td><td headers="hd_h_ch2.appf.tab1_1_1_1_4 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab1_1_1_1_5 hd_b_ch2.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appf.tab1_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.appf.tab1_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.appf.tab1_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch2.appf.tab1_4"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population and intervention respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2appftab2"><div id="ch2.appf.tab2" class="table"><h3><span class="label">Table 24</span><span class="title">Clinical evidence profile: Home monitoring versus ambulatory/clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appf.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appf.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.appf.tab2_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch2.appf.tab2_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch2.appf.tab2_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch2.appf.tab2_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab2_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch2.appf.tab2_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab2_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch2.appf.tab2_1_1_1_1" id="hd_h_ch2.appf.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch2.appf.tab2_1_1_1_1" id="hd_h_ch2.appf.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch2.appf.tab2_1_1_1_1" id="hd_h_ch2.appf.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch2.appf.tab2_1_1_1_1" id="hd_h_ch2.appf.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch2.appf.tab2_1_1_1_1" id="hd_h_ch2.appf.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch2.appf.tab2_1_1_1_1" id="hd_h_ch2.appf.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch2.appf.tab2_1_1_1_1" id="hd_h_ch2.appf.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch2.appf.tab2_1_1_1_2" id="hd_h_ch2.appf.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Home monitoring without TM</th><th headers="hd_h_ch2.appf.tab2_1_1_1_2" id="hd_h_ch2.appf.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Ambulatory/clinic monitoring</th><th headers="hd_h_ch2.appf.tab2_1_1_1_3" id="hd_h_ch2.appf.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch2.appf.tab2_1_1_1_3" id="hd_h_ch2.appf.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_1 hd_h_ch2.appf.tab2_1_1_2_2 hd_h_ch2.appf.tab2_1_1_2_3 hd_h_ch2.appf.tab2_1_1_2_4 hd_h_ch2.appf.tab2_1_1_2_5 hd_h_ch2.appf.tab2_1_1_2_6 hd_h_ch2.appf.tab2_1_1_2_7 hd_h_ch2.appf.tab2_1_1_1_2 hd_h_ch2.appf.tab2_1_1_2_8 hd_h_ch2.appf.tab2_1_1_2_9 hd_h_ch2.appf.tab2_1_1_1_3 hd_h_ch2.appf.tab2_1_1_2_10 hd_h_ch2.appf.tab2_1_1_2_11 hd_h_ch2.appf.tab2_1_1_1_4 hd_h_ch2.appf.tab2_1_1_1_5" id="hd_b_ch2.appf.tab2_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in blood pressure - Systolic (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_1 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_2 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_3 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_4 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_5 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_6 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_7 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab2_1_1_1_2 hd_h_ch2.appf.tab2_1_1_2_8 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">73</td><td headers="hd_h_ch2.appf.tab2_1_1_1_2 hd_h_ch2.appf.tab2_1_1_2_9 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">72</td><td headers="hd_h_ch2.appf.tab2_1_1_1_3 hd_h_ch2.appf.tab2_1_1_2_10 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab2_1_1_1_3 hd_h_ch2.appf.tab2_1_1_2_11 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 2.1 lower (6.8 lower to 2.6 higher)</td><td headers="hd_h_ch2.appf.tab2_1_1_1_4 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab2_1_1_1_5 hd_b_ch2.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_1 hd_h_ch2.appf.tab2_1_1_2_2 hd_h_ch2.appf.tab2_1_1_2_3 hd_h_ch2.appf.tab2_1_1_2_4 hd_h_ch2.appf.tab2_1_1_2_5 hd_h_ch2.appf.tab2_1_1_2_6 hd_h_ch2.appf.tab2_1_1_2_7 hd_h_ch2.appf.tab2_1_1_1_2 hd_h_ch2.appf.tab2_1_1_2_8 hd_h_ch2.appf.tab2_1_1_2_9 hd_h_ch2.appf.tab2_1_1_1_3 hd_h_ch2.appf.tab2_1_1_2_10 hd_h_ch2.appf.tab2_1_1_2_11 hd_h_ch2.appf.tab2_1_1_1_4 hd_h_ch2.appf.tab2_1_1_1_5" id="hd_b_ch2.appf.tab2_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in blood pressure - Diastolic (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_1 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_2 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_3 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_4 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_5 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_6 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab2_1_1_1_1 hd_h_ch2.appf.tab2_1_1_2_7 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab2_1_1_1_2 hd_h_ch2.appf.tab2_1_1_2_8 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">73</td><td headers="hd_h_ch2.appf.tab2_1_1_1_2 hd_h_ch2.appf.tab2_1_1_2_9 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">72</td><td headers="hd_h_ch2.appf.tab2_1_1_1_3 hd_h_ch2.appf.tab2_1_1_2_10 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab2_1_1_1_3 hd_h_ch2.appf.tab2_1_1_2_11 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 1.4 lower (4.3 lower to 1.5 higher)</td><td headers="hd_h_ch2.appf.tab2_1_1_1_4 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab2_1_1_1_5 hd_b_ch2.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appf.tab2_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.appf.tab2_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2appftab3"><div id="ch2.appf.tab3" class="table"><h3><span class="label">Table 25</span><span class="title">Clinical evidence profile: Home monitoring with telemonitoring versus home monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appf.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appf.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.appf.tab3_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch2.appf.tab3_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch2.appf.tab3_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch2.appf.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab3_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch2.appf.tab3_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab3_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch2.appf.tab3_1_1_1_1" id="hd_h_ch2.appf.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch2.appf.tab3_1_1_1_1" id="hd_h_ch2.appf.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch2.appf.tab3_1_1_1_1" id="hd_h_ch2.appf.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch2.appf.tab3_1_1_1_1" id="hd_h_ch2.appf.tab3_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch2.appf.tab3_1_1_1_1" id="hd_h_ch2.appf.tab3_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch2.appf.tab3_1_1_1_1" id="hd_h_ch2.appf.tab3_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch2.appf.tab3_1_1_1_1" id="hd_h_ch2.appf.tab3_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch2.appf.tab3_1_1_1_2" id="hd_h_ch2.appf.tab3_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Home monitoring with TM</th><th headers="hd_h_ch2.appf.tab3_1_1_1_2" id="hd_h_ch2.appf.tab3_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Home monitoring without TM</th><th headers="hd_h_ch2.appf.tab3_1_1_1_3" id="hd_h_ch2.appf.tab3_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch2.appf.tab3_1_1_1_3" id="hd_h_ch2.appf.tab3_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_h_ch2.appf.tab3_1_1_2_3 hd_h_ch2.appf.tab3_1_1_2_4 hd_h_ch2.appf.tab3_1_1_2_5 hd_h_ch2.appf.tab3_1_1_2_6 hd_h_ch2.appf.tab3_1_1_2_7 hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_h_ch2.appf.tab3_1_1_2_9 hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_h_ch2.appf.tab3_1_1_2_11 hd_h_ch2.appf.tab3_1_1_1_4 hd_h_ch2.appf.tab3_1_1_1_5" id="hd_b_ch2.appf.tab3_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Cardiovascular events (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_3 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_4 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_5 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_6 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_7 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>11/330</p>
|
|
<p>(3.3%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_9 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.7%</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.91 (0.41 to 2.04)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_11 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 fewer per 1,000 (from 22 fewer to 38 more)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_4 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_5 hd_b_ch2.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_h_ch2.appf.tab3_1_1_2_3 hd_h_ch2.appf.tab3_1_1_2_4 hd_h_ch2.appf.tab3_1_1_2_5 hd_h_ch2.appf.tab3_1_1_2_6 hd_h_ch2.appf.tab3_1_1_2_7 hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_h_ch2.appf.tab3_1_1_2_9 hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_h_ch2.appf.tab3_1_1_2_11 hd_h_ch2.appf.tab3_1_1_1_4 hd_h_ch2.appf.tab3_1_1_1_5" id="hd_b_ch2.appf.tab3_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Clinic blood pressure, systolic (follow-up 1 years; better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_3 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_4 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_5 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_6 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_7 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">327</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_9 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">328</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_11 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 1.00 lower (3.51 lower to 1.51 higher)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_4 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_5 hd_b_ch2.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_h_ch2.appf.tab3_1_1_2_3 hd_h_ch2.appf.tab3_1_1_2_4 hd_h_ch2.appf.tab3_1_1_2_5 hd_h_ch2.appf.tab3_1_1_2_6 hd_h_ch2.appf.tab3_1_1_2_7 hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_h_ch2.appf.tab3_1_1_2_9 hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_h_ch2.appf.tab3_1_1_2_11 hd_h_ch2.appf.tab3_1_1_1_4 hd_h_ch2.appf.tab3_1_1_1_5" id="hd_b_ch2.appf.tab3_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Clinic blood pressure, diastolic (follow-up 1 years; better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_3 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_4 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_5 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_6 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_7 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">328</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_9 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">328</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_11 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.90 higher (0.62 lower to 2.42 higher)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_4 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_5 hd_b_ch2.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_h_ch2.appf.tab3_1_1_2_3 hd_h_ch2.appf.tab3_1_1_2_4 hd_h_ch2.appf.tab3_1_1_2_5 hd_h_ch2.appf.tab3_1_1_2_6 hd_h_ch2.appf.tab3_1_1_2_7 hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_h_ch2.appf.tab3_1_1_2_9 hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_h_ch2.appf.tab3_1_1_2_11 hd_h_ch2.appf.tab3_1_1_1_4 hd_h_ch2.appf.tab3_1_1_1_5" id="hd_b_ch2.appf.tab3_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Overall defined daily dose (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_3 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_4 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_5 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_6 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_7 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">330</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_9 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">328</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_11 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.27 higher (0 to 0.54 higher)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_4 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_5 hd_b_ch2.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_h_ch2.appf.tab3_1_1_2_3 hd_h_ch2.appf.tab3_1_1_2_4 hd_h_ch2.appf.tab3_1_1_2_5 hd_h_ch2.appf.tab3_1_1_2_6 hd_h_ch2.appf.tab3_1_1_2_7 hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_h_ch2.appf.tab3_1_1_2_9 hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_h_ch2.appf.tab3_1_1_2_11 hd_h_ch2.appf.tab3_1_1_1_4 hd_h_ch2.appf.tab3_1_1_1_5" id="hd_b_ch2.appf.tab3_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Average number of GP visits (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_3 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_4 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_5 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_6 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_7 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>4/51</p>
|
|
<p>(7.8%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_9 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12.2%</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.64 (0.19 to 2.13)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_11 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">44 fewer per 1,000 (from 99 fewer to 138 more)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_4 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_5 hd_b_ch2.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_h_ch2.appf.tab3_1_1_2_3 hd_h_ch2.appf.tab3_1_1_2_4 hd_h_ch2.appf.tab3_1_1_2_5 hd_h_ch2.appf.tab3_1_1_2_6 hd_h_ch2.appf.tab3_1_1_2_7 hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_h_ch2.appf.tab3_1_1_2_9 hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_h_ch2.appf.tab3_1_1_2_11 hd_h_ch2.appf.tab3_1_1_1_4 hd_h_ch2.appf.tab3_1_1_1_5" id="hd_b_ch2.appf.tab3_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Mean number of consultations for hypertension (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_3 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_4 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_5 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_6 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_7 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">330</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_9 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">328</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_11 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.40 higher (0.01 to 0.79 higher)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_4 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_5 hd_b_ch2.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_h_ch2.appf.tab3_1_1_2_3 hd_h_ch2.appf.tab3_1_1_2_4 hd_h_ch2.appf.tab3_1_1_2_5 hd_h_ch2.appf.tab3_1_1_2_6 hd_h_ch2.appf.tab3_1_1_2_7 hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_h_ch2.appf.tab3_1_1_2_9 hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_h_ch2.appf.tab3_1_1_2_11 hd_h_ch2.appf.tab3_1_1_1_4 hd_h_ch2.appf.tab3_1_1_1_5" id="hd_b_ch2.appf.tab3_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Dizziness (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_1 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_2 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_3 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_4 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_5 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_6 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab3_1_1_1_1 hd_h_ch2.appf.tab3_1_1_2_7 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_8 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>72/326</p>
|
|
<p>(22.1%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_2 hd_h_ch2.appf.tab3_1_1_2_9 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15.4%</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_10 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.43 (1.03 to 1.98)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_3 hd_h_ch2.appf.tab3_1_1_2_11 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">66 more per 1,000 (from 5 more to 151 more)</td><td headers="hd_h_ch2.appf.tab3_1_1_1_4 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab3_1_1_1_5 hd_b_ch2.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appf.tab3_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.appf.tab3_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.appf.tab3_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2appftab4"><div id="ch2.appf.tab4" class="table"><h3><span class="label">Table 26</span><span class="title">Clinical evidence profile: Home monitoring with telemonitoring versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appf.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appf.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.appf.tab4_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch2.appf.tab4_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch2.appf.tab4_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch2.appf.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab4_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch2.appf.tab4_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab4_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1" id="hd_h_ch2.appf.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch2.appf.tab4_1_1_1_1" id="hd_h_ch2.appf.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch2.appf.tab4_1_1_1_1" id="hd_h_ch2.appf.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch2.appf.tab4_1_1_1_1" id="hd_h_ch2.appf.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch2.appf.tab4_1_1_1_1" id="hd_h_ch2.appf.tab4_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch2.appf.tab4_1_1_1_1" id="hd_h_ch2.appf.tab4_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch2.appf.tab4_1_1_1_1" id="hd_h_ch2.appf.tab4_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch2.appf.tab4_1_1_1_2" id="hd_h_ch2.appf.tab4_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Home monitoring with telemonitoring versus clinic/office monitoring</th><th headers="hd_h_ch2.appf.tab4_1_1_1_2" id="hd_h_ch2.appf.tab4_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_ch2.appf.tab4_1_1_1_3" id="hd_h_ch2.appf.tab4_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch2.appf.tab4_1_1_1_3" id="hd_h_ch2.appf.tab4_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>5</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>2/246</p>
|
|
<p>(0.81%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0%</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Peto OR 7.45 (0.46 to 119.44)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 more per 1,000 (from 0.01 fewer to 0.02 more)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Cardiovascular events (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>15/576</p>
|
|
<p>(2.6%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.69%</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.43 (0.66 to 3.08)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 more per 1,000 (from 6 fewer to 35 more)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - Emotional scale (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">247</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.6 higher (2.45 lower to 3.65 higher)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - Physical (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">247</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.4 lower (5.53 lower to 4.73 higher)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - General (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">247</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.1 lower (3.75 lower to 3.55 higher)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in clinic BP - change in clinic systolic BP (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>4</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup><sup>,</sup><sup>5</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1189</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1168</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 3.08 lower (4.71 to 1.44 lower)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in clinic BP - change in clinic diastolic BP (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup><sup>,</sup><sup>5</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1189</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1168</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.83 lower (1.51 to 0.15 lower)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Uncontrolled BP (not meeting trial target; follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup><sup>,</sup><sup>5</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>90/616</p>
|
|
<p>(14.6%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16.4%</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.90 (0.69 to 1.15)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16 fewer per 1,000 (from 51 fewer to 25 more)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion controlled to a target (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>91/246</p>
|
|
<p>(37%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30.4%</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.22 (0.95 to 1.56)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">67 more per 1,000 (from 15 fewer to 170 more)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_19_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Overall defined daily dose (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">330</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">350</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.42 higher (0.16 to 0.68 higher)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_21_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Mean number of consultations for hypertension (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">330</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">350</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.10 higher (0.25 lower to 0.45 higher)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_h_ch2.appf.tab4_1_1_2_3 hd_h_ch2.appf.tab4_1_1_2_4 hd_h_ch2.appf.tab4_1_1_2_5 hd_h_ch2.appf.tab4_1_1_2_6 hd_h_ch2.appf.tab4_1_1_2_7 hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_h_ch2.appf.tab4_1_1_2_9 hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_h_ch2.appf.tab4_1_1_2_11 hd_h_ch2.appf.tab4_1_1_1_4 hd_h_ch2.appf.tab4_1_1_1_5" id="hd_b_ch2.appf.tab4_1_1_23_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Dizziness (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_1 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_2 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_3 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_4 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_5 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_6 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab4_1_1_1_1 hd_h_ch2.appf.tab4_1_1_2_7 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_8 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>72/326</p>
|
|
<p>(22.1%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_2 hd_h_ch2.appf.tab4_1_1_2_9 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17.5%</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_10 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.26 (0.93 to 1.71)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_3 hd_h_ch2.appf.tab4_1_1_2_11 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">45 more per 1,000 (from 12 fewer to 124 more)</td><td headers="hd_h_ch2.appf.tab4_1_1_1_4 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab4_1_1_1_5 hd_b_ch2.appf.tab4_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appf.tab4_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.appf.tab4_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.appf.tab4_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="ch2.appf.tab4_4"><p class="no_margin">‘Downgraded by 1 or 2 incrments due to heterogeneity, unexplained by subgroup analyses so random effects was used.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="ch2.appf.tab4_5"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect intervention respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2appftab5"><div id="ch2.appf.tab5" class="table"><h3><span class="label">Table 27</span><span class="title">Clinical evidence profile: Home monitoring with telemonitoring and pharmacist care versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appf.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appf.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.appf.tab5_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch2.appf.tab5_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch2.appf.tab5_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch2.appf.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab5_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch2.appf.tab5_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab5_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1" id="hd_h_ch2.appf.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch2.appf.tab5_1_1_1_1" id="hd_h_ch2.appf.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch2.appf.tab5_1_1_1_1" id="hd_h_ch2.appf.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch2.appf.tab5_1_1_1_1" id="hd_h_ch2.appf.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch2.appf.tab5_1_1_1_1" id="hd_h_ch2.appf.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch2.appf.tab5_1_1_1_1" id="hd_h_ch2.appf.tab5_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch2.appf.tab5_1_1_1_1" id="hd_h_ch2.appf.tab5_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch2.appf.tab5_1_1_1_2" id="hd_h_ch2.appf.tab5_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Home monitoring with TM and pharmacist interaction</th><th headers="hd_h_ch2.appf.tab5_1_1_1_2" id="hd_h_ch2.appf.tab5_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Clinic/office monitoring</th><th headers="hd_h_ch2.appf.tab5_1_1_1_3" id="hd_h_ch2.appf.tab5_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch2.appf.tab5_1_1_1_3" id="hd_h_ch2.appf.tab5_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_h_ch2.appf.tab5_1_1_2_3 hd_h_ch2.appf.tab5_1_1_2_4 hd_h_ch2.appf.tab5_1_1_2_5 hd_h_ch2.appf.tab5_1_1_2_6 hd_h_ch2.appf.tab5_1_1_2_7 hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_h_ch2.appf.tab5_1_1_2_9 hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_h_ch2.appf.tab5_1_1_2_11 hd_h_ch2.appf.tab5_1_1_1_4 hd_h_ch2.appf.tab5_1_1_1_5" id="hd_b_ch2.appf.tab5_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - Emotional scale (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_3 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_4 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_5 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_6 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_7 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_9 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">247</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_11 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.20 higher (3.14 lower to 3.54 higher)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_4 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_5 hd_b_ch2.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_h_ch2.appf.tab5_1_1_2_3 hd_h_ch2.appf.tab5_1_1_2_4 hd_h_ch2.appf.tab5_1_1_2_5 hd_h_ch2.appf.tab5_1_1_2_6 hd_h_ch2.appf.tab5_1_1_2_7 hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_h_ch2.appf.tab5_1_1_2_9 hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_h_ch2.appf.tab5_1_1_2_11 hd_h_ch2.appf.tab5_1_1_1_4 hd_h_ch2.appf.tab5_1_1_1_5" id="hd_b_ch2.appf.tab5_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - Physical (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_3 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_4 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_5 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_6 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_7 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_9 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">247</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_11 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 2.90 higher (1.93 lower to 7.73 higher)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_4 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_5 hd_b_ch2.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_h_ch2.appf.tab5_1_1_2_3 hd_h_ch2.appf.tab5_1_1_2_4 hd_h_ch2.appf.tab5_1_1_2_5 hd_h_ch2.appf.tab5_1_1_2_6 hd_h_ch2.appf.tab5_1_1_2_7 hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_h_ch2.appf.tab5_1_1_2_9 hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_h_ch2.appf.tab5_1_1_2_11 hd_h_ch2.appf.tab5_1_1_1_4 hd_h_ch2.appf.tab5_1_1_1_5" id="hd_b_ch2.appf.tab5_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - General (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_3 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_4 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_5 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_6 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_7 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_9 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">247</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_11 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.10 lower (3.9 lower to 3.7 higher)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_4 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_5 hd_b_ch2.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_h_ch2.appf.tab5_1_1_2_3 hd_h_ch2.appf.tab5_1_1_2_4 hd_h_ch2.appf.tab5_1_1_2_5 hd_h_ch2.appf.tab5_1_1_2_6 hd_h_ch2.appf.tab5_1_1_2_7 hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_h_ch2.appf.tab5_1_1_2_9 hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_h_ch2.appf.tab5_1_1_2_11 hd_h_ch2.appf.tab5_1_1_1_4 hd_h_ch2.appf.tab5_1_1_1_5" id="hd_b_ch2.appf.tab5_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Non-fatal Cardiovascular events (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_3 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_4 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_5 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_6 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_7 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>3/237</p>
|
|
<p>(1.3%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_9 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.81%</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.56 (0.26 to 9.27)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_11 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 more per 1,000 (from 6 fewer to 67 more)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_4 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_5 hd_b_ch2.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_h_ch2.appf.tab5_1_1_2_3 hd_h_ch2.appf.tab5_1_1_2_4 hd_h_ch2.appf.tab5_1_1_2_5 hd_h_ch2.appf.tab5_1_1_2_6 hd_h_ch2.appf.tab5_1_1_2_7 hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_h_ch2.appf.tab5_1_1_2_9 hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_h_ch2.appf.tab5_1_1_2_11 hd_h_ch2.appf.tab5_1_1_1_4 hd_h_ch2.appf.tab5_1_1_1_5" id="hd_b_ch2.appf.tab5_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_3 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_4 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_5 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_6 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_7 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1/237</p>
|
|
<p>(0.42%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_9 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0%</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Peto OR 7.71 (0.15 to 388.76)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_11 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0 more per 1,000 (from 0.01 fewer to 0.02 more)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_4 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_5 hd_b_ch2.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_h_ch2.appf.tab5_1_1_2_3 hd_h_ch2.appf.tab5_1_1_2_4 hd_h_ch2.appf.tab5_1_1_2_5 hd_h_ch2.appf.tab5_1_1_2_6 hd_h_ch2.appf.tab5_1_1_2_7 hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_h_ch2.appf.tab5_1_1_2_9 hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_h_ch2.appf.tab5_1_1_2_11 hd_h_ch2.appf.tab5_1_1_1_4 hd_h_ch2.appf.tab5_1_1_1_5" id="hd_b_ch2.appf.tab5_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in systolic BP (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_3 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_4 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_5 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_6 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_7 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_9 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">247</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_11 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 8.90 lower (11.43 to 6.37 lower)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_4 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_5 hd_b_ch2.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_h_ch2.appf.tab5_1_1_2_3 hd_h_ch2.appf.tab5_1_1_2_4 hd_h_ch2.appf.tab5_1_1_2_5 hd_h_ch2.appf.tab5_1_1_2_6 hd_h_ch2.appf.tab5_1_1_2_7 hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_h_ch2.appf.tab5_1_1_2_9 hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_h_ch2.appf.tab5_1_1_2_11 hd_h_ch2.appf.tab5_1_1_1_4 hd_h_ch2.appf.tab5_1_1_1_5" id="hd_b_ch2.appf.tab5_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in diastolic BP (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_3 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_4 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_5 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_6 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_7 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_9 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">247</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_11 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 3.50 lower (4.91 to 2.09 lower)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_4 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_5 hd_b_ch2.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_h_ch2.appf.tab5_1_1_2_3 hd_h_ch2.appf.tab5_1_1_2_4 hd_h_ch2.appf.tab5_1_1_2_5 hd_h_ch2.appf.tab5_1_1_2_6 hd_h_ch2.appf.tab5_1_1_2_7 hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_h_ch2.appf.tab5_1_1_2_9 hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_h_ch2.appf.tab5_1_1_2_11 hd_h_ch2.appf.tab5_1_1_1_4 hd_h_ch2.appf.tab5_1_1_1_5" id="hd_b_ch2.appf.tab5_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion controlled to a target (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_1 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_2 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_3 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_4 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_5 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_6 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab5_1_1_1_1 hd_h_ch2.appf.tab5_1_1_2_7 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_8 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>134/237</p>
|
|
<p>(56.5%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_2 hd_h_ch2.appf.tab5_1_1_2_9 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30.8%</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_10 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.84 (1.48 to 2.28)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_3 hd_h_ch2.appf.tab5_1_1_2_11 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">259 more per 1,000 (from 148 more to 394 more)</td><td headers="hd_h_ch2.appf.tab5_1_1_1_4 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁⨁◯</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_ch2.appf.tab5_1_1_1_5 hd_b_ch2.appf.tab5_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appf.tab5_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.appf.tab5_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect intervention respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.appf.tab5_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2appftab6"><div id="ch2.appf.tab6" class="table"><h3><span class="label">Table 28</span><span class="title">Clinical evidence profile: Home monitoring with telemonitoring and pharmacist care versus home monitoring with telemonitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appf.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appf.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.appf.tab6_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch2.appf.tab6_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch2.appf.tab6_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch2.appf.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab6_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch2.appf.tab6_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab6_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch2.appf.tab6_1_1_1_1" id="hd_h_ch2.appf.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch2.appf.tab6_1_1_1_1" id="hd_h_ch2.appf.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch2.appf.tab6_1_1_1_1" id="hd_h_ch2.appf.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch2.appf.tab6_1_1_1_1" id="hd_h_ch2.appf.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch2.appf.tab6_1_1_1_1" id="hd_h_ch2.appf.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch2.appf.tab6_1_1_1_1" id="hd_h_ch2.appf.tab6_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch2.appf.tab6_1_1_1_1" id="hd_h_ch2.appf.tab6_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch2.appf.tab6_1_1_1_2" id="hd_h_ch2.appf.tab6_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Home monitoring with TM + pharmacist care</th><th headers="hd_h_ch2.appf.tab6_1_1_1_2" id="hd_h_ch2.appf.tab6_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Home monitoring with telemonitoring</th><th headers="hd_h_ch2.appf.tab6_1_1_1_3" id="hd_h_ch2.appf.tab6_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch2.appf.tab6_1_1_1_3" id="hd_h_ch2.appf.tab6_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_h_ch2.appf.tab6_1_1_2_3 hd_h_ch2.appf.tab6_1_1_2_4 hd_h_ch2.appf.tab6_1_1_2_5 hd_h_ch2.appf.tab6_1_1_2_6 hd_h_ch2.appf.tab6_1_1_2_7 hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_h_ch2.appf.tab6_1_1_2_9 hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_h_ch2.appf.tab6_1_1_2_11 hd_h_ch2.appf.tab6_1_1_1_4 hd_h_ch2.appf.tab6_1_1_1_5" id="hd_b_ch2.appf.tab6_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_3 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_4 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_5 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_6 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_7 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1/237</p>
|
|
<p>(0.42%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_9 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.81%</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.52 (0.05 to 5.69)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_11 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 fewer per 1,000 (from 8 fewer to 38 more)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_4 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_5 hd_b_ch2.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_h_ch2.appf.tab6_1_1_2_3 hd_h_ch2.appf.tab6_1_1_2_4 hd_h_ch2.appf.tab6_1_1_2_5 hd_h_ch2.appf.tab6_1_1_2_6 hd_h_ch2.appf.tab6_1_1_2_7 hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_h_ch2.appf.tab6_1_1_2_9 hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_h_ch2.appf.tab6_1_1_2_11 hd_h_ch2.appf.tab6_1_1_1_4 hd_h_ch2.appf.tab6_1_1_1_5" id="hd_b_ch2.appf.tab6_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Non-fatal Cardiovascular events (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_3 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_4 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_5 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_6 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_7 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>3/237</p>
|
|
<p>(1.3%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_9 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.6%</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.78 (0.18 to 3.44)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_11 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 fewer per 1,000 (from 13 fewer to 39 more)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_4 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_5 hd_b_ch2.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_h_ch2.appf.tab6_1_1_2_3 hd_h_ch2.appf.tab6_1_1_2_4 hd_h_ch2.appf.tab6_1_1_2_5 hd_h_ch2.appf.tab6_1_1_2_6 hd_h_ch2.appf.tab6_1_1_2_7 hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_h_ch2.appf.tab6_1_1_2_9 hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_h_ch2.appf.tab6_1_1_2_11 hd_h_ch2.appf.tab6_1_1_1_4 hd_h_ch2.appf.tab6_1_1_1_5" id="hd_b_ch2.appf.tab6_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in systolic BP (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_3 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_4 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_5 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_6 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_7 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_9 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_11 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 6.00 lower (8.53 to 3.47 lower)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_4 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_5 hd_b_ch2.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_h_ch2.appf.tab6_1_1_2_3 hd_h_ch2.appf.tab6_1_1_2_4 hd_h_ch2.appf.tab6_1_1_2_5 hd_h_ch2.appf.tab6_1_1_2_6 hd_h_ch2.appf.tab6_1_1_2_7 hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_h_ch2.appf.tab6_1_1_2_9 hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_h_ch2.appf.tab6_1_1_2_11 hd_h_ch2.appf.tab6_1_1_1_4 hd_h_ch2.appf.tab6_1_1_1_5" id="hd_b_ch2.appf.tab6_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in diastolic BP (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_3 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_4 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_5 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_6 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_7 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_9 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_11 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 2.60 lower (4.01 to 1.19 lower)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_4 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_5 hd_b_ch2.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_h_ch2.appf.tab6_1_1_2_3 hd_h_ch2.appf.tab6_1_1_2_4 hd_h_ch2.appf.tab6_1_1_2_5 hd_h_ch2.appf.tab6_1_1_2_6 hd_h_ch2.appf.tab6_1_1_2_7 hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_h_ch2.appf.tab6_1_1_2_9 hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_h_ch2.appf.tab6_1_1_2_11 hd_h_ch2.appf.tab6_1_1_1_4 hd_h_ch2.appf.tab6_1_1_1_5" id="hd_b_ch2.appf.tab6_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - Emotional scale (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_3 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_4 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_5 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_6 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_7 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_9 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_11 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.40 lower (3.67 lower to 2.87 higher)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_4 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_5 hd_b_ch2.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_h_ch2.appf.tab6_1_1_2_3 hd_h_ch2.appf.tab6_1_1_2_4 hd_h_ch2.appf.tab6_1_1_2_5 hd_h_ch2.appf.tab6_1_1_2_6 hd_h_ch2.appf.tab6_1_1_2_7 hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_h_ch2.appf.tab6_1_1_2_9 hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_h_ch2.appf.tab6_1_1_2_11 hd_h_ch2.appf.tab6_1_1_1_4 hd_h_ch2.appf.tab6_1_1_1_5" id="hd_b_ch2.appf.tab6_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - Physical (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_3 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_4 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_5 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_6 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_7 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_9 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_11 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 3.30 higher (1.77 lower to 8.37 higher)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_4 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_5 hd_b_ch2.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_h_ch2.appf.tab6_1_1_2_3 hd_h_ch2.appf.tab6_1_1_2_4 hd_h_ch2.appf.tab6_1_1_2_5 hd_h_ch2.appf.tab6_1_1_2_6 hd_h_ch2.appf.tab6_1_1_2_7 hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_h_ch2.appf.tab6_1_1_2_9 hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_h_ch2.appf.tab6_1_1_2_11 hd_h_ch2.appf.tab6_1_1_1_4 hd_h_ch2.appf.tab6_1_1_1_5" id="hd_b_ch2.appf.tab6_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life - General (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_1 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_2 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_3 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_4 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_5 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_6 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab6_1_1_1_1 hd_h_ch2.appf.tab6_1_1_2_7 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_8 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">237</td><td headers="hd_h_ch2.appf.tab6_1_1_1_2 hd_h_ch2.appf.tab6_1_1_2_9 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_10 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab6_1_1_1_3 hd_h_ch2.appf.tab6_1_1_2_11 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.00 higher (3.85 lower to 3.85 higher)</td><td headers="hd_h_ch2.appf.tab6_1_1_1_4 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab6_1_1_1_5 hd_b_ch2.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appf.tab6_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.appf.tab6_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect intervention respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.appf.tab6_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2appftab7"><div id="ch2.appf.tab7" class="table"><h3><span class="label">Table 29</span><span class="title">Clinical evidence profile: Home-monitoring (with self-titration) and telemonitoring versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appf.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appf.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.appf.tab7_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch2.appf.tab7_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch2.appf.tab7_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch2.appf.tab7_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab7_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch2.appf.tab7_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab7_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch2.appf.tab7_1_1_1_1" id="hd_h_ch2.appf.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch2.appf.tab7_1_1_1_1" id="hd_h_ch2.appf.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch2.appf.tab7_1_1_1_1" id="hd_h_ch2.appf.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch2.appf.tab7_1_1_1_1" id="hd_h_ch2.appf.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch2.appf.tab7_1_1_1_1" id="hd_h_ch2.appf.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch2.appf.tab7_1_1_1_1" id="hd_h_ch2.appf.tab7_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch2.appf.tab7_1_1_1_1" id="hd_h_ch2.appf.tab7_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch2.appf.tab7_1_1_1_2" id="hd_h_ch2.appf.tab7_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Self-monitoring (with selftitration) and telemonitoring</th><th headers="hd_h_ch2.appf.tab7_1_1_1_2" id="hd_h_ch2.appf.tab7_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Clinic monitoring</th><th headers="hd_h_ch2.appf.tab7_1_1_1_3" id="hd_h_ch2.appf.tab7_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch2.appf.tab7_1_1_1_3" id="hd_h_ch2.appf.tab7_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_h_ch2.appf.tab7_1_1_2_3 hd_h_ch2.appf.tab7_1_1_2_4 hd_h_ch2.appf.tab7_1_1_2_5 hd_h_ch2.appf.tab7_1_1_2_6 hd_h_ch2.appf.tab7_1_1_2_7 hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_h_ch2.appf.tab7_1_1_2_9 hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_h_ch2.appf.tab7_1_1_2_11 hd_h_ch2.appf.tab7_1_1_1_4 hd_h_ch2.appf.tab7_1_1_1_5" id="hd_b_ch2.appf.tab7_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Clinic blood pressure, systolic, final score (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_3 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_4 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_5 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_6 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_7 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">234</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_9 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_11 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 5.60 lower (8.91 to 2.29 lower)</td><td headers="hd_h_ch2.appf.tab7_1_1_1_4 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab7_1_1_1_5 hd_b_ch2.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_h_ch2.appf.tab7_1_1_2_3 hd_h_ch2.appf.tab7_1_1_2_4 hd_h_ch2.appf.tab7_1_1_2_5 hd_h_ch2.appf.tab7_1_1_2_6 hd_h_ch2.appf.tab7_1_1_2_7 hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_h_ch2.appf.tab7_1_1_2_9 hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_h_ch2.appf.tab7_1_1_2_11 hd_h_ch2.appf.tab7_1_1_1_4 hd_h_ch2.appf.tab7_1_1_1_5" id="hd_b_ch2.appf.tab7_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Clinic blood pressure, diastolic, final score (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_3 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_4 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_5 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_6 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_7 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">234</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_9 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_11 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 2.30 lower (4.41 to 0.19 lower)</td><td headers="hd_h_ch2.appf.tab7_1_1_1_4 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab7_1_1_1_5 hd_b_ch2.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_h_ch2.appf.tab7_1_1_2_3 hd_h_ch2.appf.tab7_1_1_2_4 hd_h_ch2.appf.tab7_1_1_2_5 hd_h_ch2.appf.tab7_1_1_2_6 hd_h_ch2.appf.tab7_1_1_2_7 hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_h_ch2.appf.tab7_1_1_2_9 hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_h_ch2.appf.tab7_1_1_2_11 hd_h_ch2.appf.tab7_1_1_1_4 hd_h_ch2.appf.tab7_1_1_1_5" id="hd_b_ch2.appf.tab7_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Quality of life, EQ-5D, (follow-up 1 years; Better indicated by higher values)</th></tr><tr><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_3 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_4 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_5 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_6 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_7 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">234</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_9 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_11 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.01 lower (0.06 lower to 0.03 higher)</td><td headers="hd_h_ch2.appf.tab7_1_1_1_4 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab7_1_1_1_5 hd_b_ch2.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_h_ch2.appf.tab7_1_1_2_3 hd_h_ch2.appf.tab7_1_1_2_4 hd_h_ch2.appf.tab7_1_1_2_5 hd_h_ch2.appf.tab7_1_1_2_6 hd_h_ch2.appf.tab7_1_1_2_7 hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_h_ch2.appf.tab7_1_1_2_9 hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_h_ch2.appf.tab7_1_1_2_11 hd_h_ch2.appf.tab7_1_1_1_4 hd_h_ch2.appf.tab7_1_1_1_5" id="hd_b_ch2.appf.tab7_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Mean number of consultations for hypertension (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_3 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_4 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_5 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_6 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_7 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">234</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_9 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_11 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.30 lower (0.72 lower to 0.12 higher)</td><td headers="hd_h_ch2.appf.tab7_1_1_1_4 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab7_1_1_1_5 hd_b_ch2.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_h_ch2.appf.tab7_1_1_2_3 hd_h_ch2.appf.tab7_1_1_2_4 hd_h_ch2.appf.tab7_1_1_2_5 hd_h_ch2.appf.tab7_1_1_2_6 hd_h_ch2.appf.tab7_1_1_2_7 hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_h_ch2.appf.tab7_1_1_2_9 hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_h_ch2.appf.tab7_1_1_2_11 hd_h_ch2.appf.tab7_1_1_1_4 hd_h_ch2.appf.tab7_1_1_1_5" id="hd_b_ch2.appf.tab7_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Mean number of antihypertensive drugs (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_1 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_2 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_3 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_4 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_5 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_6 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab7_1_1_1_1 hd_h_ch2.appf.tab7_1_1_2_7 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_8 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">234</td><td headers="hd_h_ch2.appf.tab7_1_1_1_2 hd_h_ch2.appf.tab7_1_1_2_9 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">246</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_10 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab7_1_1_1_3 hd_h_ch2.appf.tab7_1_1_2_11 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.40 higher (0.12 to 0.68 higher)</td><td headers="hd_h_ch2.appf.tab7_1_1_1_4 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab7_1_1_1_5 hd_b_ch2.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appf.tab7_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.appf.tab7_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch2appftab8"><div id="ch2.appf.tab8" class="table"><h3><span class="label">Table 30</span><span class="title">Clinical evidence profile: Pharmacy versus clinic monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appf.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appf.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch2.appf.tab8_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_ch2.appf.tab8_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_ch2.appf.tab8_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_ch2.appf.tab8_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab8_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_ch2.appf.tab8_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_ch2.appf.tab8_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_ch2.appf.tab8_1_1_1_1" id="hd_h_ch2.appf.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_ch2.appf.tab8_1_1_1_1" id="hd_h_ch2.appf.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_ch2.appf.tab8_1_1_1_1" id="hd_h_ch2.appf.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_ch2.appf.tab8_1_1_1_1" id="hd_h_ch2.appf.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_ch2.appf.tab8_1_1_1_1" id="hd_h_ch2.appf.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_ch2.appf.tab8_1_1_1_1" id="hd_h_ch2.appf.tab8_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_ch2.appf.tab8_1_1_1_1" id="hd_h_ch2.appf.tab8_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_ch2.appf.tab8_1_1_1_2" id="hd_h_ch2.appf.tab8_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Pharmacy</th><th headers="hd_h_ch2.appf.tab8_1_1_1_2" id="hd_h_ch2.appf.tab8_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Clinic/office</th><th headers="hd_h_ch2.appf.tab8_1_1_1_3" id="hd_h_ch2.appf.tab8_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_ch2.appf.tab8_1_1_1_3" id="hd_h_ch2.appf.tab8_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_1 hd_h_ch2.appf.tab8_1_1_2_2 hd_h_ch2.appf.tab8_1_1_2_3 hd_h_ch2.appf.tab8_1_1_2_4 hd_h_ch2.appf.tab8_1_1_2_5 hd_h_ch2.appf.tab8_1_1_2_6 hd_h_ch2.appf.tab8_1_1_2_7 hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_8 hd_h_ch2.appf.tab8_1_1_2_9 hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_10 hd_h_ch2.appf.tab8_1_1_2_11 hd_h_ch2.appf.tab8_1_1_1_4 hd_h_ch2.appf.tab8_1_1_1_5" id="hd_b_ch2.appf.tab8_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 1 years)</th></tr><tr><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_1 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_2 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_3 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_4 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_5 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_6 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_7 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_8 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0/131</p>
|
|
<p>(0%)</p>
|
|
</td><td headers="hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_9 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.8%</td><td headers="hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_10 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Peto OR 0.13 (0 to 6.72)</td><td headers="hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_11 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 fewer per 1,000 (from 3 fewer to 1 more)</td><td headers="hd_h_ch2.appf.tab8_1_1_1_4 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab8_1_1_1_5 hd_b_ch2.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_1 hd_h_ch2.appf.tab8_1_1_2_2 hd_h_ch2.appf.tab8_1_1_2_3 hd_h_ch2.appf.tab8_1_1_2_4 hd_h_ch2.appf.tab8_1_1_2_5 hd_h_ch2.appf.tab8_1_1_2_6 hd_h_ch2.appf.tab8_1_1_2_7 hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_8 hd_h_ch2.appf.tab8_1_1_2_9 hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_10 hd_h_ch2.appf.tab8_1_1_2_11 hd_h_ch2.appf.tab8_1_1_1_4 hd_h_ch2.appf.tab8_1_1_1_5" id="hd_b_ch2.appf.tab8_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in clinic BP, systolic (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_1 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_2 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_3 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_4 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_5 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_6 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_7 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_8 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">131</td><td headers="hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_9 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">129</td><td headers="hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_10 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_11 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 4.90 lower (8.75 to 1.05 lower)</td><td headers="hd_h_ch2.appf.tab8_1_1_1_4 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab8_1_1_1_5 hd_b_ch2.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_1 hd_h_ch2.appf.tab8_1_1_2_2 hd_h_ch2.appf.tab8_1_1_2_3 hd_h_ch2.appf.tab8_1_1_2_4 hd_h_ch2.appf.tab8_1_1_2_5 hd_h_ch2.appf.tab8_1_1_2_6 hd_h_ch2.appf.tab8_1_1_2_7 hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_8 hd_h_ch2.appf.tab8_1_1_2_9 hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_10 hd_h_ch2.appf.tab8_1_1_2_11 hd_h_ch2.appf.tab8_1_1_1_4 hd_h_ch2.appf.tab8_1_1_1_5" id="hd_b_ch2.appf.tab8_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Reduction in clinic BP, diastolic (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_1 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_2 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_3 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_4 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_5 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_6 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_7 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_8 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">131</td><td headers="hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_9 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">129</td><td headers="hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_10 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_11 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 2.90 lower (5.7 to 0.1 lower)</td><td headers="hd_h_ch2.appf.tab8_1_1_1_4 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab8_1_1_1_5 hd_b_ch2.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_1 hd_h_ch2.appf.tab8_1_1_2_2 hd_h_ch2.appf.tab8_1_1_2_3 hd_h_ch2.appf.tab8_1_1_2_4 hd_h_ch2.appf.tab8_1_1_2_5 hd_h_ch2.appf.tab8_1_1_2_6 hd_h_ch2.appf.tab8_1_1_2_7 hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_8 hd_h_ch2.appf.tab8_1_1_2_9 hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_10 hd_h_ch2.appf.tab8_1_1_2_11 hd_h_ch2.appf.tab8_1_1_1_4 hd_h_ch2.appf.tab8_1_1_1_5" id="hd_b_ch2.appf.tab8_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Contacts per patients with all resources (excluding pharmacists), 12 months (follow-up 1 years; Better indicated by lower values)</th></tr><tr><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_1 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_2 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_3 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_4 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_5 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_6 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_ch2.appf.tab8_1_1_1_1 hd_h_ch2.appf.tab8_1_1_2_7 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_8 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">131</td><td headers="hd_h_ch2.appf.tab8_1_1_1_2 hd_h_ch2.appf.tab8_1_1_2_9 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">129</td><td headers="hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_10 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_ch2.appf.tab8_1_1_1_3 hd_h_ch2.appf.tab8_1_1_2_11 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0 higher (0 to 0 higher)</td><td headers="hd_h_ch2.appf.tab8_1_1_1_4 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_ch2.appf.tab8_1_1_1_5 hd_b_ch2.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="ch2.appf.tab8_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="ch2.appf.tab8_2"><p class="no_margin">Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect intervention respectively.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="ch2.appf.tab8_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobch2appgfig1"><div id="ch2.appg.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2053.%20Flow%20chart%20of%20health%20economic%20study%20selection%20for%20the%20guideline.&p=BOOKS&id=578044_ch2appgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK578044/bin/ch2appgf1.jpg" alt="Figure 53. Flow chart of health economic study selection for the guideline." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 53</span><span class="title">Flow chart of health economic study selection for the guideline</span></h3><div class="caption"><p>* Non-relevant population, intervention, comparison, design or setting; non-English language</p></div></div></article><article data-type="table-wrap" id="figobch2appitab1"><div id="ch2.appi.tab1" class="table"><h3><span class="label">Table 31</span><span class="title">Studies excluded from the clinical review that were included in the previous guideline (CG127)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appi.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appi.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch2.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Study</th><th id="hd_h_ch2.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exclusion details</th></tr></thead><tbody><tr><td headers="hd_h_ch2.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bray 2010<a class="bibr" href="#ch2.ref18" rid="ch2.ref18"><sup>18</sup></a></td><td headers="hd_h_ch2.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review with relevant PICO. Each individual study included within the review was assessed for inclusion. The majority of the studies were conducted before the year 2000 and so were excluded. Other studies had a follow up of less than 12 months and so did not meet the inclusion criteria for this review.</td></tr><tr><td headers="hd_h_ch2.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conen 2009<a class="bibr" href="#ch2.ref33" rid="ch2.ref33"><sup>33</sup></a></td><td headers="hd_h_ch2.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design with less than minimum follow up duration. Not all participants were assessed at 12 months.</td></tr><tr><td headers="hd_h_ch2.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ishikawa 2008<a class="bibr" href="#ch2.ref59" rid="ch2.ref59"><sup>59</sup></a></td><td headers="hd_h_ch2.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review with relevant PICO. Each individual study included within the review was assessed for inclusion. The majority of the studies were conducted before the year 2000 and so were excluded. Other studies were not included because they compared antihypertensive drugs rather than measurement methods.</td></tr><tr><td headers="hd_h_ch2.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Niiranen 2006<a class="bibr" href="#ch2.ref95" rid="ch2.ref95"><sup>95</sup></a></td><td headers="hd_h_ch2.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum follow up duration. The follow up was 24 weeks, not meeting the 12 month minimum follow up specified by the protocol.</td></tr><tr><td headers="hd_h_ch2.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Staessen 2004<a class="bibr" href="#ch2.ref128" rid="ch2.ref128"><sup>128</sup></a></td><td headers="hd_h_ch2.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison. All participants had home and clinic monitoring, resulting in the control group not being a control group and all were using the same target.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appitab2"><div id="ch2.appi.tab2" class="table"><h3><span class="label">Table 32</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appi.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appi.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Study</th><th id="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exclusion reason</th></tr></thead><tbody><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abdoh 2003<a class="bibr" href="#ch2.ref1" rid="ch2.ref1"><sup>1</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aekplakorn 2016<a class="bibr" href="#ch2.ref2" rid="ch2.ref2"><sup>2</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Albasri 2017<a class="bibr" href="#ch2.ref3" rid="ch2.ref3"><sup>3</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anderegg 2016<a class="bibr" href="#ch2.ref4" rid="ch2.ref4"><sup>4</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anderson 2017<a class="bibr" href="#ch2.ref5" rid="ch2.ref5"><sup>5</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anonymous 2004<a class="bibr" href="#ch2.ref6" rid="ch2.ref6"><sup>6</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Antonicelli 1995<a class="bibr" href="#ch2.ref7" rid="ch2.ref7"><sup>7</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aoki 2004<a class="bibr" href="#ch2.ref8" rid="ch2.ref8"><sup>8</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Artinian 2001<a class="bibr" href="#ch2.ref10" rid="ch2.ref10"><sup>10</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Artinian 2007<a class="bibr" href="#ch2.ref9" rid="ch2.ref9"><sup>9</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Asayama 2016<a class="bibr" href="#ch2.ref11" rid="ch2.ref11"><sup>11</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bailey 1999<a class="bibr" href="#ch2.ref12" rid="ch2.ref12"><sup>12</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bliziotis 2012<a class="bibr" href="#ch2.ref13" rid="ch2.ref13"><sup>13</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bosworth 2007<a class="bibr" href="#ch2.ref14" rid="ch2.ref14"><sup>14</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bosworth 2009<a class="bibr" href="#ch2.ref15" rid="ch2.ref15"><sup>15</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in IPD - no extra outcomes to add</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bosworth 2011<a class="bibr" href="#ch2.ref16" rid="ch2.ref16"><sup>16</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in IPD - no extra outcomes to add</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bray 2010 <a class="bibr" href="#ch2.ref18" rid="ch2.ref18"><sup>18</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bray 2015<a class="bibr" href="#ch2.ref19" rid="ch2.ref19"><sup>19</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in IPD - no extra outcomes to add</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breaux-Shropshire 2015<a class="bibr" href="#ch2.ref20" rid="ch2.ref20"><sup>20</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brzozowska-Kiszka 2010<a class="bibr" href="#ch2.ref21" rid="ch2.ref21"><sup>21</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Carnahan 1975<a class="bibr" href="#ch2.ref22" rid="ch2.ref22"><sup>22</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Carter 2008<a class="bibr" href="#ch2.ref25" rid="ch2.ref25"><sup>25</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Carter 2009<a class="bibr" href="#ch2.ref23" rid="ch2.ref23"><sup>23</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Carter 2009<a class="bibr" href="#ch2.ref24" rid="ch2.ref24"><sup>24</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Castro 2006<a class="bibr" href="#ch2.ref26" rid="ch2.ref26"><sup>26</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Celis 2005<a class="bibr" href="#ch2.ref27" rid="ch2.ref27"><sup>27</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chabot 2003<a class="bibr" href="#ch2.ref28" rid="ch2.ref28"><sup>28</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chambers 2013<a class="bibr" href="#ch2.ref29" rid="ch2.ref29"><sup>29</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chatellier 1996<a class="bibr" href="#ch2.ref30" rid="ch2.ref30"><sup>30</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chen 2013<a class="bibr" href="#ch2.ref31" rid="ch2.ref31"><sup>31</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conen 2009 <a class="bibr" href="#ch2.ref33" rid="ch2.ref33"><sup>33</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design, inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dalfó i Baqué 2005<a class="bibr" href="#ch2.ref37" rid="ch2.ref37"><sup>37</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Davidson 2015<a class="bibr" href="#ch2.ref38" rid="ch2.ref38"><sup>38</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dean 2014<a class="bibr" href="#ch2.ref39" rid="ch2.ref39"><sup>39</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Doane 2018<a class="bibr" href="#ch2.ref40" rid="ch2.ref40"><sup>40</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Duan 2017<a class="bibr" href="#ch2.ref41" rid="ch2.ref41"><sup>41</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic Review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Earle 2001<a class="bibr" href="#ch2.ref43" rid="ch2.ref43"><sup>43</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Earle 2010<a class="bibr" href="#ch2.ref42" rid="ch2.ref42"><sup>42</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fikri-Benbrahim 2013<a class="bibr" href="#ch2.ref44" rid="ch2.ref44"><sup>44</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Franssen 2017<a class="bibr" href="#ch2.ref45" rid="ch2.ref45"><sup>45</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fuchs 2013<a class="bibr" href="#ch2.ref46" rid="ch2.ref46"><sup>46</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fujiwara 2002<a class="bibr" href="#ch2.ref47" rid="ch2.ref47"><sup>47</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">George 2010<a class="bibr" href="#ch2.ref48" rid="ch2.ref48"><sup>48</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Halme 2005<a class="bibr" href="#ch2.ref50" rid="ch2.ref50"><sup>50</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hansen 2014<a class="bibr" href="#ch2.ref51" rid="ch2.ref51"><sup>51</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">He 2017<a class="bibr" href="#ch2.ref52" rid="ch2.ref52"><sup>52</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hebert 2012<a class="bibr" href="#ch2.ref53" rid="ch2.ref53"><sup>53</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in IPD - no extra outcomes to add</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Heinemann 2008<a class="bibr" href="#ch2.ref54" rid="ch2.ref54"><sup>54</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hond 2004<a class="bibr" href="#ch2.ref55" rid="ch2.ref55"><sup>55</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hosseininasab 2014<a class="bibr" href="#ch2.ref56" rid="ch2.ref56"><sup>56</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hunt 2008<a class="bibr" href="#ch2.ref57" rid="ch2.ref57"><sup>57</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Irving 2016<a class="bibr" href="#ch2.ref58" rid="ch2.ref58"><sup>58</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ishikawa 2008 <a class="bibr" href="#ch2.ref59" rid="ch2.ref59"><sup>59</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jegatheswaran 2017<a class="bibr" href="#ch2.ref60" rid="ch2.ref60"><sup>60</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design. No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jones 2013<a class="bibr" href="#ch2.ref61" rid="ch2.ref61"><sup>61</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kaambwa 2010<a class="bibr" href="#ch2.ref63" rid="ch2.ref63"><sup>63</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kaihara 2014<a class="bibr" href="#ch2.ref64" rid="ch2.ref64"><sup>64</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kawano 2010<a class="bibr" href="#ch2.ref65" rid="ch2.ref65"><sup>65</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kerby 2012<a class="bibr" href="#ch2.ref66" rid="ch2.ref66"><sup>66</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kerry 2013<a class="bibr" href="#ch2.ref67" rid="ch2.ref67"><sup>67</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kim 2015<a class="bibr" href="#ch2.ref69" rid="ch2.ref69"><sup>69</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kim 2016<a class="bibr" href="#ch2.ref68" rid="ch2.ref68"><sup>68</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kushiro 2017<a class="bibr" href="#ch2.ref71" rid="ch2.ref71"><sup>71</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Maciejewski 2014<a class="bibr" href="#ch2.ref75" rid="ch2.ref75"><sup>75</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in IPD - no extra outcomes to add</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Madsen 2008<a class="bibr" href="#ch2.ref77" rid="ch2.ref77"><sup>77</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Magid 2013<a class="bibr" href="#ch2.ref78" rid="ch2.ref78"><sup>78</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Different treatment pathways. Unclear interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Margolis 2010<a class="bibr" href="#ch2.ref80" rid="ch2.ref80"><sup>80</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Unavailable. Conference abstract</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Margolis 2013<a class="bibr" href="#ch2.ref79" rid="ch2.ref79"><sup>79</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Martinez 2017<a class="bibr" href="#ch2.ref81" rid="ch2.ref81"><sup>81</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mckinstry 2013<a class="bibr" href="#ch2.ref82" rid="ch2.ref82"><sup>82</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">McManus 2005<a class="bibr" href="#ch2.ref87" rid="ch2.ref87"><sup>87</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population setting</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">McManus 2009<a class="bibr" href="#ch2.ref83" rid="ch2.ref83"><sup>83</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design. Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">McManus 2014<a class="bibr" href="#ch2.ref86" rid="ch2.ref86"><sup>86</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">More than 20% population indirectness</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myers 2012<a class="bibr" href="#ch2.ref88" rid="ch2.ref88"><sup>88</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myers 2012<a class="bibr" href="#ch2.ref89" rid="ch2.ref89"><sup>89</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not all receiving same treatment pathway</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nakao 2004<a class="bibr" href="#ch2.ref90" rid="ch2.ref90"><sup>90</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Niiranen 2006 <a class="bibr" href="#ch2.ref95" rid="ch2.ref95"><sup>95</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Niiranen 2010<a class="bibr" href="#ch2.ref94" rid="ch2.ref94"><sup>94</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">O’Brien 1996<a class="bibr" href="#ch2.ref97" rid="ch2.ref97"><sup>97</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">O’Brien 2013<a class="bibr" href="#ch2.ref96" rid="ch2.ref96"><sup>96</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ogedegbe 2005<a class="bibr" href="#ch2.ref98" rid="ch2.ref98"><sup>98</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Omboni 2011<a class="bibr" href="#ch2.ref101" rid="ch2.ref101"><sup>101</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Omboni 2013<a class="bibr" href="#ch2.ref100" rid="ch2.ref100"><sup>100</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severely indirect population</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Omboni 2015<a class="bibr" href="#ch2.ref99" rid="ch2.ref99"><sup>99</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Onzenoort 2010<a class="bibr" href="#ch2.ref103" rid="ch2.ref103"><sup>103</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Onzenoort 2012<a class="bibr" href="#ch2.ref102" rid="ch2.ref102"><sup>102</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Parati 1996<a class="bibr" href="#ch2.ref106" rid="ch2.ref106"><sup>106</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Parati 2009<a class="bibr" href="#ch2.ref104" rid="ch2.ref104"><sup>104</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not all participants were receiving antihypertensive treatment</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Parati 2013<a class="bibr" href="#ch2.ref105" rid="ch2.ref105"><sup>105</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Piper 2015<a class="bibr" href="#ch2.ref108" rid="ch2.ref108"><sup>108</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison. Systematic review: study designs inappropriate</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Poteshkina 2015<a class="bibr" href="#ch2.ref109" rid="ch2.ref109"><sup>109</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Qi 2017<a class="bibr" href="#ch2.ref110" rid="ch2.ref110"><sup>110</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not all receiving same treatment pathway</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ragot 2000<a class="bibr" href="#ch2.ref111" rid="ch2.ref111"><sup>111</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ralston 2014<a class="bibr" href="#ch2.ref112" rid="ch2.ref112"><sup>112</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in IPD - no extra outcomes to add</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reboldi 2014<a class="bibr" href="#ch2.ref113" rid="ch2.ref113"><sup>113</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rifkin 2013<a class="bibr" href="#ch2.ref114" rid="ch2.ref114"><sup>114</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rogers 2001<a class="bibr" href="#ch2.ref117" rid="ch2.ref117"><sup>117</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rogers 2002<a class="bibr" href="#ch2.ref116" rid="ch2.ref116"><sup>116</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Santschi 2014<a class="bibr" href="#ch2.ref118" rid="ch2.ref118"><sup>118</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Schrader 2000<a class="bibr" href="#ch2.ref119" rid="ch2.ref119"><sup>119</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Schroeder 2004<a class="bibr" href="#ch2.ref120" rid="ch2.ref120"><sup>120</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sharman 2012<a class="bibr" href="#ch2.ref121" rid="ch2.ref121"><sup>121</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Smith 2016<a class="bibr" href="#ch2.ref123" rid="ch2.ref123"><sup>123</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Soghikian 1992<a class="bibr" href="#ch2.ref124" rid="ch2.ref124"><sup>124</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Published before 2000</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spieker 1991<a class="bibr" href="#ch2.ref125" rid="ch2.ref125"><sup>125</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spruill 2015<a class="bibr" href="#ch2.ref126" rid="ch2.ref126"><sup>126</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Staessen 1997<a class="bibr" href="#ch2.ref127" rid="ch2.ref127"><sup>127</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Staessen 2004<a class="bibr" href="#ch2.ref128" rid="ch2.ref128"><sup>128</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stahl 1984<a class="bibr" href="#ch2.ref129" rid="ch2.ref129"><sup>129</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stergiou 2011<a class="bibr" href="#ch2.ref130" rid="ch2.ref130"><sup>130</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stewart 2014<a class="bibr" href="#ch2.ref132" rid="ch2.ref132"><sup>132</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Torres 2010<a class="bibr" href="#ch2.ref134" rid="ch2.ref134"><sup>134</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Uhlig 2013<a class="bibr" href="#ch2.ref137" rid="ch2.ref137"><sup>137</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - references checked</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulm 2010<a class="bibr" href="#ch2.ref138" rid="ch2.ref138"><sup>138</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in IPD - no extra outcomes to add</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Van der Wel 2011<a class="bibr" href="#ch2.ref139" rid="ch2.ref139"><sup>139</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Varis 2010<a class="bibr" href="#ch2.ref140" rid="ch2.ref140"><sup>140</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No usable outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Verberk 2003<a class="bibr" href="#ch2.ref142" rid="ch2.ref142"><sup>142</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Verberk 2007<a class="bibr" href="#ch2.ref143" rid="ch2.ref143"><sup>143</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no outcomes to add to IPD</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Verberk 2011<a class="bibr" href="#ch2.ref141" rid="ch2.ref141"><sup>141</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review is not relevant to review question or unclear PICO</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Verdecchia 2016<a class="bibr" href="#ch2.ref144" rid="ch2.ref144"><sup>144</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vollmer 2005<a class="bibr" href="#ch2.ref145" rid="ch2.ref145"><sup>145</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wakefield 2011<a class="bibr" href="#ch2.ref146" rid="ch2.ref146"><sup>146</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not all receiving same treatment pathway</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wakefield 2012<a class="bibr" href="#ch2.ref147" rid="ch2.ref147"><sup>147</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not all receiving same treatment pathway</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wakefield 2014<a class="bibr" href="#ch2.ref148" rid="ch2.ref148"><sup>148</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wang 2011<a class="bibr" href="#ch2.ref149" rid="ch2.ref149"><sup>149</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not all receiving same treatment pathway</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Weber 2010<a class="bibr" href="#ch2.ref150" rid="ch2.ref150"><sup>150</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Xu 2017<a class="bibr" href="#ch2.ref151" rid="ch2.ref151"><sup>151</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yatabe 2018<a class="bibr" href="#ch2.ref152" rid="ch2.ref152"><sup>152</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yates 2004<a class="bibr" href="#ch2.ref153" rid="ch2.ref153"><sup>153</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zarnke 1997<a class="bibr" href="#ch2.ref155" rid="ch2.ref155"><sup>155</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Less than minimum duration</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zarnke 1998<a class="bibr" href="#ch2.ref154" rid="ch2.ref154"><sup>154</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant outcomes</td></tr><tr><td headers="hd_h_ch2.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zhao 2012<a class="bibr" href="#ch2.ref156" rid="ch2.ref156"><sup>156</sup></a></td><td headers="hd_h_ch2.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population. Incorrect interventions</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appitab3"><div id="ch2.appi.tab3" class="table"><h3><span class="label">Table 33</span><span class="title">Studies excluded from the health economic review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appi.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appi.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th><th id="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reason for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Boubouchairopoulou 2014<a class="bibr" href="#ch2.ref17" rid="ch2.ref17"><sup>17</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. It is a cost comparison and a within trial analysis. However, given that a more applicable UK analysis<a class="bibr" href="#ch2.ref32" rid="ch2.ref32"><sup>32</sup></a> was available that is also a cost utility analysis, this study was selectively excluded.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Verberk 2007<a class="bibr" href="#ch2.ref143" rid="ch2.ref143"><sup>143</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. It is a cost consequences analysis. However, given that a more applicable UK analysis<a class="bibr" href="#ch2.ref32" rid="ch2.ref32"><sup>32</sup></a> was available that is also a cost utility analysis, this study was selectively excluded.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lorgelly 2003<a class="bibr" href="#ch2.ref74" rid="ch2.ref74"><sup>74</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with very serious limitations as it is an observational study not an RCT, and there are methodological concerns about costing methods.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rodriguez-Roca 2006<a class="bibr" href="#ch2.ref115" rid="ch2.ref115"><sup>115</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with very serious limitations as it is based on a cross sectional study and not an RCT.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Panaloza-Ramos 2016<a class="bibr" href="#ch2.ref107" rid="ch2.ref107"><sup>107</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as not applicable because the population is a high-risk population that is excluded from the clinical review. It is, however, a UK cost utility analysis.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Madsen 2011<a class="bibr" href="#ch2.ref76" rid="ch2.ref76"><sup>76</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with very serious limitations because the clinical trial the economic evaluation is based on did not meet the length of follow up criteria on the clinical protocol.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stoddart 2013<a class="bibr" href="#ch2.ref133" rid="ch2.ref133"><sup>133</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with very serious limitations because the clinical trial the economic evaluation is based on did not meet the length of follow up criteria on the clinical protocol.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Parati 2008<a class="bibr" href="#ch2.ref104" rid="ch2.ref104"><sup>104</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with very serious limitations because the clinical trial the economic evaluation is based on is a study protocol and therefore does not meet the review criteria.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">McManus 2005<a class="bibr" href="#ch2.ref87" rid="ch2.ref87"><sup>87</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as not applicable because the clinical trial the economic evaluation is based on does not have the right comparison.</td></tr><tr><td headers="hd_h_ch2.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Staessen 2004<a class="bibr" href="#ch2.ref128" rid="ch2.ref128"><sup>128</sup></a></td><td headers="hd_h_ch2.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as not applicable because the clinical trial the economic evaluation is based on does not have the right comparison.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch2appjtab1"><div id="ch2.appj.tab1" class="table"><h3><span class="title">Criteria for selecting high-priority research recommendations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK578044/table/ch2.appj.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch2.appj.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_ch2.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PICO question</th><td headers="hd_b_ch2.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Population: People with atrial fibrillation with or suspected to have hypertension.</p>
|
|
<p>Target condition: Hypertension</p>
|
|
<p>Index test: measurement of blood pressure using automated blood pressure monitors.</p>
|
|
<p>Reference test: measurement of blood pressure using a manual mercury sphygmomanometer.</p>
|
|
<p>Outcome(s): accuracy as defined by a recognised validation protocol, for example, BHS, ESH or AAMI (level of agreement with reference standard).</p>
|
|
</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients or the population</th><td headers="hd_b_ch2.appj.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment of both hypertension and atrial fibrillation aims to reduce stroke risk. The accurate measurement of blood pressure is a prerequisite for hypertension management.</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</th><td headers="hd_b_ch2.appj.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High quality research in this area may enable future updates of this guidance to make a strong recommendation on the use of automated blood pressure monitoring in atrial fibrillation, which was not possible in the present guideline due to the lack of good quality evidence.</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to the NHS</th><td headers="hd_b_ch2.appj.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Most blood pressure measurement in the NHS utilises automated blood pressure monitors and this is likely to be the case even in AF. Inaccurate measurement of blood pressure in these people may lead to both over and under treatment of hypertension.</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National priorities</th><td headers="hd_b_ch2.appj.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</th><td headers="hd_b_ch2.appj.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evidence for blood pressure measurement in people with atrial fibrillation was not reviewed, However the suerveillance review informing the update of this guideline didn’t identify sufficient new evidence to inform this, so the research recommendation has been carried forward.</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</th><td headers="hd_b_ch2.appj.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None.</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_ch2.appj.tab1_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Validation study.</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</th><td headers="hd_b_ch2.appj.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No major feasibility or ethical issues.</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other comments</th><td headers="hd_b_ch2.appj.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance</th><td headers="hd_b_ch2.appj.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High: the research is essential to inform future updates of key recommendations in the guideline.</td></tr><tr><th id="hd_b_ch2.appj.tab1_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">commendations in the guideline.</th><td headers="hd_b_ch2.appj.tab1_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|